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Extracellular vesicles 
Extracellular vesicles (EVs) are nanosized vesicles released by all cells. EVs can 
be further classified in exosomes, microvesicles and apoptotic bodies (Figure 1) 
(1, 2). Although EVs have been discovered more than three decades ago (3), 
EVs were initially considered cellular waste (4, 5). Only recently their diverse 
roles in biology have been uncovered. One of these functions is to transfer 
information from one cell to another, thereby altering recipient cell behavior (1, 
4). This information transfer is mediated by lipids, proteins, nucleic acids and 
sugars contained in EVs (1).  
Among EVs, there has been special interest in exosomes, because they are 
thought to be specifically packaged with cytosolic proteins and RNA (6). 
Commonly used exosome markers include proteins involved in their formation, 
such as tetraspanins (CD9, CD63, CD81), intracellular membrane transporters 
(flotillin, annexin) and multivesicular body proteins (ALIX, TSG-101) (7). 
Pivotal biological roles have now been ascribed to EVs, including in immunity, 
reproductive system, bone calcification and kidney injury repair (1).  
 
Urinary extracellular vesicles 
For centuries, the analysis of urine has been an essential part of the diagnostic 
evaluation in clinical medicine and changes in urinary composition can 
frequently be linked to disease. Urine has therefore been extensively studied as a 
source of biomarkers for renal and urological disease. This search has been 
facilitated by technological progress in protein mass spectrometry and RNA-
sequencing (8, 9). Urine, however, is a complex biofluid, because it contains 
proteins, such as Tamm-Horsfall protein, which reduce the detection sensitivity 
for low-abundant proteins present in urinary EVs (uEVs) (9, 10). The 
characterization of uEVs has provided a novel approach to urinary biomarker 
discovery, because uEVs appear to reflect renal epithelial cell status and contain 
various disease-associated proteins and RNA (11-13). 
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Figure 1: Formation of microvesicles and exosomes.  
A cell is depicted, with microvesicles being formed by outward budding from the plasma 
membrane. Exosomes are formed by endocytosis, fusion with and formation within 
multivesicular bodies, and finally release of multivesicular body content into extracellular space.   
   
 
 
Content, function and isolation of uEVs 
It is estimated that in healthy subjects, approximately 3% of total urinary 
protein is contained in uEVs (7). Proteomic analysis of uEVs has shown that 
they contain more than 1600 membrane bound and cytosolic proteins from all 
segments of the kidney and the urinary tract (14). Although most studies have 
focused on the use of uEVs as biomarkers, other functions include paracrine 
effects between nephron segments, and a defense mechanism against urinary 
pathogens (15-17).  Several techniques have been used to isolate uEVs, 
Multivesicular Body
Exosomes
Microvesicles
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including immuno-isolation, filtration, precipitation and ultracentrifugation 
(11). This latter technique remains the gold standard, but ultracentrifugation is 
a time-consuming and laborious technique that also requires a large sample 
volume. Potential biomarkers in uEVs have been identified for different renal 
disorders (18, 19). These include acute kidney injury, glomerular disease, renal 
tubular disorders, salt-sensitive hypertension, and autosomal dominant 
polycystic kidney disease (ADPKD). In this thesis, we studied salt-sensitive 
hypertension and ADPKD because urinary markers for both conditions are 
needed. 
 
Salt-sensitive hypertension 
Dietary sodium intake is linked to blood pressure, with a pivotal regulatory role 
of sodium excretion by the kidney (20-22). Many hypertensive disorders are 
due to increased renal sodium reabsorption (23). The factors contributing to 
primary hypertension include age, body weight and salt intake, whereas 
secondary forms of hypertension are caused by a specific etiology (24). These 
include activation of renal sodium transporters due to single gene mutations or 
through hormone-excess, as occurs in primary aldosteronism or Cushing’s 
syndrome (CS) (21). Clinical and biochemical clues may indicate increased 
activity of renal sodium transporters. However, analyzing them directly was so 
far not possible in humans without a kidney biopsy. With the discovery of renal 
sodium transporter in uEVs, measuring their abundances and post-translational 
modifications is now possible and being investigated to further differentiate the 
cause of hypertension and possibly personalize treatment (12, 14, 25-28).  
 
Autosomal dominant polycystic kidney disease 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
inherited kidney disease, affecting approximately 3 per 10.000 subjects in the 
general population (29). In the majority of cases it is caused by a mutation in 
one of the genes encoding for polycystin 1 or 2 (PKD1 or PKD2), resulting in 
progressive bilateral cyst formation, disruption of normal renal parenchyma, 
and ultimately renal failure in approximately 70% of patients (30-34). With 
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emerging treatment options for ADPKD, such as the recent approval of the 
vasopressin V2 receptor antagonist tolvaptan, identification of patients at high 
risk for rapid disease progression has become increasingly important (35, 36). 
Table 1 shows the markers that are associated with disease progression in 
ADPKD. Among other factors, the causative gene mutation is the major 
determinant of the rate of progression, with a median age of onset of renal 
failure of 54 years for PKD1 and 74 years for PKD2 (34, 37, 38). However, 
family members who share the same mutation have variable courses of disease 
progression, possibly related to somatic mosaicism (34, 39). The potential of 
uEVs as a source of biomarkers for ADPKD has recently been demonstrated, as 
they are enriched for polycystins and also interact with primary cilia, which are 
involved in the pathophysiology of ADPKD (40, 41). The ratio of polycystin 
proteins to transmembrane protein 2 in uEVs correlated with total kidney 
volume, and could thus be used to monitor ADPKD (40). 
 
Category Marker Reference 
Imaging High total kidney volume* (42) 
Low renal blood flow (43, 44) 
Genetic PKD1 disease, in particular PKD1 truncating mutations* (34, 45) 
Clinical Early onset of hypertension* (46, 47) 
Gross hematuria* (46, 48) 
Early decrease in GFR* (42, 49) 
Biomarker Serum: copeptin, uric acid (50-52) 
Urine: NGAL, KIM-1, overt proteinuria, uEVs (40, 53-55) 
 
Table 1: Markers of disease progression in ADPKD (adapted from (36, 56)).  
*Best validated markers. KIM-1, kidney injury molecule 1; NGAL, neutrophil gelatinase-
associated lipocalin; uEVs, urinary extracellular vesicles 
 
 
 
Disease progression is also influenced by total kidney volume, proteinuria and 
hypertension (46, 48, 57). Early development of hypertension in ADPKD is 
common and the mechanism likely multifactorial (58). Although salt-sensitivity 
suggests activation of the circulating renin-angiotensin system, no evidence has 
been provided in support of this hypothesis (59-61). Locally produced or 
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filtered renin-angiotensin components may activate the intra-renal renin-
angiotensin system, thereby contributing to hypertension (62). Indeed, previous 
studies show a higher urinary angiotensinogen level in ADPKD (63, 64). 
Targeting the intrarenal renin-angiotensin system reduced cyst growth in an 
animal model of ADPKD (65). Taken together, the intra-renal renin-angiotensin 
system in ADPKD may have a prominent contributing role in hypertension and 
disease progression. 
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AIMS OF THE THESIS 
 
1. To explore the role of uEVs in renal physiology and pathophysiology, and 
their potential for biomarker discovery 
 
2. To develop a novel technique to isolate, quantify, and characterize uEV 
proteins  
 
3. To test the hypothesis that renal sodium transporters in uEVs correlate with 
salt-sensitive hypertensive disorders 
 
4. To identify novel biomarkers for ADPKD in uEVs using proteomics 
 
5. To test the hypothesis that increased urinary excretion of components of the 
renin-angiotensin system is a unique characteristic of ADPKD 
 
This thesis is divided into three sections with uEVs as the common 
denominator.  
Section 1 provides insight into the function of uEVs, their isolation, and 
characterization. In Chapter 2, the different roles of uEVs in nephrology are 
reviewed. This chapter also deals with the methodological issues of isolating 
and characterizing uEVs. In Chapter 3 a novel method to isolate, quantify, and 
characterize uEVs is presented. 
 
Section 2 assesses the role of uEVs as markers for salt-sensitive hypertension. 
Chapter 4 provides an overview of the use of uEVs as an approach to assess 
renal sodium transport. In Chapter 5-7, uEVs are studied in salt-sensitive 
hypertensive disorders, including CS (Chapter 5), primary aldosteronism 
(Chapter 6) and Liddle syndrome (Chapter 7). Furthermore, a novel disease-
causing mutation of Liddle syndrome is presented in Chapter 7. 
 
In Section 3, markers for ADPKD, including uEVs are studied. In Chapter 8 we 
set out to discover novel biomarkers in uEVs of patients with ADPKD, using 
proteomics. In Chapter 9, we compared urinary markers of the renin-
angiotensin system in ADPKD and chronic kidney disease.  
The appendix includes the methods of the DIPAK1 study, a cohort used for the 
studies in Section 3. 
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ABSTRACT  
 
Extracellular vesicles have been isolated in various body fluids including urine. 
The cargo of urinary extracellular vesicles (uEVs) is composed of proteins and 
nucleic acids reflecting the physiological and possibly the pathophysiological 
state of cells lining the nephron. Because urine is a non-invasive and readily 
available biofluid, the discovery of uEVs has opened a new field of biomarker 
research. Their potential use as diagnostic, prognostic, or therapeutic 
biomarkers for various kidney diseases, including glomerulonephritis, acute 
kidney injury, tubular disorders and polycystic kidney disease is currently being 
explored. Some challenges, however, remain. These challenges include the need 
to standardize isolation methods, normalization between samples, and 
validation of candidate biomarkers. Also, the development of a high-
throughput platform to isolate and analyze uEVs, for example an enzyme-
linked immunosorbent assay, is desirable. Here, we review recent studies on 
uEVs dealing with kidney physiology and pathophysiology. Furthermore, we 
discuss new and exciting developments regarding vesicles, including their role in 
cell-to-cell communication and the possibility to use vesicles as therapy for 
kidney disorders. 
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INTRODUCTION 
 
Urine contains vesicles derived from the kidney and the urinary tract. Vesicles 
may be released into the pre-urine by direct shedding or budding from the 
plasma membrane, or through the fusion of intracellular multivesicular 
bodieswith the plasma membrane (1). The latter resembles a process of 
exocytosis, and the vesicles formed in this way are often called “exosomes” (2). 
Exosomes are vesicles with a lipid bilayer membrane that are 30 to 120 
nanometer in size and flote at a density of 1.15 to 1.19 g/ml in continuous 
sucrose gradient (3). Although these characteristics are ascribed to exosomes, 
other vesicles are usually co-purified. This was illustrated by one study that 
used immune-electron microscopy to demonstrate that podocalyxin-positive 
vesicles differ from exosomes in their biogenesis and may be used as a 
biomarker for podocyte injury (4). Because strict separation between the 
different vesicle populations in urine has not been established, we will use the 
term urinary extracellular vesicles (uEVs) throughout this review (5-7). Figure 1 
shows uEVs as visualized by electron microscopy. Proteomic analysis has 
shown that uEVs contain proteins from glomerular, tubular, prostate, and 
bladder cells (2, 8). Two online databases showing the proteins that have thus 
far been identified in uEVs are publically accessible at 
dir.nhlbi.nih/gov/papers/lkem/exosome and exocarta.org. Commonly identified 
proteins in uEVs are tetraspanins, ALIX, and TSG-101, which are now 
commonly used as uEV markers (9, 10). In addition to proteins, uEVs also 
contain nucleic acids (11). Although mRNA profiles from whole cells in urine 
are being studied as disease markers (12), the use of mRNA in uEVs may have 
specific advantages. Namely, the RNA integrity profile in uEVs was similar to 
that of kidney tissue and was better preserved than RNA in whole urine, 
because the  membrane protects against RNase (11, 13). Of interest, uEVs also 
contain miRNA, which are small non-coding RNAs that regulate mRNA 
processing (13). It appears that small RNAs including miRNAs make up the 
majority of RNA species contained in uEVs (13). In addition to analyzing 
proteins, mRNA or miRNA in uEVs, analysis of post-translational modification 
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of plasma membrane proteins in uEVs may be another method for biomarker 
discovery, as was recently illustrated for polycystic kidney disease (5). Our aim 
in this review is to summarize the techniques used to isolate and characterize 
uEVs and to discuss the kidney disorders in which uEVs have been used for 
biomarker discovery.  
 
 
 
ISOLATION OF URINARY EXTRACELLULAR VESICLES 
 
Methods used to isolate EVs from biofluids and cell culture media include 
ultracentrifugation, filtration, precipitation and immunoisolation (Table 1) (6, 
14). Because storage and the use of reducing agents and detergents are related 
to the isolation procedure, we start this section with a brief discussion on these 
topics. 
 
Storage 
For large biomarker studies, optimal storage conditions of urine samples are 
essential to prevent proteolysis. The addition of protease inhibitors has been 
shown to prevent degradation of uEVs (10, 15). In addition, storage at -80 ºC, 
compared to +4 or -20 ºC seemed better to prevent degradation, although 
freshly processed urine is most favorable (15). Importantly, it seems that 
degradation of uEVs could occur within 2 hours of urine collection (15). It is 
therefore recommended that urine samples are stored immediately after 
addition of a protease inhibitor. uEVs can be recovered from urine up to 7 
months after freezing (10). In our hands, uEVs could be recovered from urine 
samples that had been stored even longer, although it is not known if more 
degradation had occurred in these samples (unpublished observation). 
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Figure 1: Electron Microscopy Image of uEVs From Rat Urine Isolated With 
Ultracentrifugation. 5 µL of uEVs were spotted onto a Formvar-coated grid (200 mesh) and 
negatively stained using 4% uranylacetate. Samples were examined by a Philips CM100 
electron microscope at 80 kV. Arrows indicate uEVs, ranging in size between 30 and 200 nm. 
 
 
 
Use of Reducing Agents and Detergents 
Urine frozen at -20 or -70°C forms calcium-containing precipitates after 
thawing, mainly composed of calcium oxalate and amorphous calcium crystals, 
giving it a cloudy appearance (16). This precipitate co-sediments proteins such 
as Tamm Horsfall protein (THP, also called uromodulin) at low-speed 
centrifugation (16). THP is a high-molecular-weight polymeric glycoprotein 
secreted by the epithelial cells lining the thick ascending limb of the loop of 
Henle. Under physiological conditions, THP is the most abundant protein in 
urine, excreted at a rate of about 20 to 100 mg/day (17). THP is capable of 
entrapping uEVs by forming polymers that precipitate at low-speed 
centrifugation (relative centrifugal force 17,000 x g), leading to a reduced yield 
of isolated uEVs in the final ultracentrifugation pellet (9). Because THP is 
released by the thick ascending limb of the loop of Henle, uEVs from this 
nephron segment may be more likely to be entrapped. Vigorous vortexing after 
a complete thaw of samples can redissolve the calcium-precipitates (16), thereby 
reducing EV entrapment in THP (10). Further increase of the uEV yield can be 
achieved by adding dithiothreitol (DTT), a strong reducing agent capable of 
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disrupting the zona pellucida disulphide bonds of THP (9). DTT will release 
entrapped uEVs from the low-speed pellet (17,000 x g) into the high-speed 
pellet (200,000 x g). Of note, CD9 positive uEVs seem to escape the low-speed 
entrapment (9).  
CHAPS (cholamidopropyldimethylammoniopropanesulphonate) is a detergent 
that can solubilize THP aggregates, but its use is more time-consuming. A 
possible advantage of using CHAPS instead of DTT is the preservation of uEV 
associated protease activities such as dipeptidyl peptidase IV (18), a potential 
biomarker for diabetes mellitus (19).  
 
Ultracentrifugation 
Ultracentrifugation is still the most commonly used method to isolate EVs from 
biofluids. Prior to actual ultracentrifugation, most protocols use one or more 
centrifugation steps to eliminate whole cells, large vesicles, and debris. 
Ultracentrifugation is then performed, usually at 100,000 to 200,000 x g for at 
least one hour (3, 14). Of note, ultracentrifugation does not isolate all uEVs, 
because 40% of uEVs could still be isolated from the supernatant using 
ammonium sulphate precipitation (20). This is in line with earlier reports from 
cell lines, in which ultracentrifugation recovered only 5 to 25% of total EVs 
(21). Although the loss of up to 40% of uEVs during ultracentrifugation seems 
problematic, it has yet to be shown that unique biomarkers are present in this 
unisolated fraction (22). Because the buoyancy of vesicles depends on the 
density of urine, adjusting this density may increase the uEV yield with 
ultracentrifugation.   
 
Sucrose Gradient Ultracentrifugation 
While DTT and CHAPS increase the uEV yield, THP fragments remain present 
in the final pellet, leading to a reduced purity of isolated vesicles. To increase 
this purity, several flotation methods have been proposed, using single (3), 
double (23) and gradient (24-27) sucrose in heavy water giving rise to different 
populations of uEVs. One study used sucrose gradient ultracentrifugation and 
identified three fractions of different densities characterized by the presence of 
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podocin and podocalyxin (glomerular origin), polycystin proteins and 
aquaporin-1 (from  renal tubular epithelia esp. proximal tubules ), and 
aquaporin-2 (collecting duct origin) (26). While these methods enrich the final 
pellet of uEVs, they are time consuming (up to 24 hours) and require larger 
starting volumes of about 25 mL, compared to 5 mL of urine for other 
ultracentrifugation protocols (Table 1). This may result in a lower yield of 
uEVs, even less than 1% compared to the crude pellets (24).  
 
Ultracentrifugation With Size Exclusion Chromatography 
Special handling is required for isolation of EVs from urine with heavy or 
nephrotic-range proteinuria. Albumin and other proteins tend to be retained in 
the final pellet, thereby limiting the detection of uEVs. Ultracentrifugation 
followed by size exclusion chromatography results in a high (>670 kDa) and 
low (10-670 kDa) molecular weight fraction, containing uEVs and high 
abundant interfering proteins, respectively (29). This method resulted in higher 
EV purity compared to nanomembrane ultrafiltration or standard 
ultracentrifugation methods, with and without DTT (29). Although 
ultracentrifugation with size exclusion chromatography is considered the 
technique of choice for proteinuric urine, it was recently shown that the sucrose 
gradient ultracentrifugation method also reliably and reproducibly removed 
interfering proteins (27). 
 
Filtration 
Attempts to isolate uEVs using filtration-based methods, omitting 
ultracentrifugation, have shown discrepant results. This may be due to the fact 
that protein quickly accumulates on the filters blocking further flow. One 
example of a commercially available filter is a nanomembrane concentrator 
with 13 nm pore size, which requires only 0.5 mL of urine as starting volume. 
While some proteins, such as annexin V, podocalyxin and neuron specific 
enolase do not adhere to the membrane and are easily recovered, other proteins 
are more adherent, such as aquaporin-2 and TSG-101 (31). Compared to other 
isolation methods, the purity of recovered protein in uEVs remains low (25) 
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and this method therefore seems less suitable for nephrotic urine (29) and to 
isolate RNA from uEVs (25). Hydrophilized polyvinylidene difluoride 
microfilters, which have a 100 nm pore size, have been successfully used to 
isolate uEVs (30). A limiting factor for high-throughput application of these 
microfilters is the need for a stirred cell apparatus (a positive pressure filtration 
based concentrating device). Incorporation of the microfilter into a commercial 
spin filtration device may alleviate this limitation. 
 
 
 
Table 1: Methods for Isolation of uEVs.  
ELISA, enzyme-linked immunosorbent assay; HPLC, high-performance liquid chromatography; 
THP, Tamm-Horsfall protein; UC, ultracentrifugation; * including overnight incubation 
 
 
 
 
 
Isolation principle Technique Minimum 
starting 
volume 
(mL) 
Isolation 
time 
(hours) 
Suitable 
for RNA 
Advantage Disadvantage Ref 
Ultracentrifugation UC 5 1 – 2 Yes High yield THP 
entrapment 
(2, 3, 10, 28) 
 UC with 
reducing agent 
or detergent 
5 1.5 – 2.5 Yes Very high 
yield 
Loss of 
functionality  
(9, 18, 25) 
 Sucrose gradient 
UC 
25 2.5 – 24 
 
Yes High purity Low yield, time 
consuming 
(3, 23-27) 
 UC with size 
exclusion 
chromatography 
45 Unknown Unknown Suitable for 
proteinuria 
Need for 
HPLC 
(29) 
Filtration Microfiltration 12.5 Unknown Unknown No need for 
UC 
Low-
throughput 
(30) 
 Nanofiltration 0.5 5 No No need for 
UC 
Unsuitable for 
proteinuria 
(25, 29, 31) 
Precipitation ExoQuick TC 5 12* No No need for 
UC 
Not suitable 
for urine 
(25) 
 Modified 
ExoQuick TC 
5 13* Yes No need for 
UC 
Unknown 
reagent 
(25) 
Immunoisolation ELISA 0.05 5.5 No High 
throughput 
Selection of 
subpopulation 
(19, 32) 
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Precipitation 
ExoQuick™ is a commercially available precipitation kit to isolate 
microvesicles (System Biosciences, Mountain View, CA, USA). For urine, its 
current protocol results in a very low yield of both protein and RNA (25). 
Modification of the sample work-up resulted in the highest quantities of mRNA 
and miRNA and an acceptable protein yield compared to the 
ultracentrifugation methods (25). This method is relatively easy, omits the need 
for ultracentrifugation and uses less sample material (5 mL urine). However, 
the overnight incubation step limits its use for immediate diagnostic use, 
making it less suitable for disorders such as acute kidney injury. 
 
Immuno-isolation 
For clinical applications, it is desirable to be able to directly isolate vesicles 
from urine without the need for ultracentrifugation. To this end, immuno-
isolation methods may be especially attractive, as has been successfully 
performed for the water channel aquaporin-2 (33). An enzyme linked 
immunosorbent assay (ELISA) or a protein microarray, in which uEV cargo can 
be detected in a specific and high-throughput manner, is desirable. At present, 
two studies used ELISA with different capture antibodies, including AD-1 (a 
potential uEV marker) (19) and the sodium chloride cotransporter (32). In the 
first study whole urine was directly added to the wells of an AD-1 coated plate, 
which was possible because AD-1 is present at the extracellular surface of uEVs 
(19). In the second study, however, urine was first ultracentrifuged, the pellet 
was then lysed, and finally added to a plate coated with an antibody against the 
sodium chloride cotransporter (NCC) (32). This lysis step was necessary 
because the antibody targets the intracellular domain of NCC, which is located 
inside the uEVs.  Although promising, two limitations must be considered. 
First, proteins in EVs have the same orientation as the cell they originate from. 
Therefore, antibodies need to be directed against the extracellular domain of 
the protein of interest, unless EVs are lysed. While the latter approach would 
increase specificity of the identified protein, it includes an additional lysis step, 
lacks specificity for EV origin and therefore still requires an ultracentrifugation 
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or precipitation step to concentrate uEVs (32). The second limitation is that 
capture antibodies should be selected carefully to ensure that these marker 
proteins (e.g., CD9) are indeed expressed by the uEVs of interest. 
 
 
 
CHARACTERIZATION OF UEVS 
 
uEVs can be further characterized for size distribution, to normalize between 
samples, and, ultimately, to analyze differential expression of proteins of 
interest. Several techniques are available to characterize uEVs (Table 2). 
Normalization between samples remains the “holy grail” in the field of uEVs 
(22). Normalization methods that have been used include urinary creatinine, 
timed urine collection, THP, use of ‘household’ uEV markers (e.g., CD9), and 
estimating the actual number of uEVs (1, 9, 34). Urinary creatinine has been 
used most often and has the advantage that it allows for the use of spot urines 
(10, 32, 35). A potential limitation, however, is that it assumes that the number 
of uEVs correlates with the concentration of the urine sample. Although timed 
urine has the advantage that all uEVs are collected within the defined time 
period and that it accounts for intra-day variability, it is notoriously incomplete 
(1). It is also unknown if nephron loss in chronic kidney disease results in the 
formation of less uEVs. CD9, CD63, CD81, TSG-101, and ALIX have been 
proposed as uEV markers and have been used for uEV normalization 
(immunoblot) or isolation (ELISA or immunobeads coupled to flowcytometry) 
(25, 34). This approach assumes that these markers remain unchanged during 
different physiological and disease states. In addition, although this method 
accounts for uEV quantity, only a subpopulation of uEVs expressing the 
marker are quantified. To overcome these shortcomings, the ability to count the 
actual number of uEVs would be desirable. Several methods have become 
available in recent years (6, 36, 37). Currently, resistive pulse sensing and 
nanoparticle tracking analysis hold promise, as other techniques are being 
developed. Resistive pulse sensing (qNano, Izon, New Zealand) uses a 
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stretchable nanopore on a polyurethane membrane, allowing real-time 
manipulation of the pore size (38). EVs travel across the membrane pore, 
thereby altering the current, which is a measure for EV volume. This technique 
provides both the size distribution and the concentration of EVs. Protein 
content, however, cannot be measured by this technique. Nanoparticle tracking 
analysis (Nanosight Ltd, United Kingdom) measures Brownian motion of EVs 
in solution by illuminating them with a laser beam. Size is calculated through 
the Stokes-Einstein equation, whereas concentration is determined by particle 
counting. Recently, nanoparticle tracking analysis was combined with 
fluorescently labeled antibodies directed against CD24 and aquaporin-2, to 
directly quantify this subpopulation without sample processing (15). The 
upregulation of aquaporin-2 in mice after treatment of desmopressin was 
readily detectable. This method also reduced the intra-assay variability due to 
interference of larger particles, one of the limiting factors for nanoparticle 
tracking analysis in unprocessed samples (15). The approach of using two 
labeling antibodies (one against the protein of interest and one against an 
unchanged protein) has been proposed previously and may solve the 
quantification issue especially if the outcome is dichotomous (39). 
 
 
 
USE OF UEVS IN NEPHROLOGY  
 
uEVs have been used for biomarker discovery and therapeutic purposes in 
various kidney disorders, including acute kidney injury, glomerular disease, 
renal tubular disorders, and polycystic kidney disease (Table 3, Figure 2).  
 
Acute Kidney Injury 
Acute kidney injury (AKI) is characterized by a sudden deterioration in kidney 
function. It is common in hospitalized patients and associated with high 
morbidity and mortality (41). Because serum creatinine concentration starts to 
increase only when glomerular filtration rate has decreased by more than 50%, 
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earlier biomarkers of reduced kidney function are being sought (41). In one 
study, the increased abundance of the sodium hydrogen exchanger type 3 
(NHE3) in uEVs was able to differentiate between prerenal azotemia, acute 
tubular necrosis and other causes of renal failure in sixty-eight patients 
admitted to the intensive care unit (42). NHE3 in uEVs was more specific than 
the fractional excretion of sodium, a routinely used parameter to assess the 
cause of AKI. Fetuin-A, a negative acute-phase response protein synthesized by 
the liver, is another potential biomarker in AKI. It was found to be increased in 
uEVs using a rat model of cisplatin-induced AKI. 
 
The increase in fetuin A was detectable two days before the increase in serum 
creatinine. This biomarker was subsequently tested in rat model of ischemia-
reperfusion and in intensive care patients with AKI; the diagnostic utility of 
fetuin A in uEVs was also confirmed in these settings (43). The same group also 
studied activated transcription factor 3 in experimental and clinical AKI (44). 
While transcription factors are undetectable in whole urine and uEVs from 
healthy subjects – even when using proteomics (8) – they are readily detectable 
in uEVs during AKI, thereby representing a new class of biomarkers in kidney 
disease. The water channel aquaporin-1 in uEVs was found to be decreased 
after ischemia-reperfusion injury in rats and patients undergoing kidney 
transplantation (45). Although NHE3, fetuin-A, and aquaporin-1 were not 
compared directly, aquaporin-1 appears to have some advantages. That is, 
aquaporin-1 was detectable 6 to 96 hours after renal ischemia-reperfusion, 
while NHE3 was undetectable after 48 hours. In addition, fetuin-A was also 
increased in uEVs of the kidney donor, indicating a nonspecific rise in response 
to surgery or changes in hemodynamics. Besides their use as potential 
biomarkers in AKI, EVs may also have therapeutic potential. Mesenchymal 
stem cells (MSCs) have shown to contribute to the recovery of kidney injury 
(46-49). Possibly, MSCs exert their function in a paracrine fashion, releasing 
trophic growth factors, cytokines and chemokines, as they are only transiently 
present within the injured organs (50, 51). There is evidence to suggest that EVs 
play a pivotal role in this paracrine effect (52-57). Bruno et al. isolated EVs 
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derived from human bone marrow MSCs and used these EVs to test their effect 
in tubular epithelial cells and immunodeficient mice with glycerol-induced AKI. 
After labeling EVs with a PKH26 dye, uptake by TECs was visualized. 
Furthermore, blocking or trypsinizing the surface markers CD29 and CD44 
inhibited the uptake of EVs by TECs. When taken up by TECs, EVs inhibited 
apoptosis that was induced by serum deprivation, vincristine or cisplatinum. In 
vivo, treatment with either MSCs or MSC-derived EVs showed similar 
renoprotective effects, which was not observed when fibroblast-derived EVs 
were used. After infusion of fluorescently labeled EVs, an accumulation of these 
EVs in kidney tubular cells was observed only in kidneys of mice with AKI, but 
not in the control mice. Interestingly, RNase treatment abrogated the protective 
effects of MSC EVs in all studies, suggesting an RNA-dependent mechanism 
(52-56). Indeed, mRNA and miRNA seem to be specifically incorporated into 
EVs, suggesting a horizontal transfer of MSC EVs to target cells (58, 59). 
Tomasoni et al. showed that mRNA of the receptor for insulin-like growth 
factor 1 (IGF-1R) but not the mRNA of the growth factor itself was present in 
EVs excreted by MSCs (59). When fibroblast cell lines derived from mice 
lacking the IGF-1R were incubated with MSC-derived EVs, functional IGF-1R  
was transcribed. Furthermore, incubation of these cells with the EVs led to an 
increase in proliferation in cisplatin-treated proximal tubular epithelial cells. 
This effect was enhanced when IGF-1 was co-incubated. This also suggests that 
MSC-derived EVs contribute to the repair of damaged cells in an RNA-
dependent fashion.   
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Table 2: Commonly Used Techniques to Characterize Urinary EV’s 
 
 
 
Glomerular Diseases 
Urinary biomarkers may ultimately replace the need for a kidney biopsy in 
glomerular disease. As podocyte injury is a common feature of glomerular 
disease, the presence of podocytes, podocyte-derived RNA or podocyte-derived 
EVs have been postulated as potential biomarkers (60-63). A number of specific 
biomarkers for glomerular disease in uEVs have been identified, including 
Wilm’s Tumor 1, podocalyxin, α-1 antitrypsin, aminopeptidase N, vasorin 
precursor, ceruloplasmin, and miR-145 (Table 3). In animal models of focal 
segmental glomerulosclerosis and collapsing glomerulopathy, Wilm’s Tumor-1 
(WT-1) protein in uEVs, a transcription factor required for kidney 
development, increased one week earlier than urinary albumin (44) and also 
predicted the effect of angiotensin receptor blocker treatment (62). One study 
Platform Principle of 
technique 
Detection 
limit 
Normalization 
between 
samples 
Estimate 
of 
number 
uEVs 
Size 
distribution 
Need for 
EV 
isolation  
Allowing protein 
analysis 
Ref 
Western blot Protein 
separation 
followed by 
antibody 
based 
detection  
Depends 
on 
antibody 
affinity 
Yes No No Yes  Yes (3) 
ELISA Antibody 
based capture 
and detection 
Depends 
on 
antibody 
affinity 
Yes No No Sometimes Yes (19, 
25, 32) 
Flow 
cytometry 
Light 
scattering or 
fluorescence 
300 nm 
 
Yes No No Yes In combination 
with 
immunolabelling 
(28) 
Nanoparticle 
tracking 
analysis 
Brownian 
motion or 
light 
scattering 
20 nm Yes Yes Yes No In combination 
with 
immunolabeling 
(15) 
Resistive 
pulse sensing 
Physical 
passage of 
particles 
through 
micropore  
50 nm Yes Yes Yes No No (38, 
40) 
Transmission 
electron 
microscopy 
Electron 
scattering 
1 nm  No No Yes Yes In combination 
with 
immunolabeling 
(3) 
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found that WT-1 in uEVs was increased in patients with FSGS, but not in those 
with AKI or in healthy volunteers (44, 62); this finding, however, was not 
confirmed by others (64). The increase in uEV WT-1 was also associated with a 
decline in kidney function in diabetic nephropathy, suggesting early podocyte 
damage (65). Another podocyte injury marker is podocalyxin, which, unlike 
WT-1, was found in shedding vesicles (no expression of CD24 and CD63) (4, 
66). In addition to diabetic nephropathy, podocalyxin was also increased in 
uEVs isolated from patients with IgA nephropathy (67, 68). In practice, IgA 
nephropathy should often be differentiated from thin membrane disease, as 
both disorders present with glomerular erythrocyturia. Therefore, a urinary 
biomarker that could differentiate IgA nephropathy from thin membrane 
disease could potentially omit the need for a kidney biopsy. Using a label-free 
quantitative proteomic approach, four proteins in uEVs were found to be 
differentially expressed in IgA nephropathy, including α-1 antitrypsin, 
aminopeptidase N, vasorin precursor and ceruloplasmin (69). In type 1 
diabetics with diabetic nepropathy, miRNA expression profiling revealed 
differential expression of 22 out of 226 miRNAs isolated from uEVs (70). 
Increase in miR-145 was further explored in streptozotocin induced diabetic 
mice where it was found that both glomeruli and uEVs contained more miR-
145. The finding that mesangial cells exposed to high glucose had an increase in 
whole cell and exosomal miR-145 content, suggested that higher local glucose 
concentrations caused this increase. While all of these findings are promising, 
they need to be validated in larger studies.  
 
Renal Tubular Disorders 
The identification of most kidney solute and water transporters in uEVs raised 
the possibility that these proteins may be used as biomarkers for renal tubular 
disorders (1, 2, 8). Less clear is if the abundance of transporters in uEVs 
correlates with their transport activity in the kidney, although a number of 
studies suggest this may be so (34, 75). In 1995, Kanno et al. were the first to 
identify aquaporin-2 in urine (33). Aquaporin-2 is a vasopressin-sensitive water 
channel located in the principal cells of the collecting duct. Immunogold 
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labeling showed that aquaporin-2 was present in uEVs, but the nature of these 
vesicles and how they had been released in urine, was not known. The 
abundance of aquaporin-2 in urine correlated with vasopressin activity, because 
it increased after water restriction and desmopressin infusion, but was not 
increased in patients with nephrogenic diabetes insipidus. In another study, the 
abundance of aquaporin-2 in uEVs highly correlated with its abundance in 
murine kidney collecting duct cells after desmopressin stimulation (34). 
Interestingly, the transfer of uEVs from desmopressin-treated cells to untreated 
cells resulted in an increase of functional aquaporin-2 expression in the 
untreated cells (Figure 1). Similar effects were seen in rats after demopressin 
treatment, because the excretion of aquaporin-2 in uEVs increased (34). The 
good correlation between desmopressin stimulation and aquaporin-2 excretion 
in uEVs was confirmed by others (75). In addition to plasma vasopressin, 
aquaporin-2 in uEVs was also influenced by alkalization of the urine (75). 
Because sodium bicarbonate did not increase plasma vasopressin, urinary 
alkalization likely increased the sensitivity of the vasopressin type 2 receptor for 
vasopressin. The diagnostic utility of uEVs in renal tubular disorders was also 
illustrated by the absence of the sodium-potassium-chloride cotransporter 
(NKCC2) in urinary exosomes from patients with Bartter syndrome type 1, a 
rare disease caused by mutations in the gene encoding for NKCC2 (8). 
Similarly, the sodium-chloride cotransporter (NCC) was absent in urinary 
exosomes of patients with Gitelman syndrome, who have an inactivating 
mutation in the gene encoding for NCC (71). The opposite was also true, 
because patients with familial hyperkalemic hypertension, which is 
characterized by NCC overactivity, had increased NCC in urinary exosomes 
(32, 72). Because NCC is sensitive to aldosterone, we tested whether NCC 
showed the same response in uEVs as in kidney tissue from animal models of 
aldosteronism (35). Indeed, feeding rats a low sodium diet or infusing 
aldosterone increased total and phosphorylated NCC in kidney tissue and uEVs 
(Figure 3). Furthermore, the abundance of phosphorylated NCC in uEVs was 
higher in patients with primary aldosteronism than in matched patients with 
essential hypertension. Phosphorylated NCC also performed better than 
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prostasin, a serine protease known to regulate the epithelial sodium channel, 
which is also sensitive to aldosterone. Another disorder in which kidney 
transporters in uEVs were analyzed, was American cutaneous leishmaniasis 
(76). American cutaneous leishmaniasis may be complicated by defects in 
urinary concentration and acidification. The urinary concentration defect was 
associated with a reduced abundance of aquaporin-2 in uEVs, while NKCC2 
was upregulated, possibly as a compensatory response. The urinary 
acidification defect may have been explained by the increase of pendrin in 
uEVs, while increases in NHE3, and H+ ATPase may again have been 
compensatory.  
 
Polycystic Kidney Disease 
Polycystic kidney disease (PKD) is the most common inherited kidney disease 
and is caused by dysfunction of cilia (77). EVs may be important in cilia 
biology and as biomarkers for PKD (Figure 3). Primary cilia are flow-sensing 
organelles, expressed in nearly all renal epithelial cells except for the 
intercalated cells of the collecting duct (78-80). Mutations in genes encoding for 
proteins involved in the function of primary cilia lead to PKD, including 
polycystin-1, polycystin-2, and fibrocystin/polyductin (81). The proteins 
polycystin-1 and polycystin-2 form a complex that is involved in mechano-
sensing by cilia. Changes in luminal flow induce a calcium influx through the 
polycystin-2 channel, which is a non-selective cation channel (82). How are 
cilia and EVs related? Left-right asymmetry in the embryonic stage depends on 
ciliary leftward fluid flow. So called nodal vesicular particles (300-500 nm) 
contain sonic hedgehog and retinoic acid, which are both proteins involved in 
the symmetry breaking process (83). These vesicles are secreted by cells as a 
result of fibroblast growth factor and are subsequently carried to the left by 
ciliary motion. Before reaching the left wall of the ventral node, they are 
fragmented by cilia and then taken up, thereby creating left-specific intracellular 
calcium elevation in the cells of the left ventral node. Mutations in polycystin-2 
hamper this increase in intracellular calcium, disturbing the left-right breaking 
process. This in turn could lead to situs inversus, a congenital condition in 
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which the major organs are reversed (84). Furthermore, so-called PKD-positive 
vesicles seem to specifically interact with primary cilia of kidney and biliary 
epithelial cells, as observed by transmission electron microscopy images (24, 
74). Biliary derived EVs attach to cholangiocyte cilia and alter ERK signaling, 
miR-15A expression and cholangiocyte proliferation in vitro. Pharmacological 
removal of cilia by chloral hydrate abolished these effects (73). Interestingly, the 
proteins involved in the pathogenesis of PDK, polycystin-1, polycystin-2 and 
fibrocystin/polyductin, have also been found in uEVs (2, 8). Characterization of 
uEVs in which polycystin-1, polycystin-2, and fibrocystin/polyductin were 
present, identified two additional proteins previously known to be involved in 
polycystic kidney disease, namely cystin and ADP-ribosylation factor-like 6 
(24). Recently, surface glycosylation profiles in uEVs were compared between 
seven patients with PKD and seven matched healthy volunteers. Significant 
differences in surface glycosylation were identified in 6 out of 43 lectins studied, 
illustrating the potential use as biomarker. Our group is currently searching for 
potential biomarkers in uEVs for PKD using quantitative proteomics (85). 
 
 
Disorder Potential biomarkers in uEVs 
Acute kidney injury Sodium hydrogen exchanger type 3, activated transcription factor 
3, fetuin-A, aquaporin-1 
Focal segmental glomerulosclerosis Wilm’s Tumor 1 
IgA nephropathy α-1 antitrypsin, aminopeptidase N, vasorin precursor and 
ceruloplasmin, Podocalyxin 
Diabetic nephropathy Podocalyxin, dipeptidyl peptidase IV, miR-145, Wilm’s Tumor 1 
Nephrogenic diabetes insipidus Aquaporin-2 
Bartter syndrome Sodium potassium chloride cotransporter type 2 
Gitelman syndrome Sodium chloride cotransporter 
Familial hyperkalemic hypertension Sodium chloride cotransporter 
Primary aldosteronism Sodium chloride cotransporter, prostasin 
Polycystic kidney disease Polycystin-1, polycystin-2, fibrocystin/polyductin, surface 
glycosylation profiles 
 
Table 3: Potential biomarkers in uEVs for different kidney disorders 
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Figure 2: Illustration of the Many Functions of uEVs in Kidney Disorders.  
The figure shows a schematic drawing of the nephron with the glomerulus and the kidney 
tubule. Five magnifications illustrate local processes in which uEVs are involved along the 
nephron. Panel A shows uEVs containing podocalyxin and Wilm’s Tumor-1 protein, which are 
excreted after podocyte injury (4, 44, 62, 65-68). Panel B shows uEVs containing the sodium 
chloride cotransporter (NCC). These uEVs may be used in primary or secondary aldosteronism 
(Figure 3), Gitelman syndrome, or familial hyperkalemic hypertension (Table 2) (32, 35, 71, 
72). Panel C shows that EVs derived from mesenchymal stem cells (MSC) may contribute to the 
recovery of acute kidney injury, most likely in an RNA dependent fashion (see text for details, 
(52-57)). Panel D shows how uEVs may interact with primary cilia and possibly exert a 
downstream effect, for example in polycystic kidney diseases (24, 73, 74). Panel E shows 
thepossibility that uEVs transfer functional aquaporin-2 (AQP2) between kidney collectingduct 
cells (based on in vitro findings, 
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Figure 3: Aldosteronism Results in Increased Abundance of the Sodium Chloride 
Cotransporter in uEVs.  
The figure shows three panels of immunoblots performed in uEVs. Panel A shows the increase 
in the abundance of the sodium chloride cotransporter (NCC) and its phosphorylated form 
(pNCC, threonine 58 phosphorylation site) in uEVs after a two-day aldosterone (Aldo) infusion 
in rats. Panel B shows that secondary aldosteronism as induced by a low sodium diet in rats 
also increases NCC and pNCC abundance in uEVs. Panel C shows that the abundance of 
pNCC is higher in uEVs of patients with primary aldosteronism compared to patients with the 
same degree of essential hypertension. Figure adapted from (35), with kind permission. 
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ABSTRACT 
	
Although nanosized urinary extracellular vesicles (uEVs) are increasingly used 
for biomarker discovery, their isolation currently relies on time-consuming 
techniques hindering high-throughput application. To navigate this problem, 
we designed an immunoassay to isolate, quantify and normalize uEV-proteins. 
The uEV-immunoassay consists of a biotinylated CD9 antibody to isolate uEVs, 
an antibody against the protein of interest, and two conjugated antibodies to 
quantify the protein of interest and CD9. As a proof of principle, the 
immunoassay was developed to analyze the water channel aquaporin-2 (AQP2) 
and the sodium chloride cotransporter (NCC). CD9 was used as a capture 
antibody because immunoprecipitation showed that anti-CD9 antibody, but not 
anti-CD63 antibody, isolated AQP2 and NCC. CD9 correlated strongly with 
urine creatinine, allowing CD9 to be used for normalization of spot urines. The 
uEV-immunoassay detected AQP2 and NCC with high sensitivity, low 
coefficients of variance and stability in dilution series. After water loading in 
healthy subjects, the uEV-immunoassay detected decreases in AQP2 and NCC 
equally well as the traditional method using ultracentrifugation and 
immunoblot. The uEV-immunoassay also reliably detected lower and higher 
AQP2 or NCC levels in uEVs from patients with pathological water or salt 
reabsorption, respectively. In summary, we report a novel approach to analyze 
uEVs that circumvents existing isolation and normalization issues, requires 
small volumes of urine and detects anticipated changes in physiological 
responses and clinical disorders. 
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INTRODUCTION  
 
Extracellular vesicles (EVs), including exosomes, are nanosized lipid membrane 
vesicles released by cells (1). They have been identified in all biofluids, including 
urine (2). EVs contain proteins and nucleic acids, which may reflect the 
physiological and pathophysiological state of the cell from which they were 
released. Therefore, EVs have sparked interest with regard to biomarker 
discovery (1, 3). Urinary extracellular vesicles (uEVs) have the advantage that 
they can be obtained non-invasively and may be of special interest for disorders 
of the kidney or urinary tract (4, 5). Indeed, several disease biomarkers have 
recently been reported in uEVs (6-8). Ultracentrifugation followed by 
immunoblotting is currently the most widely used method to isolate uEVs and 
quantify proteins of interest (9). Other techniques to isolate uEVs rely on 
filtration, precipitation, or size exclusion chromatography, and also require 
immunoblotting for protein quantification (4, 5). All of these techniques are 
time-consuming and require large starting volumes of urine, hampering high-
throughput clinical application. Here, we report a novel approach using an 
enzyme-linked immunosorbent assay (ELISA) combined with a time-resolved 
fluorescence immunoassay to isolate uEVs, requiring small volumes of whole 
urine and allowing quantification and normalization of uEV proteins of 
interest. For proof-of-concept of the immunoassay, we assessed the regulation 
of the water channel aquaporin-2 (AQP2) and the sodium chloride 
cotransporter (NCC), because these two proteins have previously been 
identified in uEVs and are relevant in physiological and pathophysiological 
settings (2, 7).   
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MATERIALS AND METHODS 
 
Urine samples 
All urine samples were collected with protease inhibitors (Roche cOmplete, 
Woerden, The Netherlands) and centrifuged (3000 x g for 20 minutes) to 
remove cells and cell debris and were stored at -80°C. Urine samples were then 
used for the uEV-immunoassay (100 µl/well in duplicates or triplicates) or 
isolation of uEVs using high-speed and ultracentrifugation (40 ml/sample), as 
described previously (7). uEVs isolated by ultracentrifugation were solubilized 
and prepared for immunoblotting. For immunoprecipitation, we used the 
Dynabeads protein G immunoprecipitation kit according to the manufacturer’s 
instructions (Thermo Fisher Scientific, Waltham, USA). The following 
antibodies were used for immunoprecipitation: mouse anti-CD9 (R&D systems, 
Minneapolis, USA, clone 209306), anti-CD63 (BD Pharmingen, San Jose, USA, 
clone H5C6), rabbit anti-ALIX (Sigma-Aldrich, St. Louis, USA, clone 
HPA011905), and rabbit anti-AQP2 and anti-NCC (see below). Urine 
creatinine and osmolality were measured by our clinical chemistry department 
using CREP2 Cobas (Roche) and the Arkray Osmo Station (Menarini 
Diagnostics, Florence, Italy).  
 
uEV-immunoassay 
Biotin labeled mouse anti-human CD9 antibodies (eBioscience, San Diego, USA, 
clone SN4 C3-3A2) in Red Buffer containing 0.01% Tween 40 (Kaivogen, 
Turku, Finland) were added to neutravidin coated plates (Thermo Fisher) and 
incubated overnight at 4°C with gentle shaking. After incubating 100 µl of 
urine sample in the wells for one hour, captured uEVs were lysed by 0.01% 
SDS (10 minute incubation with gentle shaking). Subsequently, rabbit anti-
human AQP-2 or NCC, both generated by one of the investigators, was added 
to the wells (1 hour incubation). Anti-AQP2 antibody was described before (10) 
and anti-NCC antibody was raised in rabbit targeting the peptide 
RRDCPWKISDEEINKNR. The antibody was confirmed to be specific for NCC 
using immunohistochemistry, immunoblotting of kidney lysates and NCC-
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transfected/non-transfected cells, or immunoprecipitation followed by protein 
mass spectrometry (data not shown). Finally, the donkey anti-rabbit HRP-
conjugated antibody (Biolegend, San Diego, USA, clone poly4064) followed by 
the Europium-conjugated anti-CD9 antibody (R&D Systems, labeled as 
described before (11)) were added to the wells (each for 1 hour). Each 
incubation step (urine and antibodies) was followed by six washes with wash 
buffer (Kaivogen). Addition of ECL followed by enhancement solution (Perkin-
Elmer, Turku, Finland) allowed detection of signals at 445 nm (1 ms) and 615 
nm (time-resolved) by the Wallac Victor 2 multilabel counter (Perkin-Elmer). 
For all immunoassay-results, we report the remaining signal after subtracting 
PBS-signal.   
 
Healthy subjects and patients 
The medical ethics committee approved the water loading experiment and urine 
collections in patients (MEC-2015-204). Healthy subjects (no medical history, 
no medication) underwent thirsting (10 p.m. – noon), and then drank 20 ml/kg 
water within 30 minutes. Spot urine samples were obtained at five time points 
(10 a.m., noon, 2 p.m., 3 p.m., 5 p.m.). Nine patients were recruited from our 
outpatient clinic and included patients with central diabetes insipidus (one 
patient due to AVP-NPII mutation, one patient due to hypophysectomy), 
nephrogenic diabetes insipidus (one patient due to AVPR2 mutation, one 
patient with clinical phenotype and family history consistent with nephrogenic 
diabetes insipidus, mutation analysis pending), syndrome of inappropriate 
antidiuresis (one patient due to pituitary adenoma, one patient due to subdural 
hematoma), Gitelman syndrome (two patients with SLC12A3 mutation), and 
familial hyperkalemic hypertension (one patient due to KLHL3 mutation).  
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RESULTS 
 
Development and validation of uEV-immunoassay 
CD9 and CD63 are commonly used as uEV-markers and are thought to play a 
role in the biogenesis of uEVs (12). We first isolated uEVs from human urine by 
immunoprecipitation using antibody coated magnetic beads to analyze if CD9+ 
and CD63+ uEVs express AQP2 or NCC (Figure 1A). AQP2 and NCC were 
present in CD9+ but not in CD63+ uEVs. Analysis of ALIX, another uEV 
marker protein, suggested a lower concentration of CD63+ uEVs. This is in 
agreement with tissue distribution, as CD63 is low in abundance in the kidney 
but highly expressed in bladder and prostate (11, 13). Therefore, we selected 
CD9 as our capture antibody for uEVs. Figure 1B shows the design of our 
sandwich uEV-immunoassay. The uEV-immunoassay included four antibodies: 
(1) a biotinylated anti-CD9 antibody (capture antibody), (2) an antibody 
directed against the protein of interest (anti-AQP2 or anti-NCC), (3) a 
horseradish-peroxidase (HRP) conjugated antibody against the anti-AQP2 or 
anti-NCC antibody, and (4) a Europium conjugated anti-CD9 antibody. We 
used two conjugated antibodies to allow quantification of both the protein of 
interest and CD9 (as uEV-marker). Because our anti-AQP2 and anti-NCC 
antibodies are directed against an intracellular epitope, our uEV-immunoassay 
required the use of a detergent.  
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Figure 1: Set-up of an immunoassay for urinary extracellular vesicles  
(A) Immunoprecipitation study showing that CD9+ but not CD63+ uEVs express NCC and 
AQP2. Analysis of ALIX, another uEV-marker, suggested lower concentration of CD63+ 
uEVs. uEVs isolated with ultracentrifugation (‘uEV’) were used as positive controls. CD9-SN 
and CD63-SN refer to the supernatant that remained after immunobead isolation. To exclude 
non-specific binding, IgG was used as negative control. Black arrows show heavy (55 kDa) and 
light (25 kDa) chains of the antibodies. White arrows show glycosylated (40 kDa) and non-
glycosylated (25 kDa) AQP2. The latter overlaps with the light chain of the antibodies.   
(B) uEV-immunoassay set-up showing the neutravidin coated plate and the four antibodies, 
including the biotinylated anti-CD9 (capture) antibody, anti-AQP2 or anti-NCC antibody 
(protein of interest) targeting an intracellular domain, and the two luminescent antibodies to 
quantify the number of uEVs (Europium-conjugated anti-CD9 antibody) and the protein of 
interest (horseradish-peroxide-conjugated antibody).  
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We tested various detergents in different concentrations and with varying 
incubation times, of which 0.01% SDS for 10 minutes resulted in the most 
optimal signal to noise ratio (Figure 2A). A recent study that determined the 
lysis sensitivity in EV subpopulations, also showed that low concentrations of 
SDS (0.01%) or Triton X-100 (0.025%) were most effective (14). Subsequently, 
we validated our uEV-immunoassay by selectively removing one of the 
antibodies which resulted in loss of signal (Figure 2B). In this set of experiments 
we also confirmed the requirement of the detergent, because the signals for 
AQP2 and NCC were lost when the detergent was not added. The CD9 signal, 
however, remained intact, because the anti-CD9 antibody is directed against an 
extracellular domain of the protein. No loss of CD9 signal occurred when the 
detergent was added to the uEV-immunoassay, suggesting the detergent did not 
result in disintegration of bound uEVs and loss of membrane fragments during 
subsequent washing steps. To be practical clinically, it should be possible to use 
the uEV-immunoassay on spot urines instead of 24-hour urine. Clinically, spot 
urines are routinely used for diagnostic purposes, for example by using the 
protein-to-creatinine ratio, which shows excellent correlation with 24h urine 
protein (15). At present, urine creatinine is the most commonly used parameter 
to normalize uEV-protein abundances, assuming that the concentration of the 
urine sample correlates with uEV number. To test this assumption, we 
compared urine creatinine concentration with CD9 signal and observed an 
excellent correlation (Figure 2C). This also implies that with the current uEV-
immunoassay set-up it is no longer necessary to measure urine creatinine 
separately. It remains to be studied whether urine creatinine and CD9 truly 
correlate with uEV-number, for example by nanoparticle tracking analysis (16). 
The signals for AQP2, NCC, and CD9 remained stable in serial dilutions 
(Figure 2D), suggesting AQP2/CD9 and NCC/CD9 ratios can be used as proxy 
for the abundance of the protein of interest normalized for uEV number. The 
coefficients of variance for the uEV-immunoassay were 5.6% for AQP2 and 
3.3% for NCC up to 8-fold dilutions. All these experiments were also 
performed with uEVs isolated by ultracentrifugation, which gave similar results 
(data not shown).  
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Figure 2: validation of the uEV-immunoassay 
(A) Testing of different detergents showed that SDS 0.01% resulted in the most optimal signal 
for AQP2. Detergent was used to lyse uEVs because our anti-AQP2/NCC antibodies target an 
intracellular domain. Incubation time for all detergents was 10 min. Results are shown as 
means ± SD (experiments performed in duplicates). 
(B) Validation of uEV-immunoassay showing that selectively removing one of the antibodies 
results in loss of signal. CD9-signal did not require detergent, because our anti-CD9 antibody 
targets an extracellular domain. No loss of CD9-signal occurred when detergent was used. As 
expected, CD9 but not AQP2 and NCC were detected in serum. Results are shown as means ± 
SD (experiments performed in triplicates). 
(C) Correlation between urine creatinine and CD9. 4-5 random spot urines from four healthy 
volunteers were used.  
(D) Serial dilutions showing stable AQP2, NCC and CD9 signals. AQP2/CD9 and NCC/CD9 
ratios remained close to 1. Results are shown as means ± SD (experiments performed in 
triplicates). All experiments were performed with whole urine from healthy volunteers. A.U., 
arbitrary units.  
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Application of uEV-immunoassay in physiological and pathophysiological 
settings 
To test whether the uEV-immunoassay was capable of detecting physiological 
and pathophysiological changes in AQP2 and NCC, we tested it in normal 
subjects and patients (Figures 3 and 4). First, we performed a water loading 
experiment in healthy subjects after overnight thirsting. As expected, urine 
osmolality reflected maximally concentrated urine during thirsting and 
maximally dilute urine after water loading (Figure 3A). Urine osmolality is 
determined by the degree of water reabsorption in the collecting duct through 
AQP2 water channels, which are stimulated by vasopressin (17). More recently, 
vasopressin was also shown to activate NCC (18). We first analyzed AQP2 and 
NCC expression in uEVs during the water loading experiment with the 
conventional method using immunoblotting of uEVs isolated with 
ultracentrifugation and normalized by urine creatinine (Figure 3B). Even after 
normalization by urine creatinine, which is another measure of urinary 
concentration, the decreased abundances of AQP2 and NCC after water 
loading were clearly visible, and likely represented a decrease in vasopressin 
levels in response to hypotonicity (17). We also tested aquaporin-3, which is 
also regulated by vasopressin, but did not detect it in uEVs (data not shown), 
possibly because it is present in the basolateral plasma membrane. We analyzed 
the same urine samples (without ultracentrifugation) with our uEV-
immunoassay using AQP2/CD9 and NCC/CD9 ratios, again showing the same 
pattern (Figure 3C). The uEV-immunoassay correlated with the conventional 
method for both AQP2 and NCC (Figure 3D). The correlation for AQP2 was 
stronger than for NCC, possibly because a few data points were near the 
detection limit (dilute urine) or because of differences in the quality of the 
antibody. To test whether the uEV-immunoassay could detect 
pathophysiological changes in AQP2 or NCC we tested it in patients. We 
selected patients with inherited or acquired disease in which AQP2 or NCC 
activity is disturbed, including nephrogenic or central diabetes insipidus, 
syndrome of inappropriate antidiuresis (SIAD), Gitelman syndrome, and 
familial hyperkalemic hypertension (FHHt, also called 
pseudohypoaldosteronism type 2 or Gordon syndrome). For most of these 
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disorders, lower or higher abundances of AQP2 or NCC have been shown by 
immunoblot in uEVs isolated with ultracentrifugation (19-21). We confirmed 
lower and higher uEV-AQP2 abundances in diabetes insipidus and SIAD 
(Figure 4A). Similarly, we confirmed lower and higher uEV-NCC abundances 
in Gitelman syndrome and FHHt. 
We then tested whether the same results could be obtained with our uEV-
immunoassay using whole urine and CD9 normalization. Indeed, the uEV-
immunoassay reliably recapitulated the expected changes in AQP2 and NCC in 
uEVs in these disorders (Figure 4B).  
 
 
 
DISCUSSION 
 
We report a novel approach to isolate and analyze uEVs using an 
immunoassay. Although immunoassays have been used previously for uEVs, 
these approaches usually concerned the quantification of a single protein (9, 11, 
22). Alvarez et al. used the commercially available ExoELISA to quantify CD9 
as measure of uEV-number (9). Duijvesz et al. developed a time-resolved 
fluorescence immunoassay to quantify the number of CD9+ or CD63+ uEVs as 
biomarker for prostate cancer (11). The fact that CD9+ uEVs also derive from 
prostate may be a limiting factor for our uEV-immunoassay as it may skew the 
AQP2/CD9 or NCC/CD9 ratio and may yield different results in men. 
However, in the study by Duijvesz et al., the number of CD9+ uEVs only 
increased after digital rectal examination (11), suggesting this limitation is 
minimal. Isobe et al. developed an ELISA to quantify both total and 
phosphorylated NCC in uEVs (22). However, because they did not use a 
capture antibody to isolate uEVs, their approach still required 
ultracentrifugation. Oosthuyzen et al. used a different approach by adding a 
fluorescently labeled AQP2 antibody to whole urine and then using a 
nanoparticle tracking device to quantify AQP2+ uEVs (16). By doing so, they 
confirmed an increase in AQP2+ uEVs after desmopressin in normal mice and 
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patients with central diabetes insipidus. The studies by Isobe et al. and 
Oosthuyzen et al. still required normalization by urine creatinine, because no 
uEV-marker was quantified (16, 22). We believe our uEV-immunoassay may be 
used as template for other proteins of interest. This requires the confirmation 
that the protein of interest is indeed present in CD9+ uEVs. Previous 
immunohistochemical studies in human kidneys demonstrated high CD9 but 
low CD63 expression (13). In our study CD9+ uEVs contained both AQP2 and 
NCC (Figure 1A), suggesting CD9 must be expressed in the distal convoluted 
tubule and collecting duct. If anti-CD9 will be used as capture antibody in 
future studies, it would be important to know which tubule segments express 
CD9.  
 
Alternatively, an antibody against AQP2 or NCC may be used as capture 
antibody to isolate tubule-specific uEVs, but this would require the 
development of antibodies targeting the extracellular domains of these proteins. 
Another consideration is that the pathophysiological setting by itself may 
change the number of CD9+ uEVs (11). Although there may be a 
subpopulation of CD9- vesicles that contains AQP2 or NCC, our uEV-
immunoassay results correlated with the ultracentrifugation method which 
isolates all uEVs (Figure 3D). We believe our method is most suitable for 
plasma membrane associated proteins, as cytosol-derived proteins within uEVs 
are likely lost after lysis, although this remains to be tested. In summary, we 
report a novel approach to analyze uEVs that circumvents existing isolation and 
normalization issues and that detects anticipated changes in physiological 
responses and clinical disorders.      
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Figure 3: Application of uEV-immunoassay in physiological AQP2 and NCC regulation 
(A) Urine osmolality (means ± SEM) during thirsting and water loading in four healthy subjects. 
Spot urine samples were measured in four subjects at five time points: 12h and 14h after 
thirsting (T1 and T2), and 2h, 3h, and 5h after water loading (WL1-3). * P < 0.05 by paired T-
test. 
(B) Representative immunoblot from one of the participants of AQP2 and NCC in uEVs 
isolated by ultracentrifugation. In addition, average densitometry of immunoblots from all 
participants (n = 4) is shown at the different time-points (means ± SEM). * P < 0.05 by paired 
T-test compared to T2 after setting all individual T2-values to 1.  
(C) AQP2/CD9 and NCC/CD9 ratios obtained with the uEV-immunoassay from urine samples 
of the water loading experiments (means ± SEM). * P < 0.05 by paired T-test compared to T2 
after setting all individual T2-values to 1.   
(D) Correlations of AQP2/UCreat vs. AQP/CD9 and NCC/UCreat vs. NCC/CD9 were plotted to 
compare immunoblotting of uEVs isolated with ultracentrifugation and results from uEV-
immunoassay. 
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Figure 4: Application of the uEV-immunoassay in disorders with disturbed AQP2 or NCC 
regulation 
(A) AQP2 and NCC were immunoblotted in uEVs isolated with ultracentrifugation. Urine 
samples were collected from healthy subjects (n = 4) and patients with central (CDI, n = 2) or 
nephrogenic (NDI, n = 2) diabetes insipidus, syndrome of inappropriate antidiuresis (SIAD, n = 
2), Gitelman syndrome (GS, n = 2), and familial hyperkalemic hypertension (FHHt, n = 1). See 
Methods for details. The second NDI patient did have a visible glycosylated AQP2-band that 
ran at a higher molecular weight, which may be due to the type of the mutation (mutation 
analysis pending).   
(B) AQP2/CD9 and NCC/CD9 signals obtained with uEV-immunoassay using the urine 
samples from the healthy subjects and patients. 
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ABSTRACT  
 
Purpose of review: To summarize studies that have analyzed sodium 
transporters in urinary extracellular vesicles (uEVs) in relation to hypertension.    
 
Recent findings: The majority of kidney sodium transporters are detectable in 
uEVs. Patients with loss or gain of function mutations in sodium transporter 
genes have concomitant changes in the abundances of their corresponding 
proteins in uEVs. The expected effects of aldosterone in the kidney, including 
activation of the sodium-chloride cotransporter (NCC) and epithelial sodium 
channel (ENaC), are transferred to uEVs as increases in phosphorylated NCC 
and the γ-subunit of ENaC. Specific forms of hypertension, including 
aldosteronism and pseudohypoaldosteronism, are characterized by higher 
abundances of total or phosphorylated NCC in uEVs. The proteolytic 
processing of ENaC by urinary proteases is detectable in uEVs as cleaved γ-
ENaC, as demonstrated in hypertensive patients with diabetic nephropathy. 
Analysis of uEVs from patients with essential or salt-sensitive hypertension 
identified potential candidates for uEV-markers of hypertension, including 
retinoic acid-induced gene 2 protein and hsa-miR-4516.  
 
Summary: Analysis of sodium transporters in uEVs is a promising approach to 
study renal epithelial transport processes non-invasively in human hypertension. 
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INTRODUCTION  
 
Extracellular vesicles (EVs) are nanosized vesicles released by all cells. Based on 
their biogenesis and size, they can be classified into exosomes, microvesicles, 
and apoptotic bodies (1). Due to their overlap in size and marker proteins, they 
are collectively referred to as EVs (which is the term we will use throughout this 
review) (2). Exosomes may closely reflect regulatory processes in the cell, 
because they are indirectly derived from the endosomal pathway, and are 
formed after fusion of multivesicular bodies with the plasma membrane (3). 
EVs have been identified and characterized in virtually all biofluids, including 
urine, and have been shown to contain protein, mRNA, miRNA, and DNA (3, 
4). EVs can be isolated using ultracentrifugation, filtration, or precipitation, 
allowing subsequent analysis with mass spectrometry, immunoblotting, or RNA 
sequencing (5). Novel methods including resistive pulse indexing and 
nanoparticle tracking analysis also allow characterization, counting and 
quantification of EVs (6). Transmission electron microscopy, however, is still 
the main technique used to verify that the sizes of isolated vesicles is indeed 
consistent with EVs (30 – 1000 nanometer). Protein mass spectrometry-based 
analysis of urinary extracellular vesicles (uEVs) has identified proteins derived 
from podocytes, all kidney tubule segments, the urinary tract, and the bladder 
(3, 7). In addition to biomarker discovery, analysis of uEVs may serve as non-
invasive tool to assess renal epithelial cell function in humans. In this context, 
uEVs are increasingly used for profiling of kidney sodium transporters (8, 9). 
Indeed, most sodium transport proteins on the apical plasma membrane have 
been identified in uEVs, including the sodium hydrogen exchanger (NHE3), 
sodium potassium chloride co-transporter (NKCC2), and sodium chloride co-
transporter (NCC) (3, 7). The epithelial sodium channel (ENaC) was more 
difficult to detect in uEVs until recently (9-11). Given the link between 
disturbed renal sodium handling and hypertension, the analysis of sodium 
transporters in uEVs may offer opportunities for pathophysiological or 
biomarker studies in human hypertension (4, 12, 13). This review will 
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summarize and discuss recent studies analyzing renal sodium transporters in 
uEVs.   
 
 
 
TEXT OF REVIEW 
	
Sodium transporters in uEVs 
Initial proteomic analysis of uEVs identified several renal sodium transporters 
(3, 7), raising a number of questions that have been partly addressed by more 
recent studies. For example, is lower or higher sodium transporter activity in 
the kidney always reflected by lower or higher abundance of this transporter in 
uEVs? Are post-translational modifications detectable in uEV-proteins? Does 
gender or circadian rhythm affect uEV-protein excretion? Is the hormonal 
control of sodium transporters reflected in uEVs?  
 
 
Key points 
• Extracellular vesicles are nanosized vesicles released by all cells and classified 
into exosomes, microvesicles, and apoptotic bodies. 
• The majority of renal sodium transporters have been identified in uEVs and 
their abundance in uEVs correlates with their kidney expression as influenced 
by hormonal regulation or disease states.  
• Aldosterone increases the phosphorylated form of the sodium-chloride 
cotransporter (NCC) and the γ-subunit of the epithelial sodium channel in 
human urinary extracellular vesicles (uEVs).  
• Several hypertensive disorders exhibit increased abundance of total or 
phosphorylated NCC in uEVs, including primary aldosteronism, familial 
hyperkalemic hypertension, and calcineurin-inhibitor induced hypertension.  
• In addition to the use of uEVs as biomarkers, uEVs may also play a biological 
role in paracrine signaling, innate immunity, and kidney injury repair.    
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uEVs in genetic disorders of renal sodium transport  
The question whether the altered activity of a transporter is also observed in 
uEVs was studied in monogenetic disorders of renal sodium transport. These 
studies were performed in patients with Bartter syndrome type 1 or Gitelman 
syndrome, which are caused by loss-of-function mutations in the genes 
encoding NKCC2 and NCC, respectively (3, 7). Corbetta et al. studied the 
genetic and biochemical characteristics of patients with Bartter type 1 or 
Gitelman syndrome and correlated this with NKCC2 and NCC abundances in 
uEVs (14). NCC abundance in isolated uEVs differentiated between patients 
with Gitelman syndrome from those with Bartter syndrome or controls, 
reaching a sensitivity and specificity >80%. A more severe genetic mutation 
(frameshift or large deletions) resulted in complete absence of NCC in uEVs, 
whereas less severe mutations (missense mutations) caused NCC abundance to 
be detectable at lower levels. Similarly, patients with Bartter syndrome type 1 
due to a frameshift mutation had a complete absence of NKCC2 in uEVs.  
 
Effects of hormones on sodium transporters in uEVs 
Genetic disorders are homogenous. Therefore, a next question was whether 
uEVs can also be used in more heterogeneous settings, for example hormone-
induced changes in protein levels. A logical focus in this regard is the renin-
angiotensin-aldosterone system (RAAS). Both NCC and ENaC are aldosterone 
and angiotensin II -sensitive proteins (15-17). We recently addressed the 
question whether an increase in aldosterone would translate to increased 
abundances of NCC and ENaC in uEVs (8) (Figure 1). We navigated the 
previous difficulties to detect ENaC in uEVs by analyzing the accessory protein 
prostasin. Prostasin is a serine protease that activates ENaC by cleaving the 
inhibitory tract of γ-ENaC (18, 19). In rats, we infused aldosterone via osmotic 
minipump and also increased it endogenously by feeding the animals a low 
sodium diet. Both maneuvers increased NCC and prostasin in kidney 
homogenates and in uEVs isolated from 24h urine. Aldosterone especially 
increased the phosphorylated (active) form of NCC, illustrating the ability to 
detect post-translational modifications in uEVs. This was recently also shown in 
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healthy subjects, in whom a low potassium diet increased phosphorylated NCC 
in uEVs, as it did in mouse kidney (20).  In addition to animal models of 
aldosteronism, we also studied phosphorylated NCC and prostasin in uEVs 
isolated from patients with primary aldosteronism (8). Indeed, both 
phosphorylated NCC and prostasin were increased in uEVs from these patients. 
Olivieri et al. analyzed prostasin in whole urine and in uEVs (21). Prostasin 
correlated positively with the aldosterone–renin-ratio and with urinary sodium 
levels up to 200 mmol/l. Prostasin decreased when urine sodium exceeded 200 
mmol/l, possibly reflecting suppression of aldosterone by a high sodium diet. 
No gender differences were identified. In a subsequent study, the same group 
identified a circadian rhythm in NCC and prostasin excretion, which decreased 
from early morning to noon, but then increased towards midnight (22). This 
pattern resembled the circadian rhythm of vasopressin and urinary aquaporin-2 
excretion, but not plasma renin, aldosterone, cortisol, or ACTH. This led the 
authors to conclude that NCC and prostasin exhibit diurnal variation, which 
may be determined by vasopressin, which can regulate both NCC and ENaC 
(23) (Figure 1). Qi et al. studied the effects of a low sodium diet and 
aldosterone infusion in healthy subjects and analyzed uEVs by mass 
spectrometry after these interventions (9). NCC, all ENaC-subunits, NKCC1, 
and the chloride-bicarbonate exchanger pendrin increased after the low sodium 
diet, but only γ-ENaC and pendrin remained significant after correction for 
multiple testing. The phosphorylated form of NCC was not detectable with the 
mass spectrometry methods used in this study. Of interest, the low sodium diet 
also increased a number of proteins and proteases involved in ENaC-activation, 
including furin, kallikrein, and elastase. Surprisingly, however, the abundance 
of prostasin in uEVs was unchanged. In addition to the low sodium diet, 
aldosterone infusion also increased γ-ENaC, or, more specifically, the γ-
ENaC[112-122] peptide (Figure 1). The increased excretion of γ-ENaC[112-122] after 
low sodium diet or aldosterone infusion correlated with both the plasma 
aldosterone concentration and the urine sodium to potassium ratio (a urine 
parameter reflecting aldosterone’s action on the kidney).  
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uEVs in hypertensive disorders 
uEVs have been analyzed in various hypertensive disorders, including familial 
hyperkalemic hypertension (FHHt), calcineurin inhibitor (CNI) induced 
hypertension, and primary aldosteronism, and mostly focused on NCC (10, 11, 
24-26) (Figure 1). The focus on NCC was rational when uEVs were analyzed in 
patients with familial hyperkalemic hypertension (FHHt, also called 
pseudohypoaldosteronism type 2 or Gordon syndrome) (24). FHHt is caused by 
mutations in kinases or ligase accessory proteins that ultimately regulate NCC 
activity, including WNK1, WNK4, kelch-like 3, and cullin 3 (27). NCC 
overactivity and a brisk antihypertensive effect of thiazide diuretics are 
considered hallmarks of FHHt (28, 29). The expected overactivity of NCC was 
reflected in uEVs, as total and phosphorylated NCC levels were increased in 
uEVs from patients with FHHt due to a WNK4 mutation (24, 30). Whether 
treatment with thiazide diuretics reduced the abundances of NCC was not 
studied. FHHt shares many features with calcineurin inhibitor (CNI) induced 
hypertension. CNIs are immunosuppressive drugs that are used after most 
transplantations to prevent rejection. The occurrence of hypertension after 
kidney transplantation is associated with poorer graft and recipient survival, 
illustrating the clinical importance of CNI-induced hypertension. Although 
CNIs increase vasoconstriction or impair vasodilation, more recent studies have 
indicated that NCC activation also contributes to CNI-induced hypertension 
(31, 32). In addition to hypertension, CNIs can also cause the additional 
tubular disorders seen in FHHt, including hyperkalemia, metabolic acidosis, 
and hypercalciuria (33). Rojas-Vega et al. studied 52 patients six months after 
kidney transplantation who were using the CNI tacrolimus (25). They found 
that male participants developed hypertension more frequently than female 
participants (49 vs. 18%), although this may have been due to included women 
being younger. In uEVs of hypertensive kidney transplant recipients both total 
and phosphorylated NCC abundances were increased 1.5- to 2-fold. In 
contrast, Esteva-Font et al. failed to identify higher NCC abundance in 39 
kidney transplant recipients taking cyclosporine when comparing them to 8 
patients who used a non-CNI immunosuppressive regimen after transplantation 
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(26). Of interest, a higher abundance of NKCC2 was observed in uEVs of these 
patients. NKCC2 but also NCC abundance in uEVs correlated with the trough 
levels of cyclosporine. The effect of cyclosporine on NKCC2 is in agreement 
with a recent study showing that cyclosporine increased phosphorylation of 
NKCC2 (34). Although both tacrolimus and cyclosporine inhibit calcineurin, 
they have different binding proteins and also differ in terms of side-effects, 
including nephrotoxicity, and diabetogenic effects (35). uEVs were also studied 
in hypertensive disorders characterized by increased sodium reabsorption 
through ENaC (10, 11). As proteolytic processing of γ-ENaC increases its open 
probability, it was postulated that this cleavage would be detectable in uEVs. 
Indeed, full length and cleaved γ-ENaC are detectable in uEVs (10, 11). In fact, 
in uEVs from healthy subjects, the fully cleaved form of γ-ENaC (37 kDa) is 
relatively more abundant compared to uncleaved γ-ENaC (11). The opposite 
pattern is seen in human kidney tissue (i.e., more uncleaved γ-ENaC). Salt-
sensitive hypertension in diabetics has been postulated to result from aberrantly 
filtered plasminogen, which is converted to plasmin in pre-urine. Plasmin may 
activate ENaC by proteolytic processing either directly or through prostasin. 
The phenomenon of ENaC activation by urinary proteases was studied in type 
1 diabetics with or without diabetic nephropathy (10). Patients with diabetic 
nephropathy had increased urinary excretion of plasmin, prostasin, and 
urokinase, which correlated with the degree of albuminuria. When cortical 
collecting duct cells were exposed to urine from these patients, this evoked an 
inward potential, suggesting electrogenic transport through ENaC. 
Proteolytically cleaved γ-ENaC was present in uEVs isolated from the diabetic 
nephropathy group but not from the control group, again suggesting ENaC-
activation. 
 
uEV biomarkers of hypertension 
Protein and miRNA biomarkers have also been studied in uEVs (36, 37). 
Damkjaer et al. compared the uEV-proteome of 11 male patients with essential 
hypertension to that of 12 matched healthy control subjects (36). They 
identified two proteins with lower abundances in uEVs isolated from the 
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patients with essential hypertension, including retinoic acid-induced gene 2 
protein (RAIG-2) and syntenin. It is unclear if these proteins directly relate to 
hypertension. Retinoic acid has been implicated in nephron endowment (38), 
which may determine predisposition to hypertension, whereas syntenin appears 
to be primarily involved in the biogenesis of uEVs (36). Gildea et al. studied 
miRNAs by microarray analysis in uEVs isolated from patients with salt-
sensitive, salt-resistant, or inverse salt-sensitive hypertension (37). 194 miRNAs 
were identified in the uEVs of these patients, 45 of which were significantly 
different between the salt-sensitive and salt-resistant individuals, or between the 
inverse salt-sensitive and salt-resistant subjects. However, hsa-miR-4516 was 
the only miRNA that could differentiate salt-sensitive from inverse salt-sensitive 
hypertension. Several of the identified miRNAs pointed in the direction of 
hypertensive pathways, including PPAR-γ, EGFR, TGF-β1, and PTEN/PI3K. 
EGFR regulates PPAR-γ-mediated sodium and water reabsorption via 
upregulation of NHE3 and aquaporin-1 (39). Furthermore, PPAR-γ has been 
implicated in the regulation of ENaC via SGK1 (40). TGF-β1 inhibits prostasin 
expression and may thereby reduce the open probability of ENaC (41, 42). 
Oxidative stress (H2O2) increases activation of ENaC by increasing PI3K and 
reducing PTEN (43). Similarly, PI3K is involved in the insulin-induced 
activation of NCC (44), while PPAR-γ decreases NCC activity in obese pre-
diabetic rats (45).  
	
Role of EVs beyond biomarkers 
An emerging field is the biological role of EVs in paracrine signaling, innate 
immunity, and kidney injury repair (46-49). For example, Street et al. studied 
whether a vasopressin-induced increase in the water channel aquaporin-2 could 
be transferred to other cells via EVs (49). When desmopressin-unexposed cells 
were incubated with EVs from desmopressin-exposed cells, water transport and 
AQP2 increased, suggesting that the signal to produce more AQP2 was 
transferred via EVs. Another question is if EVs may mediate inter-nephron 
crosstalk. Gildea et al. addressed this question in vitro by using cell lines from 
different tubular segments (47). Fluorescently labeled EVs derived from 
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proximal tubule cells were taken up by proximal tubule, distal tubule and 
collecting duct cells (47). When proximal tubule cells were exposed to 
fenoldopam (a dopamine receptor agonist), EV production increased and 
transfer of these EVs to distal tubule and collecting duct cells reduced the basal 
reactive oxygen species production in these recipient cells (47), again suggesting 
transfer of EV-content. Another recent finding is the potential role of EVs in the 
innate immune response to pathogens in the urinary tract (48). Proteomic 
profiling of uEVs identified several proteins related to the innate immune 
system, including mucin-1, myeloperoxidase, lysozyme C and dermcidin. uEVs 
were then studied in a lysis assay with Escherichia Coli, the organism most 
commonly responsible for urinary tract infection. In this assay, uEVs were 
shown to be capable of inducing lysis of Escherichia Coli in a dose-dependent 
fashion. Finally, EVs derived from mesenchymal stem cells may enhance the 
morphological and functional recovery from acute kidney injury, possibly 
through miRNAs (46).  
 
 
Figure 1: The formation of urinary extracellular vesicles in cells from the distal convoluted 
tubule (DCT) and cortical collecting duct (CCD). As shown, the process resembles the 
formation of one group of vesicles, namely exosomes. Urinary exosomes are formed via 
endocytosis of (membrane) proteins and subsequent fusion of multivesicular bodies with the 
plasma membrane (here indicated by arched arrow). The figure focuses on the activation of the 
sodium chloride cotransporter (NCC) and the epithelial sodium channel (ENaC) through 
phosphorylation and proteolytic cleavage by prostasin, respectively. The boxes show factors 
that increase phosphorylated NCC and cleaved γ-ENaC both in kidney and in uEVs.  
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CONCLUSION  
 
Analysis of sodium transport proteins in uEVs allows a read-out of renal 
epithelial sodium transport. In the studies reviewed, the direction of change in 
sodium transporter abundance in uEVs was identical to the expected change in 
the kidney, although few studies directly correlated kidney and uEV proteins. 
Aldosterone-induced post-translational modifications in sodium transporters, 
including phosphorylation and proteolytic processing, are detectable in uEVs. 
Sodium transporter analysis in uEVs has provided disease correlates for 
monogenetic disorders of sodium transport, aldosteronism, and CNI-induced 
hypertension. In addition to their role as potential biomarkers, uEVs may also 
be biologically active in paracrine signaling, the innate immune response, and 
kidney injury repair. 
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ABSTRACT 
 
Context: Increased renal sodium reabsorption contributes to hypertension in 
Cushing’s syndrome (CS). Renal sodium transporters can be analyzed non-
invasively in urinary extracellular vesicles (uEVs) and correlate with their 
activity in kidney. 
 
Objective: To analyze renal sodium transporters in uEVs of patients with CS.  
 
Design: Observational study in outpatients with newly diagnosed CS.  
 
Setting: University hospital. 
 
Patients and Interventions: uEVs were isolated by ultracentrifugation and 
analyzed by immunoblotting in 10 CS patients and 7 age-matched healthy 
subjects. In 3 CS patients uEVs were analyzed before and after treatment.  
 
Results: The 10 patients with CS were hypertensive, and were divided in those 
with suppressed and non-suppressed renin-angiotensin-aldosterone system 
(RAAS, n = 5/group). CS patients with suppressed RAAS had similar blood 
pressure but significantly lower serum potassium than CS patients with non-
suppressed RAAS. Compared to healthy subjects, all CS patients had increased 
abundance of the Na+/H+ exchanger type 3  (NHE3) in uEVs. In contrast, only 
those with suppressed RAAS had higher phosphorylated Na+-K+-Cl- 
cotransporter type 2 (pNKCC2) and higher total and phosphorylated Na+-Cl- 
cotransporter (NCC) in uEVs. Serum potassium but not urinary free cortisol 
correlated with pNKCC2, pNCC, and NCC in uEVs. Treatment of CS reduced 
pNKCC2, pNCC, and NCC abundances in parallel with serum potassium.  
 
Conclusions: CS increases renal sodium transporter abundance in uEVs 
especially in patients with suppressed RAAS. Potassium has recently been 
identified as an important driver of NCC activity. Therefore, in addition to 
excess glucocorticoids, low serum potassium may also contribute to increased 
renal sodium reabsorption and hypertension in CS.  
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INTRODUCTION  
 
A common clinical feature of Cushing’s syndrome (CS) is hypertension, which 
occurs in approximately 75% of patients (1,2). Due to the pleiotropic effects of 
glucocorticoids, the pathogenesis of hypertension in CS is believed to be 
multifactorial (3-8).  
 
In the kidneys, excess glucocorticoids increase renal blood flow and increase 
renal tubular sodium reabsorption (3). In fact, glucocorticoids have been shown 
to be capable of activating all of the major sodium transport proteins along the 
nephron (9-12). This includes the Na+/H+ exchanger type 3 (NHE3) in the 
proximal tubule (9), the Na+-K+-Cl- cotransporter type 2 (NKCC2) in the thick 
ascending limb of the loop of Henle (13), the Na+-Cl- cotransporter  (NCC) in 
the distal convoluted tubule (10), and the epithelial sodium channel (ENaC) in 
the collecting duct (3,11). In addition to these sodium transporters expressed at 
the apical plasma membrane, glucocorticoids can also increase activity of the 
basolateral Na+-K+-ATPase (14). Activation of these transport proteins may be 
mediated through activation of the glucocorticoid receptor, which is expressed 
throughout the nephron (3,15). In addition, supraphysiological concentrations 
of cortisol can overwhelm the capacity of 11β-hydroxysteroid dehydrogenase 
type 2 to inactivate cortisol to cortisone. This enables activation of the 
mineralocorticoid receptor with subsequent activation of NCC and ENaC. 
Because ENaC is electrochemically coupled to potassium secretion, CS may 
cause hypokalemic hypertension, similar to primary aldosteronism (16,17). 
However, mineralocorticoid receptor antagonists do not fully prevent 
hypertension in CS, suggesting that this mechanism does not fully explain 
hypertension in CS (16,18).  
 
The effects of glucocorticoids on renal sodium transport have mainly been 
studied in vitro and in experimental animals (9-11,13,14). Urinary extracellular 
vesicles (uEVs) are nanosized vesicles that can be isolated from human urine 
and contain most renal transport proteins (19). Thus, isolation of uEVs in 
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healthy subjects and patients now allows for a non-invasive analysis of renal 
sodium transport. Previously we confirmed both in rats and humans that 
aldosterone activation of sodium transporters in the kidney results in 
corresponding changes of these transporters in uEVs (20). In the present study, 
we analyze several of the renal sodium transport proteins in uEVs isolated from 
patients with CS and hypertension. In addition to total abundances, we also 
analyze the phosphorylated forms of NCC and NKCC2, which are considered 
the active forms of these transporters (21). Because ENaC is difficult to analyze 
in uEVs, we instead analyzed one of its activating serine proteases, prostasin, as 
has been done previously (20,22). Finally, we analyzed the pleiotropic kinase 
Rac1, because it has been considered a measure of mineralocorticoid receptor 
activity, and is detectable in uEVs (23,24).   
 
	
 
MATERIALS AND METHODS 
 
Patients  
Our Medical Ethics Committee approved this study (MEC-2007-048). 
Consecutive patients who were newly diagnosed with CS in our center were 
considered for inclusion during the period 2012–2015. To analyze renal sodium 
transporters in uEVs, we excluded patients who were using interfering 
medication (renin-angiotensin inhibitors or diuretics). Although beta-blockers 
may increase plasma renin, this effect is considered less strong, and these drugs 
were therefore allowed. Using these criteria, we included 10 out of the 18 
patients who were newly diagnosed with CS. Patients with CS were further 
subdivided in those with or without suppressed plasma renin-angiotensin 
aldosterone system (RAAS). The rationale for this was that patients with 
suppressed RAAS are more likely to have increased renal sodium reabsorption, 
which may be reflected in uEV transporter status. In 3 of the 10 patients uEVs 
were analyzed before and after treatment. Seven patients were excluded from 
further analysis, including four who were started on interfering medication 
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(renin-angiotensin inhibitors or diuretics), and three in whom no remission was 
reached at the end of the study period. Healthy subjects were recruited and 
matched by age (age 44 ± 3 years; 3 men, 4 women); they did not use any drugs 
and had no hypertension or history of endocrine disorders. 
	
Measurements 
Blood pressure was measured in supine position using an automatic 
oscillometric device for at least 15 minutes; the average of the last three 
measurements was used for analysis. Hypertension was defined as systolic 
blood pressure of ≥ 135 mmHg and/or diastolic blood pressure of ≥ 85 mmHg 
(25). Both 24-hour urine and spot urines were collected. Plasma and urine 
electrolytes were measured using an ion-selective electrode (ISE indirect, Cobas, 
Roche Diagnostics, Mannheim, Germany). Creatinine was measured using an 
enzymatic colirometric method (Crep2, Cobas, Roche Diagnostics). Renin in 
plasma was measured using an immunoradiometric kit (Cisbio Bioassays, 
Codolet, France). Aldosterone was measured by solid-phase radioimmunoassay 
(Diagnostic Products Corporation, Los Angeles, California, USA) and cortisol 
was measured using liquid chromatography coupled to mass spectrometry. 
Urinary free cortisol is expressed as the fold elevation above the upper limit of 
normal. 
 
Isolation and immunoblotting of uEVs 
Spot urines were treated with a protease inhibitor (Roche Complete, Woerden, 
The Netherlands) and centrifuged (3000 x g for 5 minutes) to remove cells and 
cell debris before storage at -80 °C. uEVs were isolated using high-speed and 
ultracentrifugation, as described previously (26). Briefly, urine was first 
centrifuged at 17,000 x g for 15 minutes to pellet high-density particles, 
separating the supernatant (supernatant 1). Dithiothreitol was then used to 
disrupt the Tamm-Horsfall polymers, after which the samples were diluted in 
isolation buffer and centrifuged at 17,000 x g (supernatant 2). The two 
supernatants were then ultracentrifuged at 200,000 x g for 2 hours. The pellets 
were suspended in Laemmli buffer for immunoblot analysis, and subsequently 
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heated at 60 °C for 15 minutes. uEVs of CS patients and healthy control 
subjects were isolated simultaneously. Urine creatinine was used for 
normalization of spot samples, as done previously. SDS-PAGE was carried our 
on a gradient gel (4-20%) after which the gel was transferred to trans-blot 
turbo system (Bio-Rad, Hercules, CA, USA). The membranes were blocked in 
5% milk and incubated overnight at 4 °C. Antibodies against the following 
proteins were used: NHE3 (1:1000, Stressmarq; (27)), NCC (1:1000, 
Stressmarq; (28)), pNCC (1:500, kindly provided by Dr. Fenton; (29)), NKCC2 
(1:1000, kindly provided by Dr. Knepper; (30)), (1:2000, kindly provided by 
Dr. Mutig; (31)), Rac1 (1:500, Millipore; product # 05-389, (32)), (1:1000, 
AQP2, Stressmarq; (33)), Na+/K+-ATPase (1:250, Abcam; product # ab7671), 
CD9 (1:500, Santa Cruz Biotechnology; product # sc-13118). Secondary 
antibodies were peroxidase conjugated goat anti-rabbit or mouse (1:3000, 
Sigma-Aldrich). 
 
Statistical analysis  
Results are expressed as mean and standard deviation or median and range, as 
appropriate. Data were logarithmically transformed before analysis in case of 
non-normal distribution. Student’s t-test or analysis of variance (ANOVA) was 
used for group comparison. A paired t-test was used to analyze effects in uEVs 
before and after treatment. A P-value < 0.05 was considered statistically 
significant. Statistical analyses were performed with SPSS (version 21, IBM).  
 
 
 
RESULTS 
	
Patient characteristics 
Ten patients with CS were recruited of whom the majority had an ACTH-
producing pituitary adenoma (1 macroadenoma, 7 microadenoma) (Table 1). 
The average blood pressure was elevated (systolic blood pressure 144 ± 14 
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mmHg, diastolic blood pressure 92 ± 17 mmHg). Two patients used 
metoprolol. The ten patients with CS were further divided in those with 
suppressed RAAS and those with non-suppressed RAAS (Table 1). CS patients 
with suppressed RAAS had significantly lower body mass index, higher 
estimated glomerular filtration rate, and lower serum potassium levels. No 
differences in blood pressure were observed between the two groups.  
 
Cushing’s syndrome increases renal sodium transporters in uEVs 
Compared to healthy subjects, patients with CS expressed more NHE3 in uEVs 
regardless of whether RAAS was suppressed or not (Figure 1). The abundance 
of NHE3 was approximately two-fold higher in uEVs of patients with CS. In 
contrast, total NCC and the phosphorylated forms of NCC and NKCC2 were 
only more abundant in uEVs of patients with CS and a suppressed RAAS. In 
these patients, the uEV abundances of NCC and NKCC2 were increased three- 
to four-fold. None of the other analyzed proteins in uEVs showed significant 
differences in abundance, including aquaporin-2, Rac1, and prostasin.  
 
Serum potassium determines sodium cotransporter status in uEVs 
Although still in the normal range, serum potassium was significantly lower in 
patients with CS and suppressed RAAS (Table 1). Serum potassium has recently 
been recognized as an important driver of NCC activity (34,35). Therefore, we 
analyzed the correlation between serum potassium and aldosterone and serum 
potassium and the NKCC2 and NCC, which were upregulated in uEVs of 
patients with CS and a suppressed RAAS (Figure 1). Plasma aldosterone 
correlated with serum potassium (Figure 2). However, plasma aldosterone 
levels were suppressed despite serum potassium concentrations in the normal 
range. This suggests that cortisol exerted a mineralocorticoid effect, thereby 
both lowering plasma aldosterone and serum potassium. Furthermore, serum 
potassium negatively correlated with NCC, pNCC, and pNKCC2 abundances 
in uEVs. No correlation was observed between urinary cortisol levels, NCC, 
pNCC and pNKCC2. 
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Table 1: Clinical characteristics, blood, and urinary measurements of patients with Cushing’s 
syndrome with or without suppressed renin-angiotensin-aldosterone system (RAAS). BMI, body 
mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; N.T., not tested; 
ULN, upper limit of normal. *Average of two measurements.  
	
 
	
 
	
 
 
Parameters All patients  
(n = 10) 
Suppressed RAAS 
(n = 5) 
Non-suppressed RAAS 
(n = 5) 
P-value 
Clinical     
Age, years 43.2 ± 7.8 40.8 ± 10.9 45.6 ± 2.3 0.4 
Male gender, n (%) 2 (20) 2 (20) 3 (43) 0.6 
BMI, kg/m2 29 ± 8 24 ± 3 34 ± 8 0.02 
Cause of Cushing     
• Pituitary adenoma, n (%) 8 (80) 3 (60) 5 (80) 0.5 
• Adrenocortical adenoma, n (%) 2 (20) 2 (40) 0 0.2 
Systolic BP, mmHg 144 ± 14 141 ± 18 147 ± 11 0.5 
Diastolic BP, mmHg 92 ± 17 89 ± 23 96 ± 11 0.5 
Blood     
Sodium, mmol/L 141 ± 3 142 ± 3 140 ± 2 0.2 
Potassium, mmol/L 4.2 ± 0.4 3.9 ± 0.2 4.4 ± 0.3 0.04 
eGFR, mL/min/1.73 m2 94 ± 18 107 ± 10 80 ± 12 < 0.01 
Renin, uU/mL 18.5 (7.1–89.3) 9.7 (7.1–16.6) 41.5 (16.9–89.3) N.T. 
Aldosterone, pg/mL 40.8 (10.0–187.0) 23.5 (10.0–45.0) 81.3 (13.0–187.0) N.T. 
Urine     
Sodium, mmol/day 196 (138 – 273) 196 (138 – 273) 196 (173 - 247) 0.1 
Free cortisol, x ULN* 1.9 (0.3 – 6.1) 2.0 (0.3 – 6.1) 1.6 (1.0 – 2.3) 0.4 
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Figure 1A: Immunoblot analysis of renal sodium transporters and related proteins in urinary 
extracellular vesicles from patients with Cushing’s syndrome (CS) and healthy subjects. 
Patients with CS were divided based on a suppressed (S) or non-suppressed (NS) renin-
angiotensin-aldosterone system (RAAS).  
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Figure 1B: Group comparisons of immunoblot densitometry were performed with analysis of 
variance using log-transformed data of optical densitometries (OD). * P < 0.01.  
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Figure 2: Correlations between the serum potassium concentration and aldosterone (panel A) 
and serum potassium, pNKCC2, pNCC, and NCC (panel B) in uEVs of patients with Cushing’s 
syndrome. 
 
 
 
 
Effect of treatment 
Three patients were successfully treated during the study period and in these 
patients uEVs were analyzed before and after treatment. Patient 1 (non-
suppressed RAAS) was treated by unilateral adrenalectomy, while patients 2 
and 3 (both suppressed RAAS) were treated by ketoconazole. In all patients, 
serum potassium increased after treatment from 4.0 ± 0.3 to 4.4 ± 0.06 mmol/l. 
In uEVs, the abundances of pNKCC2, NCC, pNCC and Rac1 decreased 
significantly after treatment (2.0 to 2.6-fold, all P < 0.05, Figure 3).  
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Figure 3A: Immunoblot analysis of renal sodium transporters and related proteins in uEVs 
from patients with Cushing’s syndrome before (B) and after (A) treatment. 
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Figure 3B: The log-transformed optical densitometries (OD) were analyzed using a paired t-test 
in which the post-treatment (after) abundances were set at 1. * P < 0.05. 
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renal sodium transport proteins and reflect their activity in kidney 
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included in this study had a higher abundance of NHE3 in uEVs compared to 
healthy subjects. In contrast, only CS patients with a suppressed RAAS had 
increased abundances of NKCC2 and NCC. Of interest, this activation of 
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hypercortisolism, but rather an indirect effect induced by reduced serum 
potassium concentration. This is supported by the observation that these 
transporter abundances reduced after treatment in parallel with an increase in 
serum potassium. Indeed, potassium has recently been identified as a major 
driver of NCC activity (34,35,38,39). Our results are in perfect agreement with 
recent experimental and clinical studies showing a linear relationship between 
the serum potassium concentration and NCC expression in kidney and uEVs 
(38,40). This effect of potassium appears to be specific for NCC and it is 
therefore unclear if the observed relation between serum potassium and 
pNKCC2 can be explained by similar mechanisms (34).  
 
Together, this proof-of-principle study provides insight in renal sodium 
handling during CS and the pathogenesis of hypertension in CS (summarized in 
Figure 4). Previous studies on hypertension in CS also showed that some 
patients with CS have a suppressed RAAS, whereas others do not (41-45). 
Indeed, several mechanisms contribute to hypertension in CS. In addition to 
effects on renal sodium reabsorption, hypercortisolism can also increase the 
peripheral vascular sensitivity to adrenergic agonists (46), and the production of 
angiotensinogen by the liver (44). The increased uEV abundances of NHE3, 
pNKCC2, pNCC, and NCC in CS observed in this study merit further 
discussion. The stimulatory effect of glucocorticoids on NHE3 has long been 
recognized (47), and is likely mediated through serum and glucocorticoid 
inducible kinase 1 and the scaffold protein NHERF2 (9,48-50). Glucocorticoid-
mediated NHE3 activation may contribute to hypertension, because it limits 
pressure natriuresis (51). Based on our data, increased NHE3 activity appears a 
rather universal finding in patients with CS. Tubuloglomerular feedback can 
compensate for increased sodium reabsorption through NHE3 in the proximal 
tubule, which may explain why increased NHE3 uEV-abundance was also 
observed in patients without suppressed RAAS. The more selective increase of 
pNKCC2, pNCC, and NCC in uEVs of patients with CS and a suppressed 
RAAS, suggests that increased sodium reabsorption through these transporters 
contributed to an increase in extracellular fluid volume (and therefore 
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suppression of the RAAS). This may also explain the higher estimated 
glomerular filtration rate. The glucocorticoid activation of NCC is well 
described. In adrenalectomized rats, Velazquez et al. showed that both 
aldosterone and dexamethasone increased NCC-mediated sodium reabsorption 
fivefold (10). More recently, Ivy et al. showed that glucocorticoids cause 
nondipping of blood pressure via NCC activation (52). Glucocorticoid and 
mineralocorticoid receptors are expressed in the distal convoluted tubule, and 
activation of these receptors could therefore explain NCC activation (3). 
However, recent data indicate that NCC activation may occur indirectly via 
potassium. For example, Veiras et al. showed that angiotensin II stimulates 
sodium-potassium exchange through ENaC and the potassium channel ROMK 
(53). This results in potassium deficiency and thereby NCC activation (53). 
Wolley et al. confirmed this mechanism clinically in patients who were screened 
for primary aldosteronism using the fludrocortisone test (40). Similar to our 
data, they also showed that serum potassium was strongly and negatively 
correlated with pNCC and NCC in uEVs (40). Similarly, glucocorticoids may 
have activated ENaC and ROMK with increased potassium secretion and a 
decrease in serum potassium (11,13,54).  Unfortunately, ENaC is difficult to 
analyze in uEVs (55). We used prostasin as surrogate marker for ENaC, but 
found no consistent effect of glucocorticoids. However, ENaC activation is not 
universally accompanied by an increase of prostasin in uEVs, as recently shown 
by Qi et al (56). Finally, it is unclear how to explain the increase in pNKCC2. 
In adrenalectomized rats, Stanton did not observe that glucocorticoids increased 
sodium reabsorption in the thick ascending limb (57). Frindt and Palmer, 
however, did show an increase in NKCC2 in dexamethasone treated rats (11).  
	
A number of limitations should be mentioned. First, this was a proof-of-
principle study in a small number of patients. Because this was an observational 
study we could not discontinue anti-hypertensive drugs and therefore excluded 
patients already on renin-angiotensin inhibitors or diuretics. However, one 
could argue that the effects in these patients may have been even stronger. 
Second, although several groups have shown that transporter analysis in uEVs 
Urinary Extracellular Vesicles: Biomarkers and beyond 
 
94 
correlates with their activity in the kidney (19,20,36,37), this still remains an 
indirect measure of true transporter activity. We tried to address this by 
analyzing the phosphoproteins of the transporters, which are generally 
considered the active forms (21).  
In conclusion, CS increases renal sodium transporter abundance in uEVs 
especially in patients with suppressed RAAS. In addition to excess 
glucocorticoids, low serum potassium may also contribute to increased renal 
sodium reabsorption and hypertension in CS. 
 
 
Figure 4: Proposed model for the pathogenesis of hypertension in Cushing’s syndrome 
including vascular and renal effects. The contribution of activation of renal sodium transport is 
partly based on the results in this study.  
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ABSTRACT  
	
Urinary exosomes are vesicles derived from renal tubular epithelial cells. 
Exosomes often contain several disease-associated proteins, and are thus useful 
targets for identifying biomarkers of disease. Here, we hypothesized that the 
phosphorylated (active) form of the sodium chloride cotransporter (pNCC) or 
prostasin could serve as biomarkers for aldosteronism. We test this in two 
animal models of aldosteronism (aldosterone infusion or low sodium diet) and 
in patients with primary aldosteronism. Urinary exosomes were isolated from 
24-hour urine or spot urine using ultracentrifugation. In rats, a normal or a 
high dose of aldosterone for two, three or eight days increased pNCC 3-fold in 
urinary exosomes (p < 0.05 for all). A low sodium diet also increased pNCC in 
urinary exosomes approximately 1.5-fold after four and after eight days of 
treatment. The effects of these maneuvers on prostasin in urinary exosomes 
were less clear, showing a significant 1.5-fold increase only after two and three 
days of high aldosterone infusion. In urinary exosomes of patients with primary 
aldosteronism, pNCC was 2.6-fold higher (p < 0.05) while prostasin was 1.5-
fold higher (p = 0.07) than in patients with essential hypertension. Urinary 
exosomal pNCC and, to a lesser extent, prostasin are promising markers for 
aldosteronism in experimental animals and patients. These markers may be 
used to assess the biological activity of aldosterone and potentially as clinical 
biomarkers for primary aldosteronism.  
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INTRODUCTION 
	
Urinary proteins originate from various sources. They may be derived from 
glomerular filtration, tubular secretion, shedding, glycosylphosphatidyl inositol 
anchored protein detachment (e.g., Tamm-Horsfall protein), or exosome 
secretion (1). Exosomes are low-density membrane vesicles that originate from 
multivesicular bodies. Urinary exosomes have sparked interest as potential 
biomarkers for human disease (1-3). The presence of urinary exosomes and a 
reproducible method for their isolation was reported in 2004 by Pisitkun and 
colleagues (4). Proteomic analysis of these exosomes showed that they contain 
many disease related proteins (4, 5). However, the question remained whether 
the presence of a given protein in urinary exosomes could provide information 
on physiological or disease processes in the kidney. Studies addressing this 
question analyzed urinary exosomes in patients with monogenetic diseases 
resulting in inactivity or overactivity of renal sodium transport proteins. For 
example, in Bartter and Gitelman syndrome, in which the sodium potassium 
chloride cotransporter (NKCC2) and the sodium chloride cotransporter (NCC) 
are genetically inactivated, these proteins were also found to be absent or 
reduced in urinary exosomes (5, 6). Conversely, Mayan et al. found the 
abundance of the sodium chloride cotransporter (NCC) to be increased in 
patients with familial hyperkalemic hypertension, in which mutations in NCC-
regulating kinases cause overactivity of this cotransporter (7). Thus, in these 
homogeneous groups the expression of sodium transport proteins in urinary 
exosomes correlated with what one would expect from their renal expression. 
The next step in assessing the potential of exosomes as urinary biomarkers is to 
analyze their performance in acquired disease. Therefore, in this study, we 
asked whether various forms of aldosteronism resulted in increased expression 
of aldosterone-sensitive proteins in urinary exosomes. To address this question, 
we used animal models of primary and secondary aldosteronism and also 
studied patients with primary aldosteronism. In the kidney, the two main 
sodium transporters activated by aldosterone are NCC and the epithelial 
sodium channel (ENaC) (8, 9). It therefore appears logical to study NCC and 
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ENaC in urinary exosomes in different forms of aldosteronism. Esteva-Font et 
al., however, found no difference in the abundance of NCC in urinary 
exosomes of patients with salt-sensitive hypertension (10). Recently, it has 
become clear that the phosphorylated form of NCC (pNCC) represents the 
active form of NCC and that trafficking and phosphorylation of NCC can be 
regulated independently (11). Therefore, we propose that pNCC is a better 
reflection of NCC’s biological activity. ENaC is difficult to study in urinary 
exosomes because it is present in very low quantities (4). Instead, prostasin has 
emerged as an interesting surrogate marker of ENaC activity (12). Prostasin is a 
serine protease that can increase the activity of ENaC and is also sensitive to 
aldosterone (13). Here, we test the hypothesis that pNCC and prostasin in 
urinary exosomes are markers for aldosteronism.  
 
	
 
METHODS 
	
Animal studies 
All animal protocols were approved by the Animal Care Committee of the 
Erasmus University Medical Center Rotterdam (EUR 127-11-01 and EUR 127-
10-11). Three studies were conducted. In the first study, ten 15-week old male 
Sprague-Dawley rats (Charles River, Sulzfeld, Germany) were adrenalectomized 
via a bilateral lumbodorsal incision and randomized to receive either high-dose 
aldosterone (100µg/kg/day) or vehicle via osmotic minipump (subcutaneous 
insertion, Alzet, Cupertino CA, USA). All rats also received glucocorticoid 
replacement (dexamethasone, 5µg/kg/day) and an angiotensin receptor blocker 
(losartan, 10 mg/kg/day) to inhibit the effects of angiotensin II on pNCC and 
prostasin (14, 15). The second study was similar to the first one, but now 
included a third group of five rats that received a normal dose of aldosterone 
(50 µg/kg/day) (16). In addition, this study lasted for eight days instead of three 
days. In the second study, we also harvested the right kidney for 
immunoblotting analysis. In the third study twelve rats were randomly assigned 
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to receive a normal (0.5%) or low (0.001-0.002%) sodium chloride diet for 
eight days (Harlan diets, Harlan Laboratories, Venray, The Netherlands). In all 
three experiments, animals were housed in metabolic cages to collect 24-hour 
urine for isolation of urinary exosomes. Urinary exosomes were isolated at 
various time-points in the three studies (days 1, 2, and 3 in the first study, day 8 
in the second study, and days 0, 4, and 8 in the third study). Finally, at the end 
of each experiment, plasma renin and aldosterone as well as urine sodium were 
measured.  
 
Studies in patients 
Five patients with primary aldosteronism and four patients with essential 
hypertension were randomly selected from an ongoing study on primary 
aldosteronism (17). Briefly, patients were eligible to participate in this study 
when they had uncontrolled hypertension despite the use of at least two 
antihypertensive drugs. All patients were subjected to volume expansion (two 
litres of 0.9% NaCl during four hours) to analyze whether aldosterone was 
suppressible. Primary aldosteronism was defined as unsuppressible plasma 
aldosterone (> 235 pmol/L) after volume expansion. The patients whose post-
test aldosterone was below 235 pmol/L were considered to have essential 
hypertension. In all patients, spot urine was collected under controlled 
circumstances for isolation of urinary exosomes. Urine sodium, potassium, and 
creatinine concentrations were measured as well.  
 
Isolation and immunoblot analysis of urinary exosomes 
Urinary exosomes were isolated as reported previously (4, 18, 19); a more 
detailed protocol is provided as Online Supplement. Briefly, all urine samples 
were treated with a protease inhibitor prior to storage at –80ºC; no 
phosphatase inhibitors were used. Urinary exosomes were isolated using a two-
step centrifugation process. First, urine was centrifuged at 17,000 x g for 15 
minutes at 37ºC to remove whole cell membranes and other high density 
particles. Subsequently, the samples were subjected to ultracentrifugation at 
200,000 x g for 105 minutes at 25ºC. The pellet that formed during 
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ultracentrifugation was suspended in isolation buffer and dithiothreitol to 
disrupt the Tamm-Horsfall polymeric network (18). Finally, the suspended 
pellets were solubilized in Laemmli buffer for immunoblot analysis. 
Immunoblotting of the urinary exosomes and kidney samples was performed as 
described previously (see also Online Supplement) (8). The antibody against 
NCC phosphorylated at threonine 58 was generated by one of the 
inverstigators (RAF) and has been characterized previously (20). All other 
antibodies were obtained: prostasin (BD biosciences, Breda, The Netherlands) 
and NCC (Stessmarq biosciences, Victoria, Canada).  For the animal studies, 
the complete volume of the 24-hour urine was used to isolate urinary exosomes, 
and therefore no normalization was used in the analysis. Coomassie blue 
staining was used to confirm that there were no differences in total protein 
contents. Conversely, for the patient study, the amount of sample loaded during 
immunoblotting was normalized by the urinary creatinine concentration (1).  
 
Statistics 
All data are expressed as mean ± standard error of the mean. Group 
comparisons were made using the unpaired Student’s T-test or analysis of 
variances with a post-hoc test, as appropriate. For analysis, the natural 
logarithm of the plasma aldosterone concentration was used to yield a normal 
distribution. P ≤ 0.05 was considered statistically significant. 
 
 
 
RESULTS 
	
Three-day infusion of aldosterone increased pNCC and prostasin in urinary 
exosomes 
Adrenalectomized rats were infused with high-dose aldosterone or vehicle for 
three days. The differences in plasma aldosterone and urinary sodium between 
the two groups confirmed that both the adrenalectomy and the infusion of 
aldosterone were successful (Figure 1A). The infusion of aldosterone 
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significantly increased pNCC, NCC, and prostasin in urinary exosomes on days 
2 and 3 (Figure 1B). The abundance of pNCC in urinary exosomes increased 
2.9 ± 0.4 fold on day 2 and 3.2 ± 0.3 fold on day 3 (p < 0.05 for day 2 and p 
<0.01 for day 3). The abundance of NCC in urinary exosomes also increased 
2.3 ± 0.4 fold on day 2 and 1.8 ± 0.4 fold on day 3 (p < 0.05 for both).  The 
abundance of prostasin in urinary exosomes increased 1.8 ± 0.2 fold on days 2 
and day 3 (p < 0.05 and p < 0.01, respectively).  
 
Effects of an eight-day infusion of aldosterone on pNCC and prostasin in 
kidney and urinary exosomes 
Adrenalectomized rats were infused with vehicle, a normal or a high dose of 
aldosterone for eight days. The plasma aldosterone concentrations were 
significantly different among the three groups (Figure 2A). Both the normal and 
high aldosterone dose increased the abundance of pNCC and NCC in urinary 
exosomes (Figure 2B). pNCC increased 3.0 ± 0.4 fold with the normal dose and 
2.5 ± 0.5 fold with the high dose (p < 0.01 and p < 0.05, respectively); NCC 
increased only with the normal dose (1.5 ± 0.2 fold, p < 0.05). Although pNCC 
and NCC in exosomes showed similar responses to aldosterone compared with 
the abundances of these proteins in the kidney23, no direct correlation was 
observed (data not shown). In contrast to the three-day infusion (Figure 1C), 
the eight-day infusion of aldosterone did not increase prostasin in urinary 
exosomes. In kidney, only the high aldosterone dose increased prostasin 
significantly (1.5 ± 0.1 fold, p < 0.05).   
	
A low salt diet increased pNCC but not prostasin in urinary exosomes  
To induce a physiological increase in plasma aldosterone, two groups of rats 
were fed a normal sodium diet, after which one group was switched to a low 
sodium diet. The low sodium diet caused a higher plasma renin activity and 
higher plasma aldosterone after eight days (Figure 3A). When both groups were 
on the normal sodium diet, the abundance of pNCC and NCC in urinary 
exosomes was similar (Figure 3B). The low sodium diet increased pNCC in 
urinary exosomes on day 4 (1.7 ± 0.2 fold) and day 8 (1.4 ± 0.1 fold, p <0.05 
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for both). The low sodium diet increased NCC in urinary exosomes on day 4 
(1.5 ± 0.1 fold) and day 8 (2.0 ± 0.3 fold, p < 0.05 for both). In contrast, it did 
not cause significant changes in the abundance of prostasin in urinary exosomes 
(Figure 3C).  
 
pNCC and prostasin are increased in urinary exosomes of patients with 
primary aldosteronism   
The characteristics of five patients with primary aldosteronism and four 
patients with essential hypertension are shown in Figure 4. Both groups had a 
similar degree of hypertension, but had significant differences regarding the 
plasma aldosterone to renin ratio and the urine sodium to potassium ratio. The 
abundance of pNCC in urinary exosomes of patients with primary 
aldosteronism was higher in patients with essential hypertension (2.6 ± 0.3 fold, 
p < 0.05, Figure 4). The abundance of prostasin in urinary exosomes showed a 
trend towards being higher in the patients with primary aldosteronism (1.5 ± 
0.3 fold, p = 0.07). 
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Figure 1: Effects of chronic aldosterone infusion in rats on the abundances of pNCC and 
prostasin in urinary exosomes. Adrenalectomized rats were treated with high-dose aldosterone 
(Aldo-H, 100 µg/kg/day) or vehicle (control) for three days. A: plasma aldosterone and urine 
sodium. B: pNCC and NCC in urinary exosomes. C: prostasin in urinary exosomes 
* p < 0.05, ** p < 0.01, *** p < 0.001 by Student’s T-test 
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Figure 2: Effects of normal and high aldosterone infusion in rats for eight days on plasma 
aldosterone, pNCC and prostasin in kidney and urinary exosomes. Adrenalectomized rats 
were infused with vehicle (control), normal (Aldo, 50 µg/kg/day) or high-dose (Aldo-H, 100 
µg/kg/day) aldosterone for 8 days. A: plasma aldosterone concentrations. B: pNCC and NCC in 
urinary exosomes. C: prostasin abundance in kidney and urinary exosomes. * p < 0.05, ** p < 
0.01, *** p < 0.001 by analysis of variance and post-hoc test 
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Figure 3: A low salt diet increased pNCC but not prostasin in urinary exosomes of rats. A: 
plasma renin activity and plasma aldosterone. B: pNCC and NCC in urinary exosomes. C: 
prostasin in urinary exosomes. * p < 0.05, by Student’s T-test 
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Figure 4: Patients with primary aldosteronism show increased abundance of pNCC and 
prostasin in urinary exosomes. A: Characteristics of patients with essential hypertension (EH) 
or primary aldosteronism (PA). B: Patients with primary aldosteronism show increased 
abundance of pNCC and prostasin in urinary exosomes 
* p < 0.05 by Student’s T-test /or Mann-Whitney 
 
 
 
DISCUSSION 
 
In this study we asked whether NCC and prostasin in urinary exosomes can be 
used as markers for primary and secondary aldosteronism. In our hands, both 
total and phosphorylated NCC were superior to prostasin as a marker for 
aldosteronism . In fact, the abundance of prostasin in urinary exosomes only 
increased during high-dose, short-term treatment with aldosterone (Figure 1C), 
whereas the abundance of pNCC in urinary exosomes was higher during 
aldosteronism regardless of the duration, dose or stimulus (Figure 5). Because 
A
B
      EH                PA
pNCC (150kDa)
Prostasin (40kDa)
Chapter 6 | The Phosphorylated Sodium Chloride Cotransporter in Urinary Exosomes  
is Superior to Prostasin as a Marker for Aldosteronism 
 
 
 
111 
the changes in pNCC were more pronounced than for NCC, pNCC appears the 
better marker. In addition, pNCC was increased significantly in urinary 
exosomes of patients with primary aldosteronism compared to patients with 
essential hypertension (Figure 4). In contrast, the increase in the abundance of 
prostasin in urinary exosomes of patients with primary aldosteronism was of 
borderline significance.  
Several observations regarding the dynamics of pNCC and prostasin excretion 
in urinary exosomes during aldosteronism observed in this study merit 
discussion. For example, the results of the short-term infusion of aldosterone in 
rats suggest that it takes at least one day for both pNCC and prostasin to 
increase in urinary exosomes (Figure 1). This may be related to the time it takes 
aldosterone to increase transcription or post-translational modification of these 
proteins (21). The long-term infusion of aldosterone in rats showed that a lower 
(“physiological”) dose of aldosterone was already sufficient to increase pNCC 
(Figure 2B). In fact, pNCC expression in urinary exosomes was slightly lower 
with the high dose. This suggests that the stimulatory effect of aldosterone on 
pNCC in urinary exosomes either saturates, or that aldosterone escape has 
occurred, a defense mechanism known to reduce NCC in the kidney (22). 
Although the induction of secondary aldosteronism by a low sodium diet also 
increased pNCC in urinary exosomes (Figure 3B), the magnitude of this effect 
was less than with aldosterone infusion (Figure 5). One could have predicted 
even higher pNCC in urinary exosomes during a low sodium diet, because this 
maneuver is likely to increase both plasma angiotensin II and aldosterone. We 
recently showed that angiotensin II can increase renal pNCC independently of 
aldosterone, and that the combination of angiotensin II and aldosterone leads 
to an additive effect (15, 23). Apparently other factors limit pNCC excretion in 
urinary exosomes during a low sodium diet. Furthermore, differences in the 
plasma aldosterone concentrations in the control groups should be taken into 
consideration (virtually absent in adrenalectomized rats vs. ~100 pg/ml in rats 
on a normal sodium diet, Figure 1A and 3A). Of interest, the increase in NCC 
in urinary exosomes we observed in this study with a low sodium diet was 
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similar to the increase Esteva-Font et al. found for NCC in a separate study 
(10).       
 
Our study suggests that pNCC was better than prostasin as a marker of 
aldosteronism, which could be explained by several factors. First, although 
prostasin is sensitive to aldosterone and can activate ENaC, this does not 
necessarily render it a direct marker of ENaC activity and as such it may not be 
a direct marker of distal sodium reabsoption (12, 13). Prostasin is only one of 
the proteins present in the complex signaling cascade that regulates ENaC (24). 
Second, because prostasin is also present in prostate epithelial cells, urinary 
exosomes may also contain prostasin from this source (25). This may have 
limited the specificity of prostasin as a marker for aldosterone actions in the 
kidney, especially in males. Third, by using two-dimensional electrophoresis, 
Olivieri and colleagues have previously shown that several subunits of prostasin 
exist, only some of which are aldosterone sensitive (12). Our prostasin results 
differ from those reported by Narikiyo and coworkers (13). They found that 
rats continued to increase urinary prostasin during seven days of aldosterone 
infusion (from 1.5 to 4-fold), whereas we were unable to detect increased 
prostasin in urinary exosomes after eight days of treatment (Figure 2). This 
difference may be explained by the use of a three-fold higher aldosterone dose 
in the previous study and that their analysis of prostasin was performed on 
whole urine instead of urinary exosomes. 
 
In recent years, the potential to use proteins in urinary exosomes as markers of 
diseases affecting the kidney has attracted much interest (1-3, 26). Progress has 
been somewhat hindered by technical and normalization issues, but the 
proposal of uniform protocols has been a step in the right direction (18, 27). 
We believe that the strength of this study was to combine a controlled 
experimental setting with a clinical setting for the analysis of urinary exosomes 
in aldosteronism. Because of the well-characterized actions of aldosterone on 
distal tubular sodium transport, aldosteronism appears especially suitable for 
analysis with urinary exosomes. Clinically, primary aldosteronism is important 
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because recent studies suggest it to be a common condition among patients with 
resistant hypertension that is often difficult to diagnose (28). We do emphasize, 
however, that the primary aim of this study was to provide proof of principle 
that the abundance of aldosterone-sensitive proteins in urinary exosomes is 
increased during aldosteronism. The question whether pNCC in urinary 
exosomes has diagnostic potential in patients with primary aldosteronism 
remains to be determined. This will require larger and well-characterized 
groups of patients to be tested against a golden standard. In addition, the 
overall differences in NCC and pNCC between conditions were relatively mild 
even under controlled experimental conditions. Even if the sensitivity and 
specificity of pNCC in urinary exosomes would outweigh existing tests such as 
the ARR, the current method of exosome isolation is not suitable for clinical 
use (29). Instead, development of an enzyme-linked immunoassay for pNCC 
would be an attractive alternative.  
This study suggests several directions for future research. One obvious next step 
will be to evaluate how pNCC and prostasin in patients with primary 
aldosteronism respond to treatment with either mineralocorticoid receptor 
antagonists or adrenalectomy. Narikiyo et al. showed that urinary prostasin 
decreased in three patients with primary aldosteronism who had undergone 
adrenalectomy (13). Similarly, Olivieri et al. showed that prostasin decreased in 
normotensive subjects with aldosteronism due to a low sodium diet who were 
subsequently treated with spironolactone (12). It would also be informative to 
know whether other commonly used antihypertensive drugs such as diuretics, 
angiotensin converting enzyme inhibitors or angiotensin receptor blockers affect 
urinary exosome excretion. Because total NCC also increased, it would be 
important to known whether NCC mRNA is also present in urinary exosomes 
and if it behaves similarly. If so, it could be a more sensitive marker because the 
signal can be amplified. In kidney, however, previous studies found that the 
protein and mRNA abundances of NCC did not always correlate.22,23  Finally, 
given the recent insights into the effects of angiotensin II on distal tubular 
sodium transport (14, 15), it would be important to compare urinary exosomal 
pNCC and prostasin in patients with primary and secondary aldosteronism.  
Urinary Extracellular Vesicles: Biomarkers and beyond 
 
 
114 
 
In conclusion, in urinary exosomes of animals and patients, pNCC was superior 
to prostasin as a marker of aldosteronism. These results justify further 
evaluation of the applicability of urinary exosomes as a diagnostic tool in 
primary aldosteronism and, possibly, other forms of hypertension. 
Furthermore, pNCC and, to a lesser extent, prostasin, may be used 
experimentally as a non-invasive method to analyze the biological action of 
aldosterone in the kidney.  
 
Perspectives  
In hypertension, urinary exosomes could be applied as a diagnostic test for 
primary aldosteronism, to evaluate salt-sensitivity or the response to 
antihypertensive drugs acting on the kidney. Our study can be regarded as 
proof of principle that analysis of urinary exosomes can be applied to 
aldosteronism. Subsequent validation studies will be necessary to define their 
utility in experimental or clinical settings (30).     
 
 
 
Figure 5: Summary of the performance of urinary exosomal prostasin and pNCC as markers 
of aldosteronism. The densitometry values of the immunoblot analyses are shown. A value of 1 
represents no difference compared to the control group. * p < 0.05, ** p < 0.01 
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ABSTRACT 
 
Liddle syndrome is an autosomal dominant form of hypokalemic hypertension 
due to mutations in the β- or γ-subunit of the epithelial sodium channel 
(ENaC). For the first time, we describe a family with Liddle syndrome due to a 
mutation in αENaC. The proband was referred because of resistant 
hypokalemic hypertension, suppressed renin and aldosterone, and no mutations 
in the genes encoding β- or γENaC. Exome sequencing revealed a heterozygous, 
non-conservative T>C single nucleotide mutation in αENaC that substituted 
Cys479 to Arg (C479R). C479 is a highly conserved residue in the extracellular 
domain of ENaC and is likely involved in a disulfide bridge with the partner 
cysteine C394. In oocytes, the C479R and C394S mutations resulted in a 
similar ~2-fold fold increase in amiloride-sensitive ENaC-current. 
Quantification of mature cleaved αENaC in membrane fractions showed that 
this gain of function was not due to a higher number of channels. Trypsin, 
which increases open probability of the channel by proteolytic cleavage, 
resulted in significantly higher currents in wild-type than in C479R or C394S 
mutants. In summary, a mutation in the extracellular domain of αENaC causes 
Liddle syndrome by increasing intrinsic channel activity. This mechanism differs 
from the β- and γ-mutations that result in an increase in channel density at the 
cell surface. This mutation may explain other cases of resistant hypertension 
and also provides novel insight in ENaC activation, relevant for kidney sodium 
reabsorption and salt-sensitive hypertension.    
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INTRODUCTION  
 
Hypertension is one of the most common non-communicable disorders 
worldwide and a major risk factor for stroke, myocardial infarction, heart 
failure, and end-stage renal disease (1). Primary or essential hypertension is a 
complex genetic trait that is also influenced by other risk factors such as dietary 
sodium and potassium intake, obesity, and diabetes (2, 3). In contrast, 
monogenic forms of hypertension are very rare, but have been instrumental in 
revealing the molecular pathways contributing to primary hypertension (4). The 
majority of these pathways point towards a role for increased sodium 
reabsorption by the kidneys, especially in the aldosterone-sensitive distal 
nephron (5). Indeed, several monogenic forms of hypertension are caused by 
mutations increasing sodium reabsorption in this segment through the sodium 
chloride cotransporter or the epithelial sodium channel (ENaC) (6). In 1963 G. 
Liddle and colleagues reported a ‘familial renal disorder simulating primary 
aldosteronism but with negligible aldosterone secretion’ (7). Liddle syndrome or 
pseudoaldosteronism (OMIM# 177200) is now known as an autosomal 
dominant form of salt-sensitive hypertension that is further characterized by 
suppressed plasma renin and aldosterone, hypokalemia, and metabolic alkalosis 
(8). The syndrome was linked to mutations in the SCNN1B or SCNN1G gene, 
encoding the β- or γ-subunit of ENaC (9, 10). Mutations in SCNN1B or 
SCNN1G delete or modify the intracellular PY motifs in ENaC in such a way 
that Nedd4-2 fails to ubiquitylate the channel leading to a retention of active 
ENaC at the cell surface (11, 12). Here, we report a family with Liddle 
syndrome due to a gain of function mutation in the extracellular domain of the 
α-subunit of ENaC (SCNN1A) that predominantly increases channel open 
probability but not channel surface density.   
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RESULTS   
	
Clinical and genetic characteristics of a novel ENaC mutation 
The proband was referred because of resistant hypertension, hypokalemia, 
metabolic alkalosis, and suppressed levels of plasma renin and aldosterone. 
Despite a positive family history for hypertension (Figure 1A), no mutations in 
SCNN1B or SCNN1G were identified. Diagnostic exome sequencing revealed a 
novel heterozygous, non-conservative T>C single nucleotide mutation that 
results in the substitution of cysteine 479 to arginine (C479R) in αENaC 
(c.1435T>C(p.(Cys479Arg), Figure 1B). The mutation is reported at a very low 
frequency in a large database collecting >60,000 exomes as proxy for variant 
allele frequencies in the general population (seven times heterozygously in 
>100,000 alleles; Exome Aggregation Consortium). The ENaC-blocker 
triamterene normalized blood pressure and serum potassium in the proband. 
Genotyping of the five siblings also identified the novel C479R mutation in 
subject II-4. The mutation segregated with suppressed plasma and aldosterone, 
but not with hypertension (Figure 1C). Whole-exome sequencing in the 
proband did not identify additional mutations to explain the hypertensive trait 
in this family. Subject II-4 had mild hypertension (average ambulatory blood 
pressure 138/88 mmHg) that was sensitive to sodium chloride supplementation 
(145/91 mmHg) and also improved with triamterene (121/71 mmHg). In a 
standardized diuretic test, the natriuretic response to triamterene in the proband 
and II-4 was in the high range or increased compared to the response in healthy 
volunteers (Figure 1D) (13). Thus, two siblings (the proband and II-4) show a 
clinical picture compatible with Liddle syndrome and carry the C479R missense 
mutation.  
 
C479 is located in the extracellular domain of ENaC 
The ultimate proof of Liddle syndrome, however, is the demonstration that the 
mutation results in a gain of function of ENaC. The DNA variant that encodes 
the C479R mutant has so far never been described. The C479 is a highly 
conserved Cys residue that belongs to the second cysteine-rich domain (CRD2) 
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of the extracellular domain of ENaC that is likely involved in disulfide bridges 
(14). The hαENaC C479 is conserved not only among the ENaC subunits and 
among ENaC homologs but also among the Acid-Sensing Ion Channel 1 
(ASIC1) orthologs (Figure 2A). The crystal structure of chicken ASIC1 reveals 
that the cASIC1 C366 forms a disulfide bond with another highly conserved 
cysteine, C291 in CRD2, that corresponds in αhENaC to a disulfide bond 
between C479 and the C394 (Figure 2B) (15). Therefore, we analyzed not only 
the consequences of the C479R mutation on hENaC function in Xenopus laevis 
oocytes, but also the functional effects of the mutation of the partner Cys 
C394S involved in the disulfide bond. In addition, since C479 is a highly 
conserved Cys, we performed a similar functional analysis of the corresponding 
Cys mutations C507S and C422S in rat αENaC.  
 
Figure 1. Clinical, genetic, and structural characteristics of the αENaC mutation. (A) Pedigree 
showing three generations of the family with Liddle syndrome. Generation II was analyzed by 
genotyping and biochemical profiling. Arrow indicates the proband. (B) Sequence 
chromatogram. (C) The C479R mutation segregated with suppressed plasma renin and 
aldosterone but not with hypertension. Renin and aldosterone were measured in the absence of 
interfering drugs. Dashed lines represent lower limits of normal. Footnotes: * proband; # 
subject II-4. Abbreviations: HT, hypertension; NT, normotension; WT, wild-type. (D) Results 
of a standardized diuretic test showing the natriuretic response to a single dose of the ENaC-
blocker triamterene in the proband (*) and subject II-4 (#) in comparison to healthy volunteers 
(13).  
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C479R increases ENaC current in oocytes 
Both C479R and C394S result in a similar ~2-fold increase in amiloride-
sensitive ENaC-current (Figure 3A). These results strongly suggest that the 
channel gain of function is due to the disruption of the disulfide bond between 
the two Cys. Since the proband is heterozygous for the C479R mutation, we 
replicated this condition in vitro by co-injecting ENaC wild-type and C479R in 
a 1:1 ratio and observed still a significant increase in ENaC-current, but this 
effect was reduced by half compared to C479R expressed alone (Figure 3B). To 
provide further evidence for a gain of function due to the disruption of the 
disulfide bridge we tested the corresponding mutations in rαENaC and found 
that the C507S and C422S mutations have comparable stimulatory effects on 
ENaC activity as C479R and C394S in hαENaC (Figure 3C). These results are 
consistent with previous observations that disruption of particular disulfide 
bonds in the CRD2 of the extracellular domain of rENaC results in a channel 
gain of function (14). Furthermore both C479Arg and C507Ser substitutions in 
hαENaC and rαENaC have comparable stimulatory effects on ENaC current 
indicating that the effect does not depend on the substituting amino acid. 
Together these observations support the idea that the disruption of the C479-
C394 disulfide bridge by the C479R substitution is likely the primary cause of 
the observed gain of function in ENaC.  
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Figure 2. Sequence comparison and subunit structure of an ENaC homologue. (A) Sequence 
comparison of human (h) and rat (r) αENaC (SCAA), βENaC (SCAB), and γENaC (SCAG) 
subunit isoforms with human hASIC1 and chicken cASIC1. (B) Crystal structure of a cASIC1 
subunit with the disulfide bonds in the extracellular domain labelled in green for the first 
cysteine-rich domain (CRD1) and in yellow for CRD2. The Cys366 (red) corresponding to 
Cys479 in the human αENaC (hSCAA) makes a disulfide bond with Cys291 (purple) 
corresponding to C394 in hSCAA (inset).  
 
 
. 
A
B
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Figure 3. αENaC C479R is a gain of function mutation. (A) Amiloride-sensitive current 
increase of αC479R ENaC mutant and of the Cys partner, αC394S, mutant. Current values 
were normalized for the average INa of the wild-type (wt) control obtained in oocytes of each 
independent batch (n ≥ 4). Bars represent mean ± SD for hαENaC wt (n = 225), hαENaC 
C479R (n = 231), and hαENaC C394S (n = 18). (B) Normalized amiloride-sensitive current 
values as in A with hαENaC wt (n = 14), hαENaC C479R expressed alone (n = 13) or together 
with hαENaC wt at a cRNA weight ratio of 1:1 (n = 13). (C) Normalized amiloride-sensitive 
current values for rat αENaC wt (n = 12), C507S (n = 12) and C422S (n = 12), corresponding 
respectively to C479R and C394S in the human αENaC sequence.  
 
 
 
Surface density of C479R  channel mutant  
The increase in ENaC activity due to the C479R mutation can result from an 
increase in channel open probability, in single channel conductance, or in the 
number of channels at the cell surface. To test the latter possibility we analyzed 
on Western blot the cleaved (CL) forms of wild-type and C479R α and γENaC 
subunits (Figure 4A and B), expressed in the whole oocyte, at the cell surface 
(Figure 4C and D, Supplemental Figure 1), and analyzed urinary exosomes 
(Supplemental Figure 2) (16). It is now well established that the CL-forms of α 
and γ represent the mature ENaC subunits that are incorporated in the 
functional channel complex present at the cell surface (17). The full length (FL) 
of αENaC (93 KDa) was detected in oocytes expressing α subunit alone or 
αβγENaC wt and C479R mutant (Figure 4A). The CL form of αENaC (69kDa) 
was detected only for the αβγENaC wt and the αC479Rβγ mutant. The CL 
form of γ subunit (76 kDa) was detected for both αβγENaC wt and αC479Rβγ 
mutant. Quantification of the intensities of the CL forms of α and γ subunits 
from the αC479Rβγ ENaC complex relative to those of α and γ in the αβγENaC 
complex did not show any significant difference. Subsequently, cell surface 
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expression of ENaC wt and mutant was assessed by biotinylation of surface 
proteins and followed by affinity purification on Neutravidin-agarose beads. 
The representative immunoblot in Figure 4C shows that in oocytes expressing 
comparable amounts of αENaC wt and mutant under their FL and CL forms 
(left panel: CL 69  kDa, FL 97 kDa),  the CL band is the main detected form at 
the cell surface, at similar amounts for both channel types (right panel).  We 
quantified the FL+CL band intensities in total membrane and in cell surface 
fractions of wt and C479R mutant ENaC expressing oocytes (Figure 4D). The 
data obtained from four independent experiments show that, for a comparable 
expression of αENaC wt and C479R mutant, the amount of wt and C479R 
mutant ENaC functional channels at the cell surface is similar. Similarly, the 
αENaC C479R mutation did increase γENaC levels at the cell surface of 
injected oocytes (Supplemental Figure 1). Based on these data, we can conclude 
that the ~2-fold higher ENaC current measured for the hαC479R mutant is not 
correlated with an increase in the mature channel density at the cell surface. 
Consistently, no differences in the abundance of cleaved αENaC in urinary 
extracellular vesicles were detected in the two subjects carrying the mutation 
(Supplemental Figure 2) (16).  
 
Intrinsic activity of C479R mutant 
To test the possibility of a gain of function C479R mutation due to an increase 
in channel open probability (Po) we used trypsin, that proteolytically cleaves 
ENaC and activates the channel by increasing the Po (18). We reasoned that, if 
the C479R channel mutant has a higher Po than the ENaC wild-type, then it 
should show a higher current but a lower sensitivity to activation by trypsin. 
The magnitude of the currents in the absence of trypsin was significantly higher 
for the C479R and C394S mutants as compared to wild-type (respectively 2.1 
and 2.4-fold increase). After trypsin treatment, the currents expressed by the 
mutant forms were no longer different from that of ENaC wt although a trend 
towards higher currents was observed for the mutants (Figure 5A and 
Supplemental Figure 3 for original traces). Shown in Figure 5B for individual 
oocytes, the wild-type hENaC has a significantly lower current than either of 
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the mutants, but the trypsin-induced increase in current is higher than that for 
the C479R and C394S mutants. This smaller effect of trypsin shown for the 
C479R and C394S gain of function mutants is consistent with a higher basal 
Po. It is interesting to note that even at high ENaC baseline currents as those 
observed for the mutants, the trypsin effect plateaued at a 2-fold increase in 
INa. This suggests that the baseline Po of C479R and C394S is below or equal 
to 0.5, whereas the baseline Po of wild-type hENaC is below or equal to 0.27. 
An alternative, but less likely explanation is that the C479R and the C394S 
mutations decrease the efficiency of ENaC cleavage by trypsin, despite a gain of 
function effect of the mutation. An alternative explanation for the lower 
sensitivity to trypsin of the C479R and C394S mutants is an apparent saturable 
expression of the ENaC-current because of the limited capacity of the oocyte to 
face large inward Na+ currents (19). The latter possibility was, however, 
excluded in experiments testing the effect of trypsin on wild-type, C479R, and 
C394S hENaC at different levels of current expression by injecting increasing 
amounts of cRNAs ranging from 0.1 to 10 ng/oocyte (Figure 5C). The slope of 
this linear relation was approximately 2-fold lower for the ENaC mutants than 
for wild-type. This lower response to trypsin for the gain of function ENaC 
mutants is consistent with a higher intrinsic activity of the channel with a 
higher open probability. We then verified these observations with the 
corresponding Cys mutations, C507S and C422S, of rat ENaC, and also 
included the rβENaC Liddle mutant Y618A (Figure 6). Y618A disrupts the PY 
motif and increases the number of active channels at the cell surface (20). Wild-
type ENaC and the Y618A mutant show a significantly higher response to 
trypsin compared to the C507S and C422S mutants, in spite of the fact that the 
Y618A baseline current was significantly higher than that of wild-type and of 
the Cys mutants (Figure 6A). The linear relationship between currents with or 
without trypsin was similar for wild-type and Y618C rENaC, but 
approximately 2-fold smaller for the C507S and C422S rENaC mutants (Figure 
6B). Taken together these results suggest that the ENaC gain of function 
mutations C479R and C507S are essentially due to an increased intrinsic 
channel activity. 
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Figure 4. C479R does not increase channel surface density. (A) Anti-HA-tag (red, left) and 
anti-γENaC (green, right) Western blot analysis of Triton-soluble fractions from Xenopus 
oocytes, non-injected (n.i.), or injected with cRNAs for either hα-HA alone or with β- and 
γENaC cRNAs, together with either wild-type or C479R mutant hα-HA. (B)  The intensities of 
the bands corresponding to cleaved (CL) hα- and hγENaC were normalized to the amount of 
TCE-labeled, total protein obtained for each lane on the blot. The ratios between the thus 
calculated values for hα- and hγENaC in the hαwtβγENaC and those for hαC479RβγENaC are 
shown in the graph. Data correspond to mean ± SEM (10 blots from 7 independent 
experiments); differences are non-significant (N.S). (C) Right panel: Anti-HA immunoblot 
analysis of Neutravidin-bound fractions isolated from control (-) or cell-surface biotinylated (+) 
Xenopus oocytes, non-injected (n.i.), or injected with either αwt-HA/β/γ or αC479R-HA/β/γ cRNAs.  
Left panel: Inputs corresponding to 1% of the Triton-soluble preparations from biotinylated 
oocytes used in the pull-down experiments. (D) Values (mean ± SD) of CL+FL band intensities 
of inputs or of Neutravidin-bound fractions corresponding to experiments shown in C. Results 
from four blots with samples of four independent experiments. Differences are non-significant 
(N.S.).  
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Figure 5. Sensitivity to trypsin of human ENaC C479R and C394S gain of function mutants. 
(A) Amiloride-sensitive current (µA) of hENaC wild-type (wt, n = 17), hαENaC C479R (n = 
17), hαENaC C394S (n = 18) in the absence (-) or presence (+) of trypsin. The magnitude of the 
currents in the absence of trypsin was significantly higher for C479R and C394S as compared 
to wt (* P < 0.01 by 1-way ANOVA), whereas the currents in oocytes expressing the mutant 
forms were no longer significantly higher after trypsin treatment. (B) Relationship between 
baseline INa in the absence of trypsin and fold increase in INa after the addition of trypsin in 
wild-type and mutant human ENaC (C479R and C394S). Current values for a single oocyte 
(filled symbols) and means ± SD (open symbols) are shown (P < 0.01 by ANOVA). (C) 
Correlation between current INa (µA) values in the absence and presence of trypsin. Linear 
regression analysis give the following best-fit values for the slopes hαwt: 4.08 (95% CI 3.82-
4.35); hαC479R  2.28 (95% CI 2.14 – 2.42); hαC394S: 2.23 (95% CI 2.03 – 2.42). See 
Supplemental Figure 3 for original traces. 
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Figure 6. Sensitivities to trypsin of different types of rat ENaC gain of function mutants. (A) 
Relationship between the baseline INa in the absence of trypsin and the fold increase in INa 
after the addition of trypsin for wild-type rat ENaC (rENaCwt), two αENaC mutants (C507S 
and C422S) and the βENaC Liddle mutant Y618A. Current values for a single oocyte (filled 
symbols) and means ± SD (open symbols) are shown (P < 0.01 by ANOVA). (B) Correlation 
between current INa values (µA) in the absence and presence of trypsin. Linear regression 
analysis give best-fit values for the slopes corresponding to rαwt/rβ/rγ, rαC507S/rβ/rγ, rαC422S/rβ/rγ, 
and rαwt/rβ/rγY618A and were, respectively, 4.07 (95% CI 3.92 – 4.23),  2.09 (95% CI 2.0 – 
2.18), 1.92 (95% CI 1.74 – 2.09) , 4.04 (95% CI 3.79 – 4.30).   
 
 
 
DISCUSSION 
 
Here, we report a mutation in αENaC associated with Liddle syndrome. Our 
functional investigations of the C479R mutation show that this Cys mutation in 
the second cysteine-rich domain of the extracellular domain of αENaC is a gain 
of function mutation. Our data are consistent with a higher intrinsic ENaC 
activity due to an increase in open probability (Po), likely resulting from the 
disruption of the disulfide bonds between Cys479 and Cys394. The ENaC 
channel opener trypsin induces a lower response for the gain of function 
mutants hαC479R and rαC507S, consistent with a higher channel Po. This functional 
effect of the disruption of the Cys479–Cys394 disulfide bond is conserved in 
both rat and human ENaC channel isoforms. Our data are remarkably 
consistent with the mutational analysis of cysteine-rich domains of ENaC 
previously reported by Firsov et al.(14). They showed that the αC16S mutation 
A B
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in rat αENaC (corresponding to the C479R and C507S mutations in our work) 
resulted in a 3-fold increase in amiloride-sensitive current without changing 
channel surface expression. Furthermore, mutation of the partner cysteine 
involved in the disulfide bridge (αC7S) had the same effects. Of interest, 
mutations of the cysteines in the extracellular cysteine-rich domains can result 
either in channel loss or gain of function. Indeed, mutation of the human 
Cys133 into a tyrosine causes the mirror image of Liddle syndrome, 
pseudohypoaldosteronism type 1, a severe salt losing syndrome in neonates (14, 
21).   
 
The majority of the previously reported Liddle mutations affect the intracellular 
PY-motif of β- or γENaC, impairing channel degradation by Nedd4-2 (9, 10). A 
mutation in αENaC causing Liddle syndrome has only been reported once 
previously, and was also located in the PY-motif (22). Therefore, this report on 
an αENaC mutation causing Liddle syndrome contains two novel aspects, 
including the location in the extracellular domain and the effect on open 
probability rather than surface expression. Of note, αENaC gain-of-function 
mutations have been identified previously in patients with cystic fibrosis-like 
symptoms, but it is not known whether these mutations also caused 
hypertension (23, 24). In addition, some of the mutations in α- or βENaC 
causing atypical cystic fibrosis were located outside the PY-motif and increased 
channel Po (24, 25). A gain-of-function mutation (N530) in the putative 
extracellular domain of γENaC causing Liddle syndrome has also been reported 
previously (26). However, structural models of ENaC based on the crystal 
structure of the homolog ASIC1 predict that the N530 residue is located in the 
second transmembrane α helix of γENaC, and not in the extracellular domain 
of the channel. Finally, single nucleotide polymorphisms of the αENaC gene 
locus correlated with salt-sensitive hypertension in one Chinese study (27). 
 
Of interest, the proband had the classical Liddle syndrome phenotype, whereas 
his sibling had a milder degree of salt-sensitive hypertension and no 
hypokalemia. Such differences between affected family members, including the 
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absence of hypokalemia, have been observed previously (28). The phenotypic 
differences between the proband and II-4 suggest variable expressivity, possibly 
related to gender, environmental factors, or genetic modifiers. Alternatively, the 
proband and his hypertensive siblings without the mutation (subjects II-2, II-3, 
and II-6, Figure 1A) may have an additional genetic variant predisposing to 
hypertension, although we did not identify this using whole-exome sequencing. 
Thus, in this family, the mutation segregated with suppressed renin and 
aldosterone but not with hypertension. In addition, our family appeared to have 
a milder phenotype compared to previous Liddle kindreds (9, 10, 28). This may 
also relate to the molecular mechanism of the αENaC mutation.  
 
In vivo ENaC channel Po determined by patch-clamp technique ranged from 0.3 
to 0.7 (29). In Xenopus oocytes ENaC Po under comparable conditions was 
estimated to be 0.3 (19). Assuming that trypsin stabilizes ENaC in the open 
conformation with a Po of 1, then the slope current relations for the ENaC 
wild-type and mutants suggest that, under our experimental conditions, the Po 
of wt ENaC is around 0.25, and that of the mutants around 0.5. Such an 
increase in Po, estimated from the trypsin response, represents the main 
component of the higher ENaC current expressed by the C479R and the related 
mutants. Such a gain of function resulting from an increased Po is certainly 
limited by the functional characteristics of the channels. Since ENaC likely 
never functions physiologically with a Po of 1, a gain of function due to an 
increased channel gating would reasonably not exceed 3-4 fold. In contrast, 
Liddle gain of function mutation resulting from an increased ENaC retention at 
the cell surface may potentially enhance sodium transport to a much greater 
extent because the capacity of the membrane surface to accommodate a high 
density of ENaC channels is less restricted than the capacity of ENaC to 
increase in its Po. Along this line we observed that the Y618A mutation, 
affecting channel interaction with Nedd4-2, is more efficient than C507S in 
increasing ENaC-mediated current (Figure 6). Although an increase in single 
channel conductance could theoretically explain the C479R channel gain of 
function, we know from previous structure-function studies on ENaC that such 
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mutations are restricted to the second transmembrane domain (TM2), a region 
that participates in the ion channel pore and selectivity filter (30).  
 
In summary, we report a mutation in αENaC associated with Liddle syndrome. 
This represents the first ENaC gain of function mutation in the extracellular 
domain causing a higher intrinsic channel activity, a mechanism different from 
the previously reported mutations in β or γ associated with Liddle syndrome (9, 
10). This study raises the question about the necessity of genotyping 
unexplained cases of hypertension associated with suppressed plasma renin and 
aldosterone and with a poor response to standard antihypertensive therapy. 
Furthermore, this mutation provides novel insight in ENaC activation and 
potentially in distal nephron sodium reabsorption and salt-sensitive 
hypertension.    
 
 
 
CONCISE METHODS 
 
Studies in patients 
The patient studies were performed in accordance with the declaration of 
Helsinki. All patients provided written informed consent, and the ethics 
committee approved the study. Plasma renin concentration and plasma 
aldosterone were measured by enzyme-kinetic assay and LC/MS, respectively. 
These measurements were performed in the absence of interfering drugs (renin-
angiotensin system inhibitors or diuretics). The triamterene test was based on 
the thiazide test (31). Results were compared to a historic cohort of healthy 
subjects receiving 100 mg triamterene in a similar setting (13).    
 
Exome sequencing 
The analysis of the exome data was divided into two steps: the renal gene panel 
analysis and the exome analysis. In the renal gene panel analysis, an in silico 
enrichment of genes associated with genetic renal disorders was performed 
Chapter 7 | A Missense Mutation in the Extracellular Domain of αENAC Causes Liddle 
Syndrome 
133 
(version: DGD141114). After the patient consented for the second step, exome 
analysis, likely pathogenic variants in all coding genes were analyzed. Exome 
sequencing was performed using a Illumina HiSeq2000TM sequencer at BGI-
Europe (Copenhagen, Denmark). Read alignment to the human reference 
genome (GrCH37/hg19) and variant calling was performed at BGI using BWA 
and GATK software, respectively. Variant annotation was performed using a 
custom designed in-house annotation and variant prioritization pipeline. 
 
Site-directed mutagenesis and expression in Xenopus laevis oocytes 
Mutant forms of the wild-type forms of human α-, β-, and γENaC subunits had 
been cloned in the pBSK(+)_Xglob vector (32). In these vectors, the ENaC 
cDNAs are flanked by sequences corresponding to the 5' and 3' non-coding 
stretches of Xenopus β-globin, which boosts protein expression when injected 
into Xenopus oocytes (33). Plasmids suitable for in vitro transcription of wild-
type and mutant forms of the human αENaC subunit (hαENaC) were generated 
as described in the Complete Methods (Supplemental Material online). All 
constructs were verified by sequencing. Subsequently, healthy stage V and VI 
Xenopus laevis oocytes were pressure-injected with mixes containing equal 
amounts of cRNAs encoding α-, β-, and γ-subunits for a total of (unless stated 
otherwise) 1 or 3 ng cRNA for human and rat ENaC, respectively. Mutant and 
control cRNAs were prepared in parallel and ≥ 3 independent batches of cRNA 
were used.  
 
Electrophysiology 
Electrophysiological measurements were made 24-32 h after injection with the 
standard two-electrode voltage clamp technique, using a TEV-200A voltage 
clamp amplifier (Dagan, Minneapolis, MN), an ITC-16 digitizer interface 
(Instrutech Corp. Elmont, NY), and the PatchMaster data acquisition and 
analysis package (HEKA Elektronik Dr. Schulze GmbH, Ludwigshafen/Rhein, 
Germany). The amiloride-sensitive currents were measured in the presence of 
10 µM of this blocker adjusted in a separate solution. Inward Na+ currents were 
generated by switching from the amiloride-containing perfusion solution to that 
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without amiloride. In the experiment with proteases, the oocytes were perfused 
for 2 min with the amiloride-free solution supplemented with 2 µg/ml trypsin 
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). All INa values were 
normalized in all experiments to the mean of the amiloride-sensitive currents 
measured for wildtype ENaC with the same oocyte batch. 
 
Isolation of ENaC-enriched fractions 
To isolate membrane fractions, 15-30 oocytes were disrupted by pipetting in 
1.5 ml of membrane isolation buffer followed by centrifugation through cell 
shredders. The membrane pellets obtained after 30 min centrifugation at 
20,000 g (4°C) were resuspended in membrane solubilization solution. Proteins 
in samples were resolved, along with pre-stained molecular weight markers by 
SDS-PAGE on 5–15% acrylamide gradient minigels supplemented with 0.5% 
(v/v) of 2,2,2-Trichloroethanol (TCE) for subsequent, in-gel, fluorescently 
labelling of proteins (34). Total protein per lane was assessed densitometrically 
from these images using ImageJ. Band intensities were assessed with the 
Odyssey v2.1 software and normalized with the amount of total, TCE-labelled, 
protein in the corresponding lanes. 
 
Analysis of cell-surface biotinylated fractions 
Control or injected oocytes (~25 per condition) were incubated for 15 min on 
ice in 1 ml Biotinylation buffer. Biotinylated fractions were isolated from 
ENaC-enriched fractions which had been purified as described before (35). 
Neutravidin-bound fractions and Triton-soluble fractions (1% of total) were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and blocked 
as described before. To account for non-specific binding to Neutravidin beads, 
band intensity values from control, non-biotinylated samples were subtracted 
from the values of the corresponding, biotinylated samples. 
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Statistics 
Statistical analyses were performed using GraphPad Prism software (GraphPad 
Software). Differences between groups were assessed by 1-way ANOVA and 
the Tukey post-hoc test. P values of less than 0.05 were considered statistically 
significant 
 
A B 
 
 
 
 
Supplemental Figure 1: αENaC C479R mutation does not result in increased γENaC levels at 
the cell surface of injected oocytes. After probing with anti-HA antibody (see Figure 4), blots 
were re-blocked and analyzed with anti-γENaC antibody as described for lysates in the 
Materials and Methods section. (A) Right panel, immunoblot analysis of Neutravidin-bound 
fractions isolated from control (-) or cell-surface biotinylated (+) Xenopus oocytes, non-
injected (n.i.), or injected with either αwt-HA/β/γ or αC479R-HA/β/γ cRNAs.  Left panel. Inputs 
corresponding to 1% of the Triton-soluble preparations from biotinylated oocytes used in the 
pull-down experiments. (B) Values (mean ± SEM) of CL+FL band intensities of inputs or of 
Neutravidin-bound fractions corresponding to experiments shown in A. Results from three 
blots with samples of three independent experiments. Differences are non-significant (N.S.). 
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Supplemental Figure 2: αENaC in human urinary extracellular vesicles. αENaC in urinary 
extracellular vesicles isolated from the reported family. Urinary extracellular vesicles were 
collected in the absence of interfering medication (no renin-angiotensin inhibitors or diuretics). 
A human kidney (HK) sample was included as positive control and showed the expected bands 
at 100 kDa (full-length αENaC) and ~30 kDa (cleaved αENaC). It is unclear what the low 
intensity band at ~45 kDa represents. Of these bands, only the 30 kDa band was detected in 
human urinary extracellular vesicles. Although no firm conclusions can be drawn based on the 
small number of individuals, no clear difference in the abundance of this 30 kDa band was 
visible between the two subjects carrying the C479R mutation (II-5 and II-4) compared to 
those without the mutation (II-1, II-2, II-3, and II-6) and a healthy control (HC). II-5T and II-
4T are urinary extracellular vesicles isolated after the standardized diuretic test with triamterene 
(T). Of note, an additional band at ~55 kDa was visible in some of the subjects. Although this 
band could represent partially or atypically cleaved αENaC, it could also be non-specific, as it 
was also vaguely visible in kidneys of αENaC -/- mice (Sorensen et al., Kidney Int, 2013).  
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Supplemental Figure 3: Three original traces from hENaCwt, C479R, and C394S in the 
absence (left) or presence (right) of trypsin. Results from independent experiments; please note 
the current and time scales. 
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ABSTRACT  
	
Novel therapies in autosomal dominant polycystic kidney disease (ADPKD) 
signal the need for markers of disease progression or response to therapy. This 
study aimed to identify disease-associated proteins in urinary extracellular 
vesicles (uEVs), which include exosomes, in patients with ADPKD. We 
performed quantitative proteomics on uEVs using a labeled approach (healthy 
vs. ADPKD) and then using a label-free approach in different subjects (healthy 
vs. ADPKD vs. non-ADPKD chronic kidney disease [CKD]). In both 
experiments, thirty proteins were consistently more abundant (≥ 2-fold) in 
ADPKD-uEVs compared with healthy and CKD uEVs. Of these proteins, 
periplakin, envoplakin, villin-1, complement C3 and C9 were selected for 
confirmation, because (1) they were also significantly overrepresented in 
pathway analysis, and (2) they have been previously implicated in the 
pathogenesis of ADPKD. Immunoblotting was used to validate the proteomics 
results, confirming higher abundances of the selected proteins in uEVs from 
three independent groups of ADPKD-patients. While villin-1, periplakin, and 
envoplakin were increased in advanced stages of the disease, complement was 
already higher in uEVs of young ADPKD patients with preserved kidney 
function. Furthermore, all five proteins correlated positively with total kidney 
volume. The proteins of interest were also analyzed in kidney tissue from 
kidney-specific-tamoxifen-inducible Pkd1-deletion mice, demonstrating higher 
expression in more severe stages of the disease and correlation with kidney 
weight. In summary, proteomic analysis of uEVs identified plakins and 
complement as disease-associated proteins in ADPKD. These proteins are new 
candidates for evaluation as biomarkers or targets for therapy in ADPKD. 
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INTRODUCTION 
	
Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
inherited kidney disease, affecting approximately 4 in 10,000 individuals (1). It 
is caused by mutations in the PKD1 or PKD2 gene, encoding for polycystin-1 
and polycystin-2 proteins (2). Both proteins associate with primary cilia and are 
thought to play a role in stretch-activated signaling. Loss of function of 
polycystins results in the development of fluid-filled cysts, ultimately leading to 
disruption of the normal kidney parenchyma. In the last decade, urinary 
extracellular vesicles (uEVs, which also include the so-called “exosomes” (3)) 
have emerged as promising markers for kidney disease (4-6). These nanosized 
vesicles are released by direct shedding or by fusion of multivesicular bodies 
with the plasma membrane (7). Their content comprises proteins and nucleic 
acids, both of which have been explored as biomarkers (5). More specific, uEVs 
appear to mirror the cellular make-up of renal epithelial cells. For example, we 
previously showed that aldosterone increased the sodium chloride cotransporter 
both in the kidney and in uEVs (8). Twenty to sixty percent of renal cysts in 
ADPKD remain connected with the parent nephron (9, 10), so that a significant 
portion of uEVs in ADPKD may be derived from cyst epithelial cells. Studying 
uEVs in ADPKD may address the pathophysiology of the disease, as uEVs 
contain polycystins and have been shown to interact with primary cilia (11). 
We therefore hypothesize that studying uEVs in ADPKD is more advantageous 
than studying whole urine. Accordingly, the aims of this study were to (1) 
compare the proteome of whole urine with the proteome of uEVs (2), identify 
disease-associated proteins in uEVs from ADPKD patients.  
 
 
 
 
 
 
 
Urinary Extracellular Vesicles: Biomarkers and beyond 	
	
146 
RESULTS 
 
Characteristics of participants 
uEVs were isolated in four groups of ADPKD patients due to a PKD1 mutation 
to identify and confirm disease-associated proteins (Table 1, Figure 1, 
Supplementary Table 1 online). In the identification cohort we used labeled 
proteomics to identify proteins with higher or lower abundance in uEVs of 
patients with ADPKD. We also analyzed the proteome of whole urine to 
compare it with the uEV proteome. In confirmation cohort 1 we used label-free 
proteomics, and included different patients with ADPKD and also included 
patients with non-ADPKD chronic kidney disease (CKD). CKD patients were 
matched by age, sex, and estimated glomerular filtration rate (eGFR) and this 
group was used to exclude proteins that may be related to impaired kidney 
function in general. The reason to use both labeled and label-free proteomics 
techniques is that the two approaches complement each other in terms of 
quantitation (labeled) and sensitivity (label-free). In confirmation cohort 2, 
uEVs were isolated and compared with the uEVs of the CKD patients from the 
validation cohort. Finally, confirmation cohort 3 cohort consisted of healthy 
control subjects, young ADPKD patients with preserved renal function (CKD 
stage 1) and those with more progressive disease (CKD stages 2-4).  
 
Qualitative comparison of the urinary proteome: whole urine versus uEVs 
Figure 2A shows that 1048 proteins were identified in whole urine and 1245 
proteins in uEVs of which 527 overlapped (see www.proteomexchange.org, 
identifier PXD003298 for a list of all proteins). The total number of identified 
proteins in urine was therefore 1766. Of interest, despite the fact that whole 
urine still contained uEVs, 718 proteins were only identified in uEVs. This 
suggests that isolation of uEVs results in a different set of proteins not found in 
whole urine. Figure 2B characterizes how the unique proteins distribute to the 
different cellular components. Whole urine showed more cell surface, plasma 
membrane, and extracellular proteins, whereas uEVs showed more cytoplasmic, 
cytoskeletal, endosomal, and mitochondrial proteins. Of the 517 unique 
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proteins in whole urine, the majority (389 proteins, 75%) had a molecular 
weight below the cut-off for glomerular filtration (< 70 kDa) (12). We also 
performed a qualitative comparison to identify over-represented pathways in 
whole urine and uEVs of patients with ADPKD (Table 2) (13). Using the 
DAVID annotation tool (14), we identified that significantly over-represented 
pathways in ADPKD-uEVs consisted of actin-related processes and immune 
system processes, including complement activation. The latter finding was 
confirmed by an analysis using the Kyoto Encyclopedia of Genes and Genomes 
(KEGG), which also indicated that ‘complement and coagulation cascades’ 
(hsa04610) were over-represented in ADPKD (37 proteins, P = 0.012).  
	
 
 
Figure 1: Sample collection, processing, and analysis in the four study groups.  
A and B: Identification and confirmation cohorts used for proteomic analysis. Quantitative 
proteomics was performed using dimethyl-labeling in the identification cohort and label-free 
methods in confirmation cohort 1 (see Concise Methods).  
C and D: Confirmation cohorts 2 and 3 were used for the immunoblotting analysis.  
* Patients from validation cohort.  
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Quantitative proteomics of ADPKD-uEVs 
We performed quantitative proteomics in the identification cohort and 
confirmation cohort 1 in order to select proteins that were consistently higher 
or lower in uEVs of patients with ADPKD and not related to CKD (Figure 1). 
Table 3 shows the 30 proteins with consistently higher abundance in ADPKD-
uEVs and the 4 proteins with lower abundance, including the ratios for the 
mean ion intensities (ratios were not calculated if proteins in one of the control 
groups were absent or very low abundant). Among the identified proteins were 
the actin modulating protein villin-1, as well as plakins such as envoplakin, and 
periplakin. Complement-related proteins were also more abundant in ADPKD-
uEVs, including complement C3 and C9.  
	
 
Cohort Subjects Age % Male CKD stage eGFR HtTKV UAlb 
Identification 
cohort 
Healthy  
(n = 6) 
49.2 ± 5.1 50 - N.M. - 2.2 ± 1.2 
 ADPKD 
(n = 6) 
48.7 ± 5.5 50 2 - 3 47.5 ± 4.2 1101 ± 346 3.0 ± 1.4 
Confirmation 
cohort 1 
Healthy 
(n = 6) 
49.7 ± 3.5 50 - N.M. - 0.5 ± 0.1 
 CKD* 
(n = 6) 
48.8 ± 3.2 50 3 45.7 ± 3.5 - 8.2 ± 4.8 
 ADPKD 
(n = 6)  
50.3 ± 3.1 50 2 - 3 49.8 ± 4.5 1481 ± 223 2.3 ± 0.4 
Confirmation 
cohort 2 
CKD  
(n = 4) 
44.3 ± 2.1 75 3 48.5 ± 4.6 - 6.5 ± 6.0 
 ADPKD 
(n = 5) 
47.6 ± 3.3 60 2 - 3 44.2 ± 10.9 1258 ± 355 6.0 ± 2.8 
Confirmation 
cohort 3 
Healthy 
(n = 4) 
30.0 ± 0.7 50 - N.M. - 6.3 ± 1.8 
 ADPKD 
(n = 6)  
27.8 ± 2.0 50 1 109.8 ± 4.3 622.3 ± 48.2 7.5 ± 2.0 
 ADPKD 
(n =11)  
43.6 ± 1.8 45 2 - 4 45.1 ± 3.8 1475 ± 297.4 2.7 ± 1.3 
 
 
Table 1: Characteristics of patients and healthy subjects. * CKD due to hypertensive 
nephropathy in all patients.  
ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; eGFR, 
estimated glomerular filtration rate (calculated by the 4 variable Modification of Diet in Renal 
Disease formula); HtTKV, height adjusted total kidney volume; N.M., not measured; UAlb, 
urinary albumin. 
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Confirmation of plakins and complement in ADPKD-uEVs 
Five proteins that were more abundant in uEVs of ADPKD-patients were 
selected for confirmation and further characterization based on the pathway 
analysis and their possible involvement in the pathophysiology of ADPKD (15-
19). These proteins included villin-1, envoplakin, periplakin, C3, and C9 (Table 
3). To confirm the quantitative proteomics results, we immunoblotted the five 
proteins using the same pooled uEV-samples as were used for the proteomics 
studies (Figure 1B, Figure 3). Indeed, the abundance of all five proteins was 
higher for the ADPKD-group compared to the two other groups. Similar 
abundances of CD9 suggested comparable number of vesicles in the three 
groups (20). Subsequently, the five proteins of interest were analyzed in uEVs 
from a third group of ADPKD patients (Figure 1C) and compared with the 
CKD group (Figure 4). Again, this analysis confirmed the higher abundance of 
the five selected proteins in ADPKD-uEVs, but now also on an individual basis. 
Because our identification and confirmation cohorts 1 and 2 consisted of older 
ADPKD patients with CKD stage 2-3, we also analyzed our proteins of interest 
in a third confirmation cohort (Figure 1D) consisting of younger ADPKD 
patients with preserved renal function and additional APDKD patients with 
CKD stages 2-4 (Figure 5). As CD9 declined with progressive CKD, we 
analyzed the ratio between uEV protein abundance and CD9. Villin-1, 
periplakin, and envoplakin were increased only in progressive CKD, whereas 
complement was already increased in uEVs from ADPKD patients with 
preserved renal function. In addition, all five proteins correlated with height 
adjusted total kidney volume (Figure 5B).  
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Figure 2: A: Venn diagram showing that urinary extracellular vesicles (uEVs) contained a 
different set of unique proteins compared to whole urine. B: Comparison of the cellular 
components to which the unique proteins identified whole urine (n=521) and uEVs (n=718) 
belong. For comparison whole urine is set at a relative abundance of 1. 
 
	
 
Biological process GO numbers* Number of proteins 
Urinary extracellular vesicles   
Actin filament-based process 0030029, 0030832, 0030036, 
0008064, 0030833 
60 
Lymphocyte mediated immunity 0002449 25 
Activation of plasma proteins involved in 
acute inflammatory response  
0002541 24 
Adaptive immune response  0002250, 0002460 24 
Complement activation  0006956 23 
Oxidation reduction  0055114 81 
Positive regulation of hydrolase activity 0051345 22 
Regulation of protein polymerization  0032271 22 
Whole urine   
Innate immune response 0045087, 0006955, 0050778, 
0002252 
107 
Programmed cell death 0012501, 0016265, 0008219 48 
Response to extracellular stimulus 0009991, 0031667 29 
Carbohydrate catabolic process  0016052 28 
Proteolysis  0006508 93 
 
Table 2: Gene Ontology (GO) biological process terms over-represented in uEVs and whole 
urine of patients with ADPKD. * Several GO-terms were combined if processes were similar 
and directly linked.  P-value ≤ 0.05 for all GO-terms as calculated by DAVID annotation tool. 
P ≤ 0.05 is considered strongly enriched. 
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Characterization of plakins and complement in uEVs 
We further characterized the five proteins by density-based fractionation using 
sucrose (Figure 6). This was done to analyze with which type of vesicles the 
proteins associate, using CD9 and CD63 as markers for exosomes (20), and 
NHE3 and AQP2 as markers for vesicles derived from the proximal tubule or 
collecting duct, respectively. An additional advantage of density-based 
fractionation is that protein complexes and large protein aggregates may be co-
isolated during ultracentrifugation, but do not float on a sucrose gradient (21). 
This analysis suggested the presence of two populations of vesicles. More 
specific, periplakin, envoplakin, villin-1, and C9 were detected in CD9 and 
CD63 positive fractions, suggesting their presence in exosomes (20). All six 
proteins were also detected in the fractions representing denser vesicles 
(fractions 2 – 4). The presence of AQP2 in these denser vesicles (mainly in 
fraction 3) suggests that some of these vesicles are derived from the collecting 
duct (22).  
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Figure 3: Immunoblot analysis of the five selected proteins using the same pooled urine as was 
used for quantitative proteomics in the validation group. The first three rows show results for 
isolated uEVs (Pellet), while the last three rows show results for the supernatant (SN), which 
was used as negative control. Anti-complement C3 antibody recognizes the C3 alpha chain 
(aC3) and its split product iC3b. H, healthy subjects; CKD, chronic kidney disease; PKD, 
polycystic kidney disease. 
	
 
	
	
 
Figure 4: Immunoblot analysis comparing the proteins of interest between individual CKD and 
ADPKD patients. uEVs were isolated from individual spot urines of CKD and ADPKD patients 
(confirmation cohort 2). Anti-complement C3 antibody recognizes the C3 alpha chain (aC3) 
and its split product iC3b. * P < 0.05.  
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Figure 5: A: Immunoblot analysis comparing the proteins of interest in uEVs from individual 
healthy subjects, young ADPKD patients with preserved renal function and ADPKD patients 
with CKD stage 2-4. * P < 0.05.  
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Figure 5: B: Correlations of abundances of the uEV proteins of interest compared to height 
adjusted total kidney volume. Spearman ρ and P-values are shown.  
HtTKV, height adjusted total kidney volume. 
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Figure 6: Sucrose gradient fractionation was performed to analyze with which type of vesicles 
the identified proteins associate. Fraction 1 represents the most dense fraction. In addition to 
the six proteins of interest, we also analyzed CD9 and CD63 (markers for urinary exosomes) 
and NHE3 and AQP2 (markers for proximal tubule and collecting duct). ‘Pellet’ refers to a 
part of the pooled ultracentrifugation pellet used for direct immunoblotting (positive control). 
Anti-complement C3 antibody recognizes the C3 alpha chain (aC3) and its split product iC3b.   
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Figure 7: A: Immunoblot analysis comparing the proteins of interest in kidney homogenates of 
three inducible ADPKD mouse models. ‘P’ indicates the post natal day at which the Pkd1-gene 
was inactivated with tamoxifen. The P40 mice were sacrificed at two different time points, 
producing a mild (normal blood urea) or severe (elevated blood urea) phenotype. Each ADPKD 
group was compared to wild-type. * P < 0.05.   
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Figure 7: B: Correlations between kidney weights and kidney abundances of villin-1, 
envoplakin, periplakin, complement C3d, C9. Spearman ρ and P-values are shown. 2KW/BW: 2 
kidney weight to body weight ratio. 
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Increased plakins and complement in ADPKD mouse models 
To analyze whether the proteins of interest were also more abundant in 
polycystic kidneys, we used three variants of kidney-specific-tamoxifen-
inducible Pkd1-deletion (iKsp-Pkd1del) mice (See Supplementary Table 2 online) 
(23). Pkd1 inactivation in these mice was induced at either post natal day (P) 
10, 18 or 40, which results in distinct PKD phenotypes. The P10 model rapidly 
develops cysts primarily from distal tubules and collecting ducts (24), whereas 
the P40 model has a much slower progression with cysts derived primarily from 
the proximal part of the nephron and to a lesser extent from distal tubules and 
collecting ducts (25). The P40 mice were sacrificed after 117 or 140 days 
resulting in a mild (normal blood urea) or severe (elevated blood urea) 
phenotype. In addition, the P18- iKsp-Pkd1del mice is an adult onset model with 
cysts from all different tubular segments (26). The abundances of both 
periplakin and envoplakin were significantly higher in the P10, P18, and to a 
lesser extent the P40 severe models (Figure 7A). Villin-1 was increased in P18 
and P40. Complement C3d (the final breakdown product of activated C3) and 
C9 were increased in the P18 model, but decreased in P10. Of note, the lower 
abundances of C3d and C9 may be related to age rather than to ADPKD (wild 
type mice 4 and 5 were younger than the other wild type mice, but had the 
same age as the P10 mice, Supplementary Table 2 online). No changes in C3 
and C9 were found in the P40 models. Furthermore, we found that protein 
abundance correlated positively with total kidney weight for villin-1, 
envoplakin, complement C3d and C9 (Figure 7B).  
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Table 3A: Proteins more abundant in uEVs of patients with ADPKD. No ratio was calculated 
(N.C.) if the protein was identified in patients with ADPKD but was absent in the healthy 
subjects or patients with non-ADPKD CKD (or identified at very low levels). † These proteins 
were selected for confirmation and further characterization.  
	
 
	
 
	
 
	
Group Protein Group 1 
(vs. hlty)* 
Group 2 
(vs. hlty)*  
Group 2  
(vs. CKD)* 
Plakins Desmoplakin 4.4 N.C. N.C. 
 Envoplakin† ¶ 12.7 2.2 N.C. 
 Periplakin† 10.8 2.0 N.C. 
Complement Complement C3† 2.5 13.8 7.4 
 Complement C5 3.9 N.C. 74.8 
 Complement C4-B 3.1 5.9 4.3 
 Complement C9† 7.5 10.2 5.8 
 Complement factor B 13.7 20.3 8.5 
 Complement C1q subcomponent subunit A 2.0 N.C. N.C. 
Glycoproteins Protein tweety homolog 3 ¶ 2.2 2.1 2.5 
 Isoform 2 of Solute carrier family 22 member 13 ¶ 5.4 2.2 N.C. 
 V-set domain-containing T-cell activation inhibitor 1 3.1 2.45 3.09 
 Retinoic acid-induced protein 3 ¶ 6.6 2.15 3.45 
 Pigment epithelium-derived factor 6.0 5.23 8.27 
 Heparin cofactor 2 2.1 30.32 N.C. 
 Inter-alpha-trypsin inhibitor heavy chain H1 3.2 N.C. 21.69 
Miscellaneous Villin-1† ¶ 3.0 2.4 11.8 
 Tyrosine-protein phosphatase non-receptor type 13 ¶ 2.6 2.36 N.C. 
 Soluble of Catechol O-methyltransferase ¶ 2.1 4.10 2.98 
 Protein crumbs homolog 3 ¶ 2.6 N.C. N.C. 
 Aconitate hydratase, mitochondrial ¶ 3.0 3.05 N.C. 
 Apolipoprotein A-IV ¶ 2.6 4.30 2.82 
 Cysteine-rich C-terminal protein 1 ¶ 15.8 13.05 N.C. 
 Glycogen phosphorylase, brain form 4.1 2.03 N.C. 
 Angiotensinogen 10.5 11.70 9.95 
 Calpain-5 ¶ 2.3 2.1 9.0 
 EH domain-containing protein 4 2.6 2.2 15.1 
 Gamma-synuclein 2.2 3.4 N.C. 
 Prothrombin 6.0 3.96 2.82 
 Plasminogen 23.6 4.84 2.77 
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Table 3B: Proteins less abundant in uEVs of patients with ADPKD. * Mean ion intensities were 
compared and are reported as ratios. ¶ These proteins were not identified in whole urine. CKD, 
chronic kidney disease group; Hlty, healthy subjects. 
 
 
 
 
DISCUSSION 
 
Urinary extracellular vesicles (uEVs) are increasingly used to identify non-
invasive markers of disease, including ADPKD. Here, we show higher 
abundances of complement-related proteins (C3 and C9) and cytoskeletal 
proteins (villin-1 and plakins) in ADPKD-uEVs, and suggest these proteins may 
be used as disease markers. Complement C3 and C9 increase already early in 
the disease, whereas the cytoskeletal proteins increased with more progressive 
disease. The interpretation of proteomic analyses of uEVs deserves to be 
critical, because many aspects of uEVs remain unclear (5). However, we believe 
the strength of the approach in this study was that (1) two complementary 
proteomics approaches were used to identify proteins of interest, (2) the 
proteins of interest were higher in four independent groups of ADPKD patients, 
(3) results were compared with non-ADPKD CKD-uEVs to exclude proteins 
related to kidney function decline in general, (4) the proteins of interest 
correlate to total kidney volume, and (5) the proteins of interest were also 
increased in mouse models of ADPKD.  
 
The identification of villin-1, plakins, and complement in uEVs of patients with 
ADPKD may be biologically plausible. Villin-1 is an actin-modifying protein 
that is involved in cell morphology, actin reorganization and cell motility; in the 
Protein Group 1 (vs. hlty)* Group 2 (vs. hlty)* Group 2 (vs. CKD)* 
Annexin A2 0.12 0.41 0.49 
Contactin-1 0.43 0.26 0.14 
Syndecan-4 ¶ 0.40 0.08 0.19 
Granulins OS 0.34 0.50 0.23 
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kidney, it is mainly expressed in the brush border of the proximal tubules (27). 
Polycystin-1 is implicated in the regulation of actin cytoskeleton organization, 
migration and cell adhesion (28). Defects in polycystin-1 results in cell-polarity 
defects (29) and aberrant cell growth (30), which may explain the increase of 
villin-1. The desmosomal plaque consists of several transmembrane proteins 
belonging to the cadherin family (also called plakins (31)). Desmosomes form 
an adhesive junction at the basolateral membrane and are vital for stabilizing 
the epithelial sheet. Polycystin-1 is associated with desmosomal proteins and is 
required for the establishment of cell polarity (19, 32). In ADPKD, polycystin-1 
no longer co-localizes with desmosomes leading to mispolarization of 
desmosomal proteins from the basolateral side to the apical domain (17). This 
may explain why we found higher abundances of plakins in uEVs of patients 
with ADPKD. Complement activation has previously been implicated in both 
ARPKD and ADPKD (15, 16, 18). Gene expression analysis in cpk mice, a 
model for PKD, identified the innate immune response to be highly activated, 
specifically complement factors such as C3 (16). In humans, cyst epithelial cells 
produce complement components, including C3 and C9, as shown in 
immunohistochemical staining (15, 18). Many of the complement components 
are abundantly present in human ADPKD kidney cyst fluid (33, 34). 
Furthermore, inhibition of the complement system by rosmarinic acid in Pkd1-/- 
mice and Han:SPRD Cy/+ rats reduced cyst growth (18), suggesting that the 
complement pathway is involved in the pathogenesis of ADPKD. We identified 
nearly all complement proteins in uEVs, both from the classical (C1q, C2, and 
C4) and alternative pathways (complement factors B and D), along with 
inhibitors of this system (plasma protease C1 inhibitor, C4 binding protein and 
complement factor B). Complement C9 co-localized with the exosomal markers 
CD9 and CD63, suggesting its presence in exosomes. However, complement C3 
was mainly identified in a denser fraction, as was previously demonstrated (35). 
Other studies also reported the presence of complement in uEVs (35-37) and 
circulating EVs (38, 39). It is unclear why complement is isolated in 
ultracentrifuged urine and whether complement is physically associated with 
uEVs. In theory, complement may be filtered from plasma and end up non-
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specifically attached to uEVs. However, most complement proteins are large in 
size (the majority exceeding 70 kDa), and therefore unlikely to be filtered. A 
more plausible explanation is the local production and excretion of complement 
by renal epithelial cells (40), possibly to opsonize pathogens as a defense 
mechanism for urinary tract infections (41, 42). The higher abundance of 
components of the complement system in uEVs of patients with ADPKD may 
reflect increased production by renal cyst epithelial cells.  
Recently, Hogan et al. also studied uEVs as a source of biomarkers for ADPKD 
(43). In patients with a PKD1 mutation, they found polycystin-1 and 
polycystin-2 to be decreased, and transmembrane protein 2 (TMEM2) to be 
increased. The ratios between the two polycystins and TMEM2 allowed 
differentiation between patients with ADPKD and healthy subjects. In our 
study, polycystins were not identified in our first quantitative proteomics 
experiment (identification cohort), and therefore not selected for further 
confirmation. In the second analysis (confirmation cohort 1), polycystin-2 was 
identified and 83% lower in ADPKD compared to healthy subjects, but was not 
identified in the CKD-group. Polycystin-1 was only identified in the control 
group, and TMEM2 was not identified at all. We propose the following 
explanations for these differences. First, in order to analyze the complete 
spectrum of vesicles, we did not fractionate uEVs, whereas Hogan et al. isolated 
polycystin-positive uEVs (43). This difference in isolation methods may explain 
why polycystin-1 and polycystin-2 were 5- to 7-fold more abundant in the 
study by Hogan et al. (43). Second, our patients with ADPKD had a lower 
eGFR. In addition to the mutation, the decreasing eGFR may explain why we 
observed a larger decrease in polycystin-2 and failed to identify polycystin-1 in 
patients with ADPKD.  
 
The reason to focus on uEVs is illustrated by the comparison of the urinary 
proteome of whole urine with that of uEVs (Figure 2). The proteins identified in 
whole urine by mass spectrometry primarily consisted of extracellular proteins 
with low molecular weight and were therefore most likely plasma-derived (12). 
Despite the fact that whole urine still contained uEVs, the isolation of uEVs 
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yielded a set of 718 unique proteins that were primarily of intracellular origin. 
These differences underscore that the isolation of uEVs increases the 
identification rate of low-abundant proteins that are likely derived from renal 
epithelial cells. These proteins were not identified in whole urine, probably 
because they were masked by more abundant plasma-derived proteins. To our 
knowledge only one study has compared these two proteomes, using less 
sensitive mass-spectrometers (< 100 identified proteins in each fraction) (44). 
Gradient fractionation showed that all proteins were present in CD9+ and 
CD63+ vesicles, compatible with exosomes, but also revealed their presence in 
denser vesicles. These might be ectosomes from the glomerulus (35), but 
electron microscopy would be necessary to confirm this. The distinction in 
vesicle subtype is relevant, because polycystin 1 and 2 are excreted in exosomes. 
This implies that selectively isolating CD9, CD63 or polycystin-positive vesicles 
may be a useful strategy to more specifically analyze disease-associated 
proteins.43  
 
Our study has a number of limitations. Pooled urine was used for proteomics 
analysis to increase homogeneity, but this did not allow statistical analysis of 
the proteomics results. This was addressed by analyzing the candidate proteins 
in individual patients from a separate ADPDK group (Figures 4 and 5). 
Although the inclusion of two proteomics studies reduced the list of candidate 
proteins, we believe this approach excluded proteins related to inter-subject 
variation and non-ADPKD CKD. It is unlikely that uEV-markers will be used as 
diagnostic tool in ADPKD, as the diagnosis can usually be established by family 
history, ultrasound, or CT-scan (2). Therefore, to be clinically useful, uEV-
markers should correlate with disease progression or response to therapy The 
proteins identified in this study should therefore be considered candidate 
markers and require further evaluation in larger prospective studies using serial 
urine samples (45). Unlike the complement proteins, villin-1 and the plakins 
appear unsuitable for early monitoring of ADPKD. They may be evaluated in 
more advanced stages of ADPKD, for example for monitoring therapeutic 
response. Importantly, kidney injury unrelated to ADPKD may also increase 
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complement in uEVs, although several studies have indicated that complement 
may play a more specific role in the disease. These aspects should be taken into 
consideration in future evaluation of the candidate proteins identified in this 
study.  
 
In conclusion, we have demonstrated the advantage of uEVs to enrich the 
urinary proteome. We explored uEVs as potential biomarkers for ADPKD and 
identified several classes of proteins to be specifically increased, including 
plakins and components of the complement system. These findings warrant 
further investigation of these proteins as potential biomarkers in a larger 
prospective cohort.  
 
 
 
CONCISE METHODS 
 
Participants and isolation of uEVs 
The Medical Ethics Committee of the Erasmus Medical Center approved this 
study (MEC-2012-313 and MEC-2013-370). Patients with ADPKD were 
recruited from the ongoing DIPAK-1 and DIPAK-observational studies, which 
include ADPKD patients with preserved renal function as well as those with 
CKD stage 2-4 (46). Genetic analysis was performed for all patients. To 
increase homogeneity, we only included patients with a confirmed PKD1 
mutation (Supplementary Table 1 online). Two patients with a negative PKD2 
mutation and an ADPKD phenotype were also considered PKD1 mutation (47). 
Each individual patient was age- and gender-matched to a healthy control 
(identification cohort) or an age-, gender- and eGFR-matched patient with CKD 
(confirmation cohorts 1 and 2). Additional inclusion criteria for the patients 
with CKD were the absence of ADPKD and minimal proteinuria (< 1 gram/10 
mmol creatinine). Previously, we successfully used spot urines for uEV analysis 
(normalized by urinary creatinine) and prefer this over 24-hour urine to limit 
protein degradation and the risk of incomplete collections (8). Therefore, 
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second morning spot urines were collected, a protease inhibitor (cOmplete, 
Roche diagnostics) was added and samples were immediately stored at -80°C 
until further processing. uEVs were isolated using high-speed centrifugation and 
ultracentrifugation (see Supplemental File online for complete protocol) (8). 
Our protocol differed from a recent uEV-study in ADPKD, (48) which used 
density gradient fraction to enrich for PKD-positive uEVs. We did not use this 
approach because we were interested in all uEVs. A recent study compared 
different uEV isolation protocols and concluded they were comparable (49). 
Dithiothreitol was used in our protocol because this disrupts uromodulin which 
may entrap uEVs (20), although it may also cause loss of certain uEV proteins. 
Obtained pellets were processed for mass-spectrometry or solubilized in 
Laemmli buffer for immunoblot analysis. Supplementary Figure 2 shows a 
representative SDS-Page gel for three uEV samples stained with Coomassie 
Blue. 
 
Mass spectrometry  
Samples were prepared for mass spectrometry as described previously. Briefly, 
uEVs and acetonone-precipiated whole urine were lysed and trypsinized. 
Tryptic peptides were fractionated by HILIC and each fraction was then 
analyzed by LC-MS. For quantitative dimethyl labeling of uEVs (identification 
cohort), desalting and reductive dimethylation was performed on the SPE 
cartridge (as described in (50)) before peptide fractionation by HILIC. All LC–
MS/MS analyses were performed on a Q Exactive mass spectrometer (Thermo 
Scientific, San Jose, CA). Each Data collection cycle in the Q Exactive consisted 
of 1 full MS scan (300-1750 m/z) followed by 15 data dependent MS/MS scans. 
The proteomics data have been submitted to the ProteomeXchange Consortium 
via the PRIDE partner repository with the dataset identifier PXD003298 (51). 
 
Bioinformatics 
Raw data files were processed and analyzed using Proteome Discoverer 1.4 
(Thermo Fisher Scientific) or MaxQuant (52). MS/MS spectra were searched 
against the Uniprot database (taxonomy: Homo sapiens) with the following 
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search parameters: 15 ppm precursor ion tolerance and 0.02 Da fragment ion 
tolerance, fully tryptic digestion, up to two missed cleavages were allowed, 
posttranslational static modifications of 57.02146 Da on cysteine 
(carbamidomethyl), dynamic modifications of 15.99491 Da on methionine 
(oxidation). For dimethylation labeled uEV samples 28.031 Da on lysine and 
the peptide N-terminus (light) and 32.056 Da on lysine and the peptide N-
terminus (heavy) were added to the search parameters. The resulting data were 
analyzed using the DAVID bioinformatics tool (Database for Annotation, 
Visualization and Integrated Discovery, NIAID, Bethesda, MD) to determine 
which Gene Ontology terms are over-represented relative to the complete set of 
identified proteins. For this analysis, we excluded those pathways that were 
similarly enriched in healthy subjects or the CKD group. Gene Ontology terms 
were retrieved by the software tool for rapid annotation of proteins (STRAP 
version 1.5.0.0) (53).  
 
Immunoblotting and sucrose gradient fractionation 
The solubilized uEV pellet was preheated at 60°C for 15 min. SDS/PAGE was 
carried out on a 4-20% gradient gel and proteins were transferred to Trans-
Blot® Turbo™ (Biorad, United States). The membranes were blocked in 5% 
milk and were probed overnight at 4°C with the antibody of choice. The 
following antibodies were used: envoplakin (Santa Cruz, 1:200), periplakin 
(Abcam, 1:2000), complement C3 (Abcam, 1:1000), complement C9 (Abcam, 
1:1000), Villin-1 (anti-human: abcam, 1:10000, anti-mouse: Cell signaling, 
1:1000), CD9 (Santa Cruz, 1:200) and CD63 (BD biosciences, 1:500), NHE3 
(Stressmarq, 1:10,000), AQP2 (Stressmarq, 1:1000). The antibodies against 
mouse C3dg, C3d, and C9 were generated by one of the investigators (CvK) 
(54). After three washes (3 x 10 minutes in TBS-Tween 20), membranes were 
incubated with the secondary antibody in 5% milk (Thermo Scientific, 
Rockford, IL USA, 1:3000) for 1 hour and washed again. For visualization, 
blots were exposed to Pierce® enchanced chemiluminescent substrate and 
measured by Uvitec Alliance 2.7 (Cambridge, UK). Chemiluminescence was 
quantified using Imagequant TL (Life Sciences version 8.1), background was 
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substracted and ratios were measured in Excel. For the sucrose gradient 
fractionation, we used spot urine samples from 4 ADPKD patients. After 
pooling the samples and obtaining the uEV pellets, we ultracentrifuged uEVs 
overnight on top of a 2.5M to 0.25M sucrose gradient, corresponding to a 
density of 1.32 g/m3 to 1.03 g/m3. Each fraction was carefully removed, diluted 
in PBS and ultracentrifuged again to obtain the pellet. Fractions were 
solubilized in Laemmli for immunoblot analysis.  
  
Mouse models of ADPKD  
The local animal experimental committee of the Leiden University Medical 
Center and the Commission Biotechnology in Animals of the Dutch Ministry of 
Agriculture approved the animal experiments. The generation of the iKsp-
Pkd1del mice and tamoxifen administration to these mice were described 
previously (23). On three consecutive days the mice received a tamoxifen 
dosage of either 6 mg/kg at P10-12, 150mg/kg at P18-20, or 200 mg/kg 
tamoxifen at P40-P42 (Supplementary Table 2 online). The P10 mice were 
euthanized at 33 days of age at which the mice have relatively severe PKD. The 
P18 and the P40 mice were euthanized at the onset of renal failure (defined as a 
blood urea level > 20 mmol/L, as assessed by Reflotron technology; Kerkhof 
Medical Service). An additional time-point with mild PKD of the P40 mice (11 
weeks after Tamoxifen) was included. Protein extraction from these kidneys 
was performed as described previously (25).  
 
Statistical analysis  
Immunoblotting results were analyzed by Student’s T-test or Mann-Whitney U-
test, as appropriate. A P-value ≤ 0.05 was considered statistically significant. 
Gene ontology enrichment was calculated by the DAVID bioinformatic tool, 
which applies the Fisher Exact test (P ≤ 0.05 is considered strongly enriched).  
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Supplementary Figures: 
 
 
 
Supplementary figure 1: immunoblot of whole urine or urinary extracellular vesicles loaded 
with similar protein concentrations  
 
	
	
 
 
 
Supplementary figure 2: SDS-PAGE of three uEV samples stained with Coomassie blue  
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ABSTRACT  
	
In autosomal dominant polycystic kidney disease (ADPKD) activation of the 
renin-angiotensin aldosterone system (RAAS) may contribute to hypertension 
and disease progression. Although previous studies focused on circulating 
RAAS-components, preliminary evidence suggests APDKD may increase urinary 
RAAS-components. Therefore, our aim was to analyze circulating and urinary 
RAAS-components in ADPKD. We cross-sectionally compared 60 patients with 
ADPKD to 57 patients with non-ADPKD chronic kidney disease (CKD). The 
two groups were matched by gender, estimated glomerular filtration rate 
(eGFR), blood pressure, and RAAS-inhibitor use. Despite similar plasma levels 
of angiotensinogen and renin, urinary angiotensinogen and renin excretion were 
5- to 6-fold higher in ADPKD (P<0.001). These differences persisted when 
adjusting for group differences, and were present regardless of RAAS-inhibitor 
use. In multivariable analyses, ADPKD, albuminuria, and the respective plasma 
concentrations were independent predictors for urinary angiotensinogen and 
renin excretion. In ADPKD, both plasma and urinary renin correlated 
negatively with eGFR. Total kidney volume correlated with plasma renin and 
albuminuria, but not with urinary renin or angiotensinogen excretions. 
Albuminuria correlated positively with urinary angiotensinogen and renin 
excretions in ADPKD and  CKD. In three ADPKD patients who underwent 
nephrectomy, the concentrations of albumin and angiotensinogen were highest 
in plasma followed by cyst fluid and urine; urinary renin concentrations were 
higher than cyst fluid. In conclusion, this study shows that, despite similar 
circulating RAAS-component levels, higher urinary excretions of 
angiotensinogen and renin are a unique feature of ADPKD. Future studies 
should address the underlying mechanism and whether this may contribute to 
hypertension or disease progression in ADPKD.  
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INTRODUCTION  
	
Hypertension develops early in autosomal dominant polycystic kidney disease 
(ADPKD), usually occurring before a reduction in glomerular filtration rate 
(GFR) with an average age of onset of 30 years (5, 9). Increased activity of the 
renin-angiotensin-aldosterone system (RAAS) has been implicated in the 
pathogenesis of hypertension in ADPKD. One hypothesis is that cyst expansion 
results in areas of local renal ischemia, which increases renin release (3, 5). In 
addition, renin has also been suggested to be produced by the epithelial cells 
lining the cysts and active renin can be found within the cyst fluid (12, 36). 
However, measurement of plasma renin and aldosterone in patients with 
ADPKD yielded equivocal results (Table 1). Several studies found that plasma 
renin and aldosterone concentrations were not higher in hypertensive ADPKD 
patients when compared to controls, even during specific interventions (low or 
high sodium diet, ACE-inhibition, angiotensin II infusion) (1, 7, 21, 29, 37, 40). 
Different control groups were used for these studies, including normotensive 
ADPKD patients, normotensive siblings without ADPKD, patients with 
essential hypertension, or healthy volunteers (Table 1). The observation that 
plasma renin activity was not consistently higher in hypertensive ADPKD 
patients is notable, because this is contrary to what would be expected if cysts 
caused local renal ischemia (3, 5). Therefore, to further address the role of the 
RAAS in ADPKD, it may be informative to analyze RAAS-components in urine, 
as urinary angiotensinogen and renin have previously been used as markers of 
the intra-renal renin-angiotensin system (32). Emerging data suggest that 
filtered or locally produced RAAS-components may activate this intrarenal 
renin-angiotensin system and thereby contribute to hypertension (11). Two 
recent studies reported higher urinary angiotensinogen concentrations in 
hypertensive ADPKD patients (15, 25). However, despite its postulated central 
role in the pathogenesis of hypertension, urinary renin has never been measured 
in patients with ADPKD. We recently showed that it is important to measure 
urinary renin with standardized assays, because commercial assays may 
produce ≥ 10-fold higher results (31). Therefore, here, we measured urinary 
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renin in patients with ADPKD using a validated renin immunoradiometric assay 
and an in-house enzyme kinetic assay. In addition, we also measured multiple 
other RAAS-components in plasma and urine, including plasma renin and 
aldosterone, and urine angiotensinogen, prorenin, and aldosterone. As a 
comparator, and for the first time, we used matched patients with non-ADPKD 
chronic kidney disease (CKD) to address whether the type of kidney injury 
affects the RAAS differently.  
	
Study Cases CKD 
stage 
Controls Numbers Measurement(s) Difference 
Valvo (37) ADPKD + HT 1-3 ADPKD + NT 20 vs. 12 PRA ↔ 
Bell (3) ADPKD + HT 1-2 ADPKD + NT 9 vs. 7 PRA during low/ 
high Na+ diet + ACEi 
↔ but ↑ during 
ACEi + high Na+ 
diet 
Chapman (5) ADPKD  1 Essential HT + 
healthy controls 
14 + 11 vs. 9 + 
13 
PRA and aldo during 
ACEi 
PRA and aldo ↑ in 
ADPKD + HT 
Harrap (13) ADPKD 1 Siblings 19 vs. 20 PRA and aldo PRA and aldo ↑  
Watson (40) ADPKD  1-2 Siblings 13 vs. 10 PRA ↔ 
Barrett (1) ADPKD 1-2 Siblings 21 vs. 12 PRA and aldo during 
low/high Na+ diet, 
ACEi, Ang II 
infusion 
↔ 
Martinez-
Vea (21) 
ADPKD + HT 2-3 Essential HT 20 vs. 20 PRA, aldosterone, 
ANP, Ang II 
↔ 
Ramunni 
(29) 
ADPKD + HT 1-2 ADPKD + NT 17 vs. 17 PRA ↔ 
Doulton (7) ADPKD + HT 1-2 Essential HT 11 vs. 8 PRA during low/high 
Na+ diet and ACEi 
↔ 
Kurultak 
(17) 
ADPKD 1 Healthy controls 20 vs. 20 Urinary AGT ↔ 
Kocyigit (15) ADPKD + HT 1-2 ADPKD + NT, 
healthy controls 
43 vs. 41 + 40 Plasma and urinary 
AGT 
Urinary AGT ↑ 
Park (25) ADPKD  1-5 None 186  Plasma renin+ aldo, 
urinary AGT 
Correlation 
urinary AGT with 
eGFR, TKV, BP 
Present study ADPKD 3 CKD 69 vs. 58 Plasma + urinary 
AGT, renin, aldo 
Urinary AGT + 
renin ↑ 
	
Table 1: Comparison of studies measuring RAAS-components in patients with ADPKD. 
ADPKD, autosomal dominant polycystic kidney disease; ACEi, angiotensin converting enzyme 
inhibitor; AGT, angiotensinogen; aldo, aldosterone; Ang II, angiotensin II; CKD, chronic 
kidney disease; eGFR, estimated glomerular filtration rate; HT, hypertension; NT, 
normotension; PRA, plasma renin activity; BP, blood pressure. 
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MATERIALS AND METHODS 
	
Patients 
Patients with ADPKD were recruited from one of the centers (Erasmus Medical 
Center, Rotterdam, The Netherlands) participating in a national ADPKD 
consortium (DIPAK study, with inclusion criteria CKD stage 3 at entry into the 
study and age ≤ 60 years) (23). Patients were matched to non-ADPKD CKD 
patients (referred to hereafter as ‘CKD’) from the PREVEND cohort (University 
Medical Center Groningen) (18). The Medical Ethics Committees of the 
Erasmus Medical Center and University Medical Center Groningen approved 
the studies (MEC-2012-313 and METC-90/01/022). Patients with ADPKD and 
CKD were individually matched for gender, eGFR (using the Modification of 
Diet in Renal Disease equation (19)), use of RAAS-inhibitors (defined as the use 
of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) 
and blood pressure (difference in systolic blood pressure ≤ 5 mmHg). Patients 
with a history of diabetes mellitus, or those using insulin or oral glucose 
lowering drugs were excluded, because diabetes mellitus may activate the 
intrarenal renin-angiotensin system (38). From three ADPKD patients who 
underwent elective nephrectomy (not part of the DIPAK cohort), we collected 
plasma, cyst fluid, and urine samples. For this part of the study, a separate 
approval from the Medical Ethics Committee of the University Medical Center 
Groningen was obtained (METC 2014.396). 
 
Data Collection 
Detailed description of data collection for both the DIPAK and PREVEND 
studies has been described elsewhere (18, 23). Briefly, participants of both 
studies collected 24-hour urine and visited the outpatient clinic for blood 
sampling and blood pressure measurements using an automatic oscillometric 
device. Hypertension was defined as a blood pressure > 140/90 mmHg or the 
use of anti-hypertensive medication. Participants were instructed to store urine 
at 4°C during collection. Upon arrival in the university medical center, blood 
and urine samples were immediately stored at -80°C until further use. We have 
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previously shown that in 24-hour urine, prorenin is not converted into renin 
prior to freezing (38). To determine adequate 24-hour urine collection, we 
calculated the expected 99% quantile of creatinine excretion based on 
previously defined criteria (10). Patients who exceeded the expected range were 
excluded (8 patients with ADPKD and 1 patient with CKD). ADPKD patients 
underwent magnetic resonance imaging to determine total kidney volume (23). 
The World Health Organization defined daily dose (DDD) was used to 
calculate daily RAAS-inhibitor use. 
 
Measurements  
Plasma and urine samples from the DIPAK and PREVEND cohorts were 
measured simultaneously. Renin in plasma was measured with a commercially 
available immunoradiometric kit (Renin III; Cisbio, Gif-sur-Yvette, France), 
making use of an active site-directed radiolabeled antibody (4). Total plasma 
renin was determined simultaneously using the same kit after the induction of a 
conformational change in the prorenin molecule with aliskiren (10 µmol/l for 
48 hours at 4°C), which enabled its recognition by the active site-directed 
radiolabeled antibodies applied in the Cisbio kit (2). The detection limit of this 
assay is 1 pg/ml with intra- and inter-assay coefficients of variation (CVs) of 
2.4% and 7.2%. Urinary renin and urinary total renin (after prorenin 
activation with trypsin) were measured with an in-house enzyme kinetic assay 
(EKA) (16). This measurement involves the incubation of the urine sample with 
excess sheep angiotensinogen and angiotensinase inhibitors and the subsequent 
detection of the generated Ang I by radioimmunoassay. The detection limit of 
the EKA is 0.05 ng Ang I/ml per hour with intra- and inter-assay CVs of 2.9 
and 12.6%. Ang I–generating activities were converted to renin concentrations 
based on the fact that 1 ng Ang I/ml per hour corresponds with 2.6 pg human 
renin/ml (16). Prorenin was determined by subtraction of renin from total 
renin. Angiotensinogen in plasma and urine was measured as the maximum 
quantity of Ang I that was generated during incubation with excess 
recombinant renin (6). The detection limit of this assay is 0.50 pmol/ml with 
intra- and inter-assay CVs of 4 and 10%. Aldosterone was measured by solid-
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phase radioimmunoassay (Diagnostic Products Corporation, Los Angeles, 
California, USA), with a detection limit of 25 pg/ml with intra- and inter-assay 
CVs of 3.3 and 8.4% (14). 
 
Statistical Analyses  
Results are expressed as mean and standard deviation or median and range, as 
appropriate. Data were logarithmically transformed before analysis in case of 
non-normal distribution. Levels that were below the detection limit were 
considered to be half the detection limit to allow for statistical analysis (8). 
Analysis of variance (ANOVA) was used for group comparison (using log-
transformed data as appropriate). Further analysis was performed using 
analysis of covariance (ANCOVA) to adjust for covariates. To analyze which 
parameters independently predicted urinary angiotensinogen or renin excretion, 
we performed multivariable linear regression. Finally, the Pearson correlation 
coefficient was analyzed for selected variables. A P-value < 0.05 was considered 
statistically significant. Statistical analyses were performed with SPSS (version 
21, IBM).  
	
	
	
RESULTS 
	
ADPKD Increases Urinary Angiotensinogen and Renin Excretion 
Table 2 shows the baseline characteristics and RAAS-component measurements 
for the ADPKD and CKD groups. Patients with ADPKD were younger (47 vs. 
68 years), taller (175 vs. 169 cm), and used more RAAS-inhibitors. While 
plasma levels of angiotensinogen, renin, and aldosterone were similar between 
the two groups, 24-hour urine volume, and urinary albumin, angiotensinogen, 
renin, and aldosterone excretions were significantly higher in patients with 
ADPKD (P < 0.05 for all). Similarly, when expressed as ratio with creatinine, 
urinary angiotensinogen and renin were also significantly higher in ADPKD 
(urinary angiotensinogen 14.6 vs. 3.3 pmol/mol creatinine, urinary renin 204 
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vs. 44 pg/mol creatinine, p < 0.01 for both). Because of the group differences in 
age, height, DDD, and albuminuria, we also performed a second analysis 
adjusting for these factors (Table 2). This analysis showed that urinary 
angiotensinogen and renin excretion were still significantly higher in ADPKD 
than CKD (P < 0.001 for both). In addition, a subanalysis was performed in 
patients (n = 17 vs. 11) with similar age, gender, height and a similar degree 
albuminuria , which also showed that urinary angiotensinogen (286.2 vs. 38.7 
pmol/day) and renin (1874 vs. 398.6 pg/day) excretions were significantly 
higher in ADPKD compared to CKD (P < 0.05 for both). 
 
Effects of RAAS-Inhibitors 
Because the use of RAAS-inhibitors increases plasma renin, this may also 
increase urinary renin. Therefore, we also report the plasma and urinary RAAS-
components in patients with and without RAAS-inhibitor use (Figure 1). 
Plasma renin was indeed significantly higher in both ADPKD and CKD patients 
using RAAS-inhibitors. In patients without RAAS-inhibitors, plasma renin was 
significantly lower in ADPKD than in CKD. Despite these differences in plasma 
renin, urinary renin excretion was consistently higher in the patients with 
ADPKD than in the patients with CKD regardless of RAAS-inhibitor use 
(Figure 1). Urinary angiotensinogen excretion was significantly higher only in 
patients with ADPKD and RAAS-inhibitor use, but this may be a power issue, 
as few patients were without RAAS-inhibitors. 
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Figure 1: Plasma concentrations and urinary excretions of angiotensinogen and renin in 
patients with ADPKD or CKD and with or without RAAS-inhibitors. Box-and-whisker plots of 
plasma concentrations and urinary excretions of renin and angiotensinogen for ADPKD (light 
grey) and CKD (dark grey). Groups were subdivided into those with (+) and without (-) use of 
RAAS-inhibitors (RAASi). Of the 60 patients with ADPKD, 10 patients did not use RAASi; of 
the 57 CKD patients, 13 patients did not use RAASi. Boxes show the median, interquartile 
range and range. ANOVA was used for comparison with * P < 0.05. 
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Category Parameter ADPKD 
(n = 60) 
CKD  
(n = 57) 
P-value* P-value** 
Clinical 
data 
Age, years 47 ± 8 68 ± 8 < 0.001  
 Male gender, n (%) 25 (42) 25 (44) N.T.¶  
 Height, cm 175 ± 10 169 ± 9 0.001  
 Weight, kg 81.6 ± 17.0 81.2 ± 11.9 0.9  
 Hypertension, n (%)† 56 (93) 49 (86) N.T.  
 SBP, mmHg 131 ± 14 134 ± 14 N.T.  
 DBP, mmHg 79 ± 9 76 ± 7 N.T.  
 RAAS-inhibitors, n (%) 50 (83) 44 (77) N.T.  
 DDD RAAS-inhibitors, n 1.9 ± 1.5 1.1 ± 0.9 < 0.001  
Plasma  Creatinine, mg/dL 1.5 ± 0.4 1.4 ± 0.4 0.6  
 eGFR, ml/min per 1.73 m2 48 ± 11 46 ± 9 N.T.  
 Angiotensinogen, pmol/mL 1599 (313–8067) 1455 (474–3567) 0.3  
 Renin, pg/mL 81.3 (9.6–950.0) 68.3 (14.8–464.5) 0.3  
 Aldosterone, pg/mL 121.7 (16.5–470.1) 105.9 (16.6–546.4) 0.2  
Urine  Volume, mL/day 2233 (800–6500) 1652 (530–3140) < 0.001 0.2 
 Creatinine, mmol/day 13.3 (5.2–21.2) 10.9 (6.0–18.2) < 0.001 0.8 
 Albumin, mg/day 40.0 (3.1–266.4) 26.7 (3.4–293.2) 0.05 - 
 Sodium, mmol/day 150 (40 – 354) 142 (60 – 371) 0.5  
 Angiotensinogen, pmol/day 194.4 (3.5–3384.0) 36.0 (2.3–1070) < 0.001 < 0.001 
 Renin, pg/day 2717 (375.7–69248.0) 485.5 (154.7–2293.0) < 0.001 < 0.001 
 Aldosterone, µg/day 4.6 (0.9–32.8) 3.5 (1.0–18.0) 0.02 0.2 
 
Table 2: Patient characteristics and renin-angiotensin-aldosterone system measurements.  
* Using analysis of variance (ANOVA) with log-transformed data as appropriate. ** Using 
analysis of covariance (ANCOVA) with log-transformed data as appropriate and adjustments 
for age, height, defined daily dose, and albuminuria. ¶ N.T., not tested (matching criteria).  
† Defined by use of antihypertensive drugs. ADPKD, autosomal dominant polycystic kidney 
disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; DDD, defined daily dose; 
eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure. 
 
 
 
Predictors of Urinary Angiotensinogen and Renin Excretion 
Two multivariable linear regression analyses were performed to analyze which 
factors independently predict urinary angiotensinogen or urinary renin 
excretion (Table 3). In the model we included the presence of ADPKD, eGFR, 
age, DDD, plasma concentrations of angiotensinogen and renin, and urinary 
sodium and albumin excretion. For urinary angiotensinogen excretion, 
ADPKD, eGFR, and albuminuria were identified as independent predictors. For 
urinary renin excretion, ADPKD, plasma renin, and albuminuria were identified 
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as independent predictors. When the analyses were restricted to patients with 
ADPKD, only albuminuria predicted urinary angiotensinogen excretion, and 
only plasma renin predicted urinary renin excretion (data not shown).  
 
Variable Urinary angiotensinogen excretion Urinary renin excretion 
 β P-value β P-value 
Presence of ADPKD 9.6 (3.7 – 24.5) < 0.001 4.9 (2.6 – 9.0) < 0.001 
eGFR, ml/min/1.73 m2 0.96 (0.94 – 0.99) 0.002 0.99 (0.98 – 1.01) 0.3 
Age, years 1.0 (0.9 – 1.1) 0.2 0.99 (0.97 – 1.02) 0.6 
DDD RAAS-inhibitors, n 0.8 (0.7 – 1.0) 0.1 0.9 (0.8 – 1.1) 0.2 
Plasma renin, pg/mL 0.5 (0.3 – 1.0) 0.05 1.9 (1.2 – 2.9) 0.007 
Plasma AGT, pg/mL 3.0 (0.9 – 10.7) 0.08 1.1 (0.5 – 2.4) 0.9 
Urinary sodium, mmol/day 1.6 (0.4 – 7.1) 0.5 1.0 (0.4 – 2.8) 0.9 
Albuminuria, mg/day 6.2 (3.6 – 10.7) < 0.001 1.6 (1.1 – 2.3) 0.01 
 
Table 3: Multivariable analysis of factors predicting urinary angiotensinogen and renin 
excretion. ADPKD, autosomal dominant polycystic kidney disease; AGT, angiotensinogen; 
DDD, defined daily dose; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin-
aldosterone system 
 
 
 
Correlations with Total Kidney Volume and Kidney Function 
Within the ADPKD group, we analyzed whether circulating or urinary RAAS-
components correlated with total kidney volume and kidney function (eGFR). 
A higher total kidney volume correlated with higher plasma renin, and more 
albuminuria, but not with urinary angiotensinogen or renin excretion (Figure 
2A). Both higher plasma renin and higher urinary renin excretion correlated 
with lower eGFR (Figure 2B). To analyze the possible mechanism of urinary 
angiotensinogen and renin excretion, we analyzed in the ADPKD and CKD 
groups whether these two urinary RAAS-components correlated with 
albuminuria. Indeed, both in patients with ADPKD and CKD, a higher degree 
of albuminuria correlated with higher urinary angiotensinogen or renin 
excretion, although the strength of this correlation was modest (Figure 2C). For 
urinary renin excretion, this correlation was of borderline significance in 
patients with ADPKD (P = 0.06). 
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Comparison of Concentrations in Plasma, Cyst Fluid, and Urine 
In three patients with ADPKD who underwent nephrectomy, we measured 
albumin, angiotensinogen, prorenin, and renin in plasma, cyst fluid (average 
concentration of five cysts) and urine. For all four parameters, the 
concentrations were highest in plasma followed by cyst fluid and urine (Figure 
3). Of interest, urinary concentrations were lower than cyst concentrations 
except for renin. Urinary prorenin concentrations were close to or below the 
detection limit.  
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Figure 2: Correlations of RAAS-components with total kidney volume and kidney function.  
Pearson correlation coefficients were calculated using log-transformed data. Height-adjusted 
total kidney volume was available in 51 patients with ADPKD. Correlations between urinary 
albumin, angiotensinogen, and renin excretion are shown both for patients with ADPKD and 
CKD.  
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Figure 3: Concentrations of Albumin and RAAS-components in plasma, cyst fluid, and urine. 
With plasma values set to 1, this figure shows the relative mean concentrations of albumin, 
angiotensinogen (AGT), prorenin, and renin in plasma (P), cyst fluid (C) and urine (U). The 
actual mean plasma concentrations were 42 g/L, 1814 pmol/L, 573.8 pg/mL, and 81.3 pg/mL, 
respectively. Measurements were performed in three ADPKD patients, who underwent elective 
nephrectomy to create space for kidney transplantation (45 and 52 year-old males with eGFRs 
of 12 and 9 mL/min/1.73 m2, respectively) or because of mechanical discomfort (71-year-old 
female, eGFR 18 mL/min/1.73 m2). 
 
 
 
DISCUSSION 
 
This study reveals a unique feature of patients with ADPKD, namely a 
consistently higher urinary excretion of angiotensinogen and renin compared to 
patients with CKD. Urinary angiotensinogen and renin excretions were 5- to 6-
fold higher in patients with ADPKD than in patients with CKD, who were 
matched by eGFR, blood pressure, and RAAS-inhibitor use (Table 2). ADPKD 
remained a significant predictor for urinary angiotensinogen and renin 
excretion in adjusted and in multivariable analyses (Tables 2 and 3), and 
regardless of RAAS-inhibitor use (Figure 1). Recent studies found higher 
urinary angiotensinogen to creatinine ratios in normotensive ADPKD patients 
compared to healthy controls (17), or higher levels within ADPKD patients in 
the presence of hypertension (15) or reduced kidney function (25). The 
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magnitude of the urinary angiotensinogen levels reported in these previous 
studies are comparable to our data. Our study is the first to analyze urinary 
renin and to use patients with CKD as control group (Table 1). Although our 
cross-sectional study cannot give definitive answers, our data give directions on 
the possible mechanisms and potential clinical implications of the increased 
urinary excretions.    
 
In principle, urinary angiotensinogen and renin excretion can increase in 
ADPKD because of (1) damage to the glomerular filtration barrier, (2) reduced 
proximal tubular reabsorption, (3) enhanced tubular secretion by intact 
nephrons, (4) differences in degradation, or (5) ectopic production by cyst-
lining epithelial cells.  
 
When evaluating the first two possibilities, it is important to correct for 
differences in the plasma levels. Although the correlation between total kidney 
volume and plasma renin in ADPKD patients indeed suggests that renal 
ischemia by cysts can increase plasma renin (Figure 2A), patients with ADPKD 
in general do not have higher plasma renin concentrations than patients with 
CKD (Table 2). In fact, patients with ADPKD without RAAS-inhibitors had 
significantly lower plasma renin concentrations than patients with CKD (Figure 
1). Thus, the higher urinary excretions of angiotensinogen and renin in ADPKD 
are not simply the consequence of elevated plasma RAAS concentrations 
exposed to the same degree of filtration and reabsorption as in CKD patients. 
In addition, increase of cysts (i.e. total kidney volume) did not correlate with 
increased excretion of urinary angiotensinogen or renin. Next, it is important to 
emphasize that ADPKD is a primarily a tubular disorder that is less likely to 
damage the glomerular filtration barrier (24). Indeed, previous studies have 
attributed albuminuria in animal models of ADPKD to disturbed endocytosis of 
albumin in the proximal tubule (24, 41). In these studies, immuno-
histochemistry showed less expression of the chloride channel ClC-5 and 
megalin, which are both involved in the reabsorption of low-molecular weight 
proteins. Because albumin, angiotensinogen, and renin are all reabsorbed by a 
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megalin-dependent pathway, a proximal tubular disorder should by definition 
result in higher urinary angiotensinogen and renin excretion, even in the face of 
identical or lower plasma RAAS-component levels (28, 30). In agreement with 
this concept, we recently showed that patients with Dent’s disease (who lack 
ClC-5) displayed a 20-40-fold rise in urinary angiotensinogen and renin levels, 
although their plasma RAAS levels were in the normal range (30). Similarly, 
other urinary markers of proximal tubule damage, such as fetuin-A and β2-
microglobulin, are increased in ADPKD (22, 27). The ADPKD component that 
independently predicted urinary angiotensinogen and renin excretion in our 
multivariable regression analysis therefore possibly reflects a difference in 
tubular reabsorption. We showed that albuminuria correlated with total kidney 
volume (Figure 2A), as was shown previously (34). In addition to ADPKD, 
albuminuria also independently predicted urinary renin and angiotensinogen 
excretion. This also suggests that the urinary excretions of albumin, 
angiotensinogen, and renin was at least in part due to similar mechanisms, and 
argues against selective tubular secretion of RAAS-components. This leaves the 
issue of altered degradation. Reduced reabsorption would also be expected to 
result in elevated levels of RAAS-component degrading enzymes, leading to 
enhanced degradation. Yet, higher levels of urinary RAAS-components were 
found in ADPKD. Combined with data from previous studies showing no 
evidence for urinary degradation of renin or prorenin (38), and identifying all 
urinary angiotensinogen as intact (and not cleaved) (39), it appears that reduced 
degradation does not underlie the increased urinary excretion of 
angiotensinogen and renin in ADPKD.  
 
The possibility of ectopic RAAS-component production by cyst-lining epithelial 
cells has been suggested by several investigators (20, 35). Although we cannot 
entirely exclude this possibility, such local production should have resulted in 
angiotensinogen and renin concentrations in cyst fluid that would have been at 
least comparable to, if not far above, their plasma concentrations. Remarkably, 
this was not the case (Figure 3). In fact, relative to albumin, the concentrations 
of angiotensinogen, renin and prorenin were lower in cyst fluid (Figure 3). In 
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other words, when using cyst albumin concentrations as a measure of blood-
derived proteins, cyst RAAS-component concentrations can be entirely 
explained on the basis of leakage from blood plasma. Of interest, the urinary 
concentrations of albumin, angiotensinogen, and prorenin were lower than 
their concentrations in cyst fluid. This most likely reflects further dilution 
and/or tubular reabsorption. Surprisingly, this was not the case for renin: its 
concentrations in cyst fluid and urine were similar (Figure 3). Moreover, the 
correlation between albumin and renin excretion, although modest, showed a 
different pattern in ADPKD than in CKD (Figure 2C). Taken together, these 
data suggest that ADPKD affects the urinary excretion of renin differently than 
of albumin, angiotensinogen and prorenin. This difference between renin and 
prorenin excretion (resulting in urinary prorenin levels that are virtually 
undetectable), has been observed before (30, 38). Of note, we did not measure 
the sodium concentration in cyst fluid; previously, more active renin was found 
in so-called “gradient cysts” in which the sodium concentration is low (36).  
 
Many aspects of the intra-renal renin-angiotensin system remain unclear, 
although some groups have suggested that angiotensinogen and renin in tubular 
fluid may lead to high tubular angiotensin II levels (11, 20). Such high local 
angiotensin II levels could promote renal sodium retention, hypertension, 
kidney damage, or even cystogenesis (20). Of interest in this regard is a recent 
report where targeting the intra-renal renin-angiotensin system reduced cyst 
growth in an animal model of polycystic kidney disease (33). Based on our 
cross-sectional data, we cannot conclude whether the higher urinary 
angiotensinogen and renin excretions are a cause or a consequence of the 
kidney damage in ADPKD. In other words, it is unclear if higher urinary 
angiotensinogen and renin excretion should be considered as a damage marker 
or as a potential contributor to kidney damage. Given the experimental link 
between the intra-renal renin-angiotensin system and cystogenesis, this deserves 
further study.  
 
Urinary Extracellular Vesicles: Biomarkers and beyond 190 
A number of limitations of this study should be mentioned. First, RAAS-
inhibitor use could have influenced our results. Ideally, urinary RAAS-
components should be measured before and after starting a RAAS-inhibitor. 
Previous studies have shown a decrease of urinary angiotensinogen and no 
effects on urinary renin after initiation of an angiotensin receptor blocker in 
patients with chronic kidney disease (26, 42). Therefore, if anything, our 
ADPKD group would be expected to have lower urinary angiotensinogen 
excretion, which was not the case. Second, despite matching of ADPKD with 
CKD patients by the most relevant parameters (eGFR, blood pressure, RAAS-
inhibitors), several differences remained. The difference in age was inevitable, as 
eGFR decline occurs much earlier in ADPKD than in other forms of CKD. We 
addressed these differences by using an adjusted analysis, multivariable 
analyses, and a subanalysis (Table 2, Table 3). Finally, although significant, the 
strength of the correlations observed in this study were modest, suggesting high 
inter-individual variability or a multifactorial origin.  
 
In conclusion, ADPKD uniquely increases urinary angiotensinogen and renin 
excretion despite their circulating levels being comparable to those in CKD. We 
believe these findings warrant further analysis in mechanistic or intervention 
studies.  
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SUMMARY  
 
uEVs are increasingly used for biomarker purposes in renal disorders. The 
studies presented in this thesis were aimed to develop a novel method to isolate 
and characterize uEVs, as well as to explore their use as biomarkers for salt-
sensitive hypertension and ADPKD.  
 
Chapter 2 provides an overview of uEVs, with two main focuses: 1) it compares 
different techniques currently available to isolate and characterize uEVs and 2) 
it provides an overview of the use of uEVs for biomarker discovery and 
therapeutic purposes in nephrology. Different methods are currently being used 
to isolate uEVs, including ultracentrifugation, filtration, precipitation, and 
immune-isolation. The choice of method depends on the starting material and 
the specific aim of the study. For example, ultracentrifugation requires a larger 
starting volume of urine (minimum 5 mL, usually > 20 mL) and is time-
consuming, but has the advantage of a high yield and an unselected population 
of uEVs. In contrast, immuno-isolation requires a low starting volume (0.05 
mL), is less time-consuming, but has the disadvantage of selecting a 
subpopulation of uEVs, and is unsuitable for RNA isolation. Another issue 
dealt with in this chapter is the normalization of samples, which remains the 
‘holy grail’ in the field of uEVs. The commonly used indirect normalization 
methods include urinary creatinine, timed urine collection, and the use of uEV 
markers (e.g., CD9 or CD63). Because these methods do not directly count the 
number of uEVs, each method has its own limitations, and should therefore be 
used with caution.  
 
In chapter 3 we present a novel method to quantify, normalize, and characterize 
uEVs. Because the different techniques mentioned in the previous chapter are 
time-consuming and require large starting volumes, they are unsuitable for 
high-throughput clinical application. Therefore, we developed an immunoassay 
that captures uEVs using an anti-CD9 antibody. Subsequently, uEV proteins of 
interest can be quantified. As proof-of-principle, we analyzed the sodium 
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chloride cotransporter (NCC) and the water channel aquaporin-2 (AQP2). Our 
immuno-assay allows for the simultaneous quantification of CD9 count by 
using a different label (called time-resolved fluorescence). We show that CD9 
correlates to urine creatinine, and can therefore be used to normalize for 
differences in urine concentration within the same assay, thus omitting the need 
to measure urine creatinine. We further demonstrate its applicability in the 
physiological regulation of AQP2 and NCC, and show it correlated with the 
conventional method (ultracentrifugation and followed by immunoblotting). 
Similarly, we demonstrate that our immuno-assay was capable of detecting 
dysregulation of AQP2 and NCC in human disease. We therefore conclude that 
this platform is a promising technique that can be used for high-throughput 
clinical application for potential uEV biomarkers. 
 
Chapter 4 introduces the second section of this thesis. Here, we provide an 
overview of studies in which uEV sodium transporters were analyzed in 
hypertensive disorders. We conclude that the analysis of sodium transporters in 
uEVs allows for a non-invasive read-out of renal epithelial transport, and may 
therefore be used as ‘liquid biopsy’.  
 
In chapter 5 we analyze uEV sodium transporters in CS. Glucocorticoid excess 
in CS causes hypertension. Due to the pleiotropic effects of glucocorticoids, the 
pathogenesis of hypertension in CS is multifactorial and may be related to an 
increase in vasoconstriction or renal sodium reabsorption. We show that CS 
patients with hypertension could be divided on the basis of a suppressed or 
non-suppressed renin-angiotensin-aldosterone system (RAAS). The sodium 
hydrogen exchanger type 3 (NHE3) in uEVs was higher in all patients with CS 
compared to controls. Of note, only patients with suppressed RAAS had higher 
abundances of the sodium potassium chloride cotransporter (NKCC2) and 
NCC in uEVs. We reveal that lower serum potassium concentrations were 
correlated with higher abundances of NKCC2 and NCC. This suggests a role of 
potassium deficiency in the salt-sensitivity and extracellular fluid volume 
expansion in hypertensive CS patients (1).  
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In chapter 6 we test the hypothesis that primary aldosteronism increases the 
phosphorylation of NCC (pNCC) and the abundance of prostasin (a serin 
protease involved in the activation of the epithelial sodium channel) in uEVs. 
Using two animal models of aldosteronism (infusion of aldosterone and low 
sodium diet), we demonstrate that pNCC, and to a lesser extent prostasin, 
increased both in kidney and in uEVs. Similarly, pNCC was significantly higher 
in uEVs of patients with primary aldosteronism than in patients with essential 
hypertension. We conclude that pNCC in uEVs may be used as a urinary 
biomarker for aldosteronism.   
 
Chapter 7 reports a family with a Liddle phenotype (hypokalemic hypertension 
with suppressed renin and aldosterone), but without mutations in the genes 
encoding the β- or γ-subunit of ENaC (SCNN1B or SCNN1G). Whole exome 
sequencing identified a novel heterozygous missense mutation in αENaC that 
results in the substitution of cysteine 479 to arginine (C479R). We further 
characterize this mutation using electrophysiology and showed a 2-fold increase 
in amiloride-sensitive sodium current in oocytes. Subsequently we show that the 
mutation did not increase αENaC abundance at the plasma membrane, but did 
decrease trypsin sensitivity. This suggests that increased αENaC activity is due 
to higher open probability rather than increased channel number.  This finding 
was also confirmed in analysis of αENaC in the uEVs isolated from the patients, 
as the subjects carrying the mutation had similar αENaC abundance as their 
non-affected siblings.  
 
The third section focuses on urinary markers of ADPKD, including uEV-
associated markers of ADPKD. In chapter 8 we use a quantitative proteomics 
approach to identify disease-associated markers of ADPKD in uEVs. With four 
different cohorts and two proteomic methods (labeled and label-free), we 
compare uEVs isolated from patients with ADPKD, non-ADPKD chronic 
kidney disease (CKD), and healthy controls. We identify several upregulated 
proteins, including complement and plakins, which were consistently higher in 
ADPKD in subsequent validations. More importantly, the identify proteins 
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correlated with total kidney volume, suggesting they may be used as a marker 
of disease progression. These findings were also confirmed in whole kidney 
homogenates from ADPKD mouse models. The subpopulation of uEVs that 
contained complement was of higher density than CD9+ vesicles, suggesting 
they are not of exosomal origin.  
 
Finally, in chapter 9, we tested the hypothesis that increases in the urinary 
excretion of renin-angiotensin components are a unique feature of ADPKD. We 
therefore analyze markers of both the circulating and urinary renin-angiotensin-
aldosterone system (RAAS) in 60 patients with ADPKD, and compare those to 
57 matched patients with non-ADPKD CKD. In three patients with ADPKD, 
we also compare angiotensinogen and renin concentrations in plasma, cyst 
fluid, and urine. Our main conclusions were that, despite similar circulating 
levels, urinary angiotensinogen and renin were consistently higher in patients 
with ADPKD. Importantly, albuminuria correlated with urinary 
angiotensinogen and renin suggesting they may be plasma derived. Also, cyst 
concentrations of angiotensinogen and renin were consistently lower than 
plasma, and urinary renin was higher than cyst concentrations. These results 
challenge the hypothesis of production of renin-angiotensin components by cyst 
epithelial cells.  
 
The appendix reports the design of the DIPAK1 study, which is a randomized 
controlled trial in 300 subjects with ADPKD (eGFR between 30-60 
mL/min/1.73 m2). The patients included in chapters 8 and 9 participated in this 
study.  
 
In conclusion, this thesis illustrates the use of uEVs in biomarker discovery, 
including the development of a novel isolation technique, and the application of 
uEV analysis in clinical disorders of salt-sensitive hypertension and polycystic 
kidney disease.  
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DISCUSSION AND FUTURE DIRECTIONS 
 
Urinary extracellular vesicles: potential for nephrology & novel isolation 
method 
A common and continuing issue in EV research is the method by which uEVs 
are isolated and quantified, which was discussed in chapters 2 and 3. In brief, it 
may be stated that the use of the different available platforms depends on 
availability of equipment (such as an ultracentrifuge), volume of stored urine 
and the ultimate purpose (i.e., protein or RNA quantification or in vitro use). It 
also depends on the research question at hand, as a proteomic-based untargeted 
approach may be more suitable for biomarker discovery, whereas a targeted 
approach, such as our immunoassay described in chapter 3, is more appropriate 
for diagnostic or monitoring purposes. The ideal platform should be able to 
quantify multiple uEV proteins of interest without the need for isolation. This 
poses technical challenges with the low abundance of uEVs. Here, the advances 
in proteomics may provide the solution. Qi et al. used multiple reaction 
monitoring, which is a targeted form of proteomics, to quantify several proteins 
of interest (2). They, however, still relied on isolating uEVs by 
ultracentrifugation. With increases in sensitivity and novel labeling methods in 
proteomics, co-labeling of specific uEV markers and markers of interest, may 
bypass the need for their isolation in the future (3).  
 
Another challenge is the normalization of uEVs, as commonly used methods do 
not actually count uEV number. These include timed urine collection, urine 
creatinine or protein markers (4). With timed collection or urine creatinine, it is 
assumed that uEVs are excreted in a constant manner, and are independent of 
glomerular filtration rate (GFR), which is not necessarily true. This is illustrated 
in chapter 8, where despite normalizing for urinary creatinine, the tetraspanin 
CD9 decreased with deteriorating GFR, suggesting a decrease in uEV number. 
Two methods have been developed to count uEV number, including the 
nanoparticle-tracking analysis (Nanosight, UK), which measures Brownian 
motion in fluids, and qnano (Izon, New Zealand), which uses nanopores that 
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measures change in ionic current flow (5, 6). A limitation of these methods is 
their lower detection limit of 50 nm, excluding smaller particles. A 
standardized, easy and reliable technique to sort, normalize and quantify uEVs 
is therefore still needed.  
Finally, although a standardized nomenclature for uEV subpopulations was 
proposed, there are no universally accepted morphological or structural 
markers (7). Studying subpopulations of uEVs may therefore help distinguish 
and ultimately better understand their origin and role in the kidney (8-10).  
 
Urinary extracellular vesicles: markers for salt-sensitive hypertension 
The majority of secondary forms of hypertension are due to excessive renal 
sodium reabsorption by activated sodium transporters (11). With the use of 
uEVs, it is now possible to analyze renal sodium transporter abundances (12, 
13). In this thesis, we demonstrated that abundances of renal sodium 
transporters are reflected in uEVs for renal tubular disorders (chapter 3), CS 
(chapter 5), and primary aldosteronism (chapter 6). The abundance of a sodium 
transporter, however, does not always equal activity. This may be overcome by 
analyzing post-transcriptional modifications that do reflect transporter activity, 
such as phosphorylation (demonstrated in chapters 5 and 6). Still, true 
transporter activity cannot be measured in uEVs. The activating mutation of 
αENaC in chapter 7, which increased its activity, but not its abundance, would 
therefore be missed. Despite these limitations, the analysis of renal sodium 
transporters in uEV may help to differentiate the cause of hypertension, but 
also to personalize therapy. This was recently demonstrated, as NCC 
abundance in uEVs predicted the blood pressure response to thiazides (14). 
More studies are needed to analyze renal sodium transporters in uEVs in 
hypertensive disorders, and response to therapy. High throughput platforms, 
such as demonstrated in chapter 3, may be used for this purpose.  
 
Urinary extracellular vesicles and other markers for polycystic kidney disease 
Studying urinary markers, including uEVs, in ADPKD could serve to predict 
and monitor disease progression and response to therapy, but also provide 
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insights in the pathophysiology of the disease. For example, uEVs are enriched 
for polycystins and fibrocystin, both implicated in the pathogenesis of ADPKD, 
and recently shown to inversely correlate to total kidney volume (8, 10). We 
observed an increase in plakins and complement in uEVs of patients with 
ADPKD (chapter 8). In particular, complement C3 and C9 was increased at 
early stages of disease and further increased with progression of CKD. 
Interestingly, complement has previously been linked to ADPKD, where its gene 
expression is highly activated, and its inhibition results in reduced cyst growth 
in animal models (15, 16). Further studies are needed to understand the 
pathophysiological role of complement in ADPKD and explore if complement 
could be a therapeutic target. 
 
Finally, in chapter 9, we demonstrated increased urinary RAAS components in 
ADPKD, in particular angiotensinogen and renin. This is a unique feature of 
ADPKD and not related to CKD. How and why these urinary RAAS 
components are increased is unknown, but circumstantial evidence indicates it 
is due to reduced proximal tubular reabsorption rather that cyst-derived 
production. Whether or not this accounts for increased blood pressure is yet 
unknown. Future studies should address whether higher urinary excretion of 
angiotensinogen and renin contribute to hypertension and cyst progression in 
ADPKD.   
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SAMENVATTING 
 
Extracellulaire vesikels (EVs) zijn minuscule blaasjes die door alle 
lichaamscellen worden uitgescheiden. Hoewel men voorheen aannam dat het 
cellulair afval betrof, wijst recent onderzoek uit dat EVs veel functies hebben 
binnen het menselijk lichaam. EVs komen ook voor in urine. Deze zogenaamde 
urine EVs (uEVs) worden door de niercellen uitgescheiden en geven een indruk 
van de cellen waarvan zij uitgescheiden worden. Daardoor bieden uEVs 
perspectief als potentiële biomarkers voor nieraandoeningen. In dit proefschrift 
werden verschillende aspecten van uEVs onderzocht. Zo werd een nieuwe 
methode ten behoeve van het isoleren en karakteriseren van uEVs ontwikkeld. 
Ook werden potentiële biomarkers in uEVs onderzocht voor zout-gevoelige 
hypertensie en autosomaal dominante polycysteuze nierziekte (ADPKD).  
 
Hoofdstuk 2 geeft een overzicht van uEVs met aandacht voor twee aspecten: 1) 
het vergelijkt de beschikbare technieken om uEVs te isoleren en karakteriseren 
en 2) het geeft een overzicht van het gebruik van uEVs als potentiële biomarkers 
binnen de nefrologie. Verschillende methoden zijn in gebruik om uEVs te 
isoleren, inclusief ultracentrifugatie, filtratie, precipitatie en immuno-isolatie. 
Welke methode je dient te gebruiken hangt af van de hoeveelheid beschikbare 
urine, alsook het doel van de studie. Voor bijvoorbeeld ultracentrifugatie heb je 
relatief veel urine nodig (minimaal 5 mL, maar meestal > 20 mL) en neemt de 
isolatie ervan veel tijd in beslag. Het heeft echter als voordeel een hoge 
opbrengst van niet-geselecteerde uEVs. Voor immuno-isolatie daarentegen heb 
je weinig urine nodig (0,05 mL), neemt de isolatie minder tijd in beslag, maar 
heeft als nadelen dat je selecteert op een uEV subpopulaties en dat het 
ongeschikt is voor RNA onderzoek. Een ander onderwerp waar dit hoofdstuk 
aandacht aan besteedt is het normaliseren van uEVs. De meest gebruikte en 
indirecte methoden hiervoor zijn het meten van urine creatinine, het 
normaliseren op basis van tijdgsgebonden verzameling van urine en het 
gebruiken van uEV eiwit markers (zoals CD9 of CD63). Aan al deze methoden 
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zijn nadelen verbonden aangezien zij niet het daadwerkelijk aantal uEVs tellen, 
waar rekening mee gehouden dient te worden. 
 
Hoofdstuk 3 beschrijft een nieuwe methode om uEVs te kwantificeren, 
normaliseren en ook te karakteriseren. De beschreven immunoassay isoleert 
uEVs door een anti-CD9 antilichaam. Vervolgens worden de eiwitten van 
interesse, de natrium chloride cotransporter (NCC) en het waterkanaal 
aquaporine-2 (AQP2), gekwantificeerd. Tegelijkertijd kan het CD9 eiwit 
gekwantificeerd worden door gebruik te maken van een andere label (de 
zogenaamde “time-resolved fluorescence”). Omdat CD9 correleerde met urine 
creatinine, was het mogelijk om binnen dezelfde assay CD9 te gebruiken als 
maat voor normalisatie tussen de urines. De toepasbaarheid van deze 
immunoassay wordt aangetoond door de bevindingen van fysiologische 
regulatie van het waterkanaal AQP2 en zout transporter NCC te correleren met 
de conventionele methode van uEV isolatie en karakterisatie: de ultracentrifuge 
en immunoblot methode. Ook aandoeningen die AQP2 en NCC verstoren 
worden gedetecteerd met deze immunoassay. We concluderen dat deze nieuwe 
methode een veelbelovende techniek is die mogelijk klinisch toegepast zou 
kunnen worden voor potentiële uEV biomarkers. 
 
Hoofdstuk 4 introduceert het tweede thema van dit proefschrift. Hier wordt een 
overzicht gegeven van de studies waarin zout-transporters in uEVs werden 
bestudeerd bij hypertensieve aandoeningen. Het meten van zout-transporters in 
uEVs biedt een non-invasieve uitleesmaat van renale epitheliale (zout) transport 
en zou daarom gebruikt kunnen worden als potentiële biomarker. 
 
In hoofdstuk 5 worden zout-transporters in uEVs van patiënten met het 
syndroom van Cushing bestudeerd. Het syndroom van Cushing veroorzaakt 
hypertensie als gevolg van een overschot aan glucocorticoïden. Doordat 
glucocorticoïden een pleiotroop effect hebben, kan het mechanisme van het 
ontstaan van hypertensie gerelateerd zijn aan toename van vasoconstrictie, en 
ook toegenomen heropname van zout reabsorptie door de nieren. Patiënten met 
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het syndroom van Cushing en hypertensie konden onderverdeeld worden in een 
groep met onderdrukt en een groep met niet-onderdrukt renine-angiotensine-
aldosteron systeem (RAAS). De zout-transporter die natrium en waterstof 
uitwisselt (NHE3) blijkt in uEVs hoger te zijn in alle patiënten met het 
syndroom van Cushing vergeleken met gezonden. Daarentegen hebben alleen 
patiënten met een onderdrukt RAAS meer natrium kalium chloride 
cotransporter (NKCC2) en NCC in uEVs. Ook correleert een lagere serum 
kalium-concentratie omgekeerd aan NKCC2 en NCC in uEVs. Dit suggereert 
een rol voor kalium-deficiëntie in de zout-gevoeligheid en extracellulaire volume 
expansie bij patiënten met het syndroom van Cushing met hypertensie.  
 
Hoofdstuk 6 onderzoekt de hypothese dat primair hyperaldosteronisme de 
fosforylering (activatie) van NCC en de hoeveelheid prostasin (een serine 
protease betrokken bij de activatie van het epitheliale natrium kanaal) doet 
toenemen in uEVs. Daarvoor wordt gebruik gemaakt van twee diermodellen 
van toegenoemen aldosteron: directe infusie van aldosteron en een laag zout 
dieet. We laten zien dat pNCC, en in mindere mate prostasin, beide toenemen 
in zowel de nieren, maar ook in uEVs. Deze toename wordt voor pNCC ook 
aangetoond bij patiënten met primair hyperaldosteronisme wanneer zij worden 
vergeleken met patiënten met essentiële hypertensie. Concluderend lijkt pNCC 
in uEVs een potentiële biomarker voor hyperaldosteronisme.  
 
Hoofstuk 7 beschrijft een familie met het fenotype van het syndroom van Liddle 
(hypokalïemische hypertensie met onderdrukking van renine en aldosteron), 
maar zonder mutaties in de verwachte genen coderend voor het β- of γ-subunit 
van ENaC (SCNN1B or SCNN1G). Een nieuwe missense mutatie in αENaC 
wordt geidentificeerd door middel van whole exome sequencing. Deze mutatie 
veroorzaakt een vervanging van cysteïne 479 naar arginine (C479R), met als 
gevolg een tweevoudig toename van amiloride-gevoelige natrium opname in 
oöcyten. De mutatie zorgt niet voor toename in de hoeveelheid αENaC kanalen 
op de plasma membraan, maar wel een afname van trypsine gevoeligheid. Dit 
suggereert dat de toename van αENaC activiteit wordt veroorzaakt door een 
Chapter	11	 209 
toegenomen open probability van het kanaal en niet een toegenomen aantal 
kanalen op de cel membraan. Deze bevinding wordt bevestigd doordat het 
aantal αENaC kanalen in uEVs vergelijkbaar is tussen de patiënten met en 
zonder mutatie in αENaC. 
 
Het derde thema richt zich op de urine markers voor ADPKD. In hoofdstuk 8 
wordt gebruik gemaakt van een kwantitatieve proteomics methode om ziekte-
gerelateerde biomarkers te vinden in uEVs van patiënten met ADPKD. Bij vier 
verschillende cohorten en gebruik makend van twee labeling methoden, worden 
uEVs van patiënten met ADPKD, chronische nierinsufficiëntie (CKD) en 
gezonden vergeleken. Enkele uEV eiwitten, waaronder complement en plakines, 
waren consistent hoger bij patiënten met ADPKD. Ook correleren de gevonden 
eiwitten met totaal niervolume, suggererend dat zij mogelijk toegepast kunnen 
worden als markers voor ziekteprogressie. Deze bevindingen worden ook 
bevestigd in nierhomogenaten van ADPKD muis modellen. Concluderend 
zouden complement eiwitten en plakines in uEVs kunnen dienen als biomarkers 
voor patiënten met ADPKD. 
 
In hoofdstuk 9 wordt onderzocht of de excretie van urine renine-angiotensine 
componenten een unieke eigenschap is van patiënten met ADPKD. Daarvoor 
wordt plasma en urine markers van het renine-angiotensine-aldosteron systeem 
(RAAS) gemeten bij 60 patiënten met ADPKD en vergeleken met 57 
vergelijkbare patiënten met CKD. Bij drie ADPKD patiënten wordt ook 
angiotensinogeen en renine concentraties gemeten in plasma, cyste-vloeistof en 
urine. Ondanks vergelijkbare plasma-waarden, waren urine angiotensinogeen 
en renine excreties significant hoger waren bij patiënten met ADPKD. Ook 
blijkt albuminurie te correleren met zowel urine angiotensinogeen als renine, 
suggererend dat het mechanisme berust op glomerulaire lek. Ook waren de 
cyste-concentraties van angiotensinogeen en renine lager dan plasma 
concentraties, maar urine renine concentratie hoger dan de concentratie in 
cysten. Deze bevinding is in strijd met de gedachte dat cysten angiotensinogeen 
en renine zouden produceren.  
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Het appendix beschrijft de DIPAK1 studie: een gerandomiseerde studie in 300 
patiënten met ADPKD (eGFR tussen 30-60 mL/min/1.73 m2). De geïncludeerde 
patiënten uit hoofdstuk 8 en 9 deden mee aan de DIPAK1 studie. 
 
Concluderend illustreert dit proefschrift het gebruik van uEVs als materiaal 
voor biomarkers, het ontwikkelen van een nieuwe isolatie- en kwantificatie-
methode en de klinische toepassing van uEVs bij patiënten met zoutgevoelige 
hypertensie en polycysteuze nierziekte.  
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PHD PORTFOLIO  
 
PhD candidate:  Mahdi Salih 
PhD period:   2012-2015 
Erasmus MC department: Internal Medicine 
    Division of Nephrology 
Research school: Cardiovascular Research School Erasmus University 
Rotterdam (COEUR) 
Promotors: Prof.dr. R. Zietse 
 Prof.dr. E.J. Hoorn 
 
 
 
PHD TRAINING   
Year    Workload  
   (ECTS) 
Clinical research courses 
- Basic course on rules and organization of clinical  2012        1 
trials (BROK) 
- Rotterdam Course in Electrolyte and Acid-Base            2013        0.3 
Disorders 
- Pre-ASN education: Intensive Care Nephrology            2014        0.9 
- Nephrology course (Harvard, Boston, USA)  2015        1.8 
 
Scientific courses 
- Winter school, Dutch Kidney Foundation   2012        1.2 
- Cardiovascular Pharmacology (COEUR)              2013        1.5 
- Biostatistical Methods I: Basic Principles (NIHES) 2014        5.7 
- ERA-EDTA (WGIKD) course: renal fluids and            2014        0.9 
electrolytes: from genes to bedside 
- Research seminar: SALT (COEUR)   2014        0.4 
- Molecular biology in cardiovascular research            2014        1.5 
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Year   Workload  
    (ECTS) 
- National and international conferences 
- Annual Dutch Nephrology Days                                    2012           0.6 
- Kidney week (American Society of Nephrology)            2012         1.5 
- International Society of Extracellular Vesicles            2014         1.5 
meeting* 
- Kidney week (American Society of Nephrology)** 2014         1.8 
- Annual Dutch Nephrology Days**   2014         0.9 
- Kidney Benelux meeting**               2015         0.6 
- International society of extracellular vesicles  2015         1.5 
meeting** 
- Frontiers in Regenerative Medicine*   2015         1.2 
- Kidney week (American Society of Nephrology)* 2015         1.5 
- ‘The New Kids on the Block’ scientific symposium 2015         0.3 
in Nephrology 
 
Teaching activities 
- Supervising 2 laboratory students            2013-2015   1.2 
- Minor Immunology              2015         0.3 
 
Other attendances  
- Annual DIPAK research meetings*           2012-2015   1.2 
- PLAN (platform researchers in Nephrology)*          2013-2015   1.0 
- Erasmus MC Internal Medicine science days*          2014-2015   1.2 
- COEUR lectures              2013-2015   0.3 
- Department of pharmacology weekly research           2012-2015   2.7 
meetings 
 
Total                34.5 
 
*oral presentation, ** poster presentation 
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RATIONALE AND DESIGN OF THE DIPAK1 STUDY:  
A RANDOMISED, CONTROLLED CLINICAL TRIAL 
ASSESSING THE EFFICACY OF LANREOTIDE TO HALT 
DISEASE PROGRESSION IN ADPKD 
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ABSTRACT 
 
Background: There are limited therapeutic options to slow the progression of 
autosomal dominant polycystic kidney disease (ADPKD). Recent clinical studies 
indicate that somatostatin analogues are promising for treating polycystic liver 
disease and potentially also for the kidney phenotype. We report on the design 
of the DIPAK 1 (Developing Interventions to Halt Progression of ADPKD 1) 
Study, which will examine the efficacy of the somatostatin analogue lanreotide 
on preservation of kidney function in ADPKD. 
Study design: The DIPAK1 study is an investigator driven, randomized, multi-
center, controlled clinical trial. 
Setting & participants: We plan to enroll 300 individuals with ADPKD and 
estimated glomerular filtration rate (eGFR) of 30-60 mL/min/1.73 m2 who are 
aged 18-60 years. 
Intervention: Patients will be randomized (1:1) to standard care or Lanreotide 
120 mg sc every 28 days for 120 weeks in addition to standard care. 
Outcomes: Main study outcome is the slope through serial eGFR measurements 
starting at week 12 until end of treatment for lanreotide versus standard care. 
Secondary outcome parameters include change in eGFR from pretreatment 
versus 12 weeks after treatment cessation, change in kidney volume, change in 
liver volume, and change in quality of life. 
Measurements: Blood and urine will be collected and questionnaires will be 
filled in following a fixed scheme. MRI’s will be made for assessment of kidney 
and liver volume. 
Results: Assuming an average change in eGFR of 5.2 ± 4.3 (SD) mL/min/1.73 
m2 per year in untreated patients, 150 patients are needed in each group to 
detect a 30% reduction in the rate of kidney function loss between treatment 
groups with 80% power, 2-sided α = 0.05, and 20% protocol violators and/or 
dropouts 
Limitations: The design is an open randomized controlled trial and 
measurement of our primary end point does not begin at randomization. 
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Conclusion: The DIPAK 1 Study will show whether subcutaneous 
administration of lanreotide every 4 weeks attenuates disease progression in 
patients with ADPKD. 
 
 
 
BACKGROUND 
 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
hereditary kidney disease (1, 2). It is characterized by progressive cyst formation 
in both kidneys, often leading to end-stage kidney disease between the fourth 
and seventh decades of life (1-3). Approximately 10% of patients receiving 
renal replacement therapy have ADPKD as the underlying disease (1). Cyst 
formation also is found in the liver, with an overall prevalence of 83% in a 
cohort of patients with early ADPKD (4). Symptoms of polycystic liver disease 
include abdominal distension, early satiety, dyspnea, and pain (5).  
 
The development of renoprotective treatments for ADPKD is of major 
importance for patients with ADPKD. Increasing knowledge of the 
pathophysiology of ADPKD has allowed the identification of several potential 
therapeutic targets, and animal experiments have confirmed that drugs directed 
at these targets are renoprotective. Three drug classes have been tested in 
clinical trials: mammalian target of rapamycin (mTOR) inhibitors, vasopressin 
V2 receptor (V2R) antagonists, and somatostatin analogues (6-9).  
 
Despite encouraging animal data with mTOR inhibitors (10-12), 2 controlled 
trials recently failed to show a beneficial effect on decline in kidney function in 
patients with ADPKD (13,14). A post hoc analysis of 2 open-label studies 
involving V2R antagonists, with matched untreated controls from historical 
ADPKD cohorts, suggested that these agents had renoprotective effects (15). 
Recently, a large randomized clinical trial with V2R antagonist treatment 
showed a reduction in kidney growth and preservation of kidney function in 
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1,445 patients with ADPKD with a mean estimated creatinine clearance of 81 
mL/min (16). These results are promising because for the first time, a drug was 
shown to slow the decline in kidney function in patients with ADPKD.  
 
However, there are a number of limitations to the use of V2R antagonists. First, 
the effect of these drugs probably is limited to renal tubular cells in the distal 
nephron and collecting duct (7). Although these are the predominant cysts in 
adult patients with ADPKD, kidney cysts also may originate from other parts of 
the nephron (17). Whether V2R antagonists will be effective in patients with 
chronic kidney disease (CKD) stages 3-4 is not known. Furthermore, V2R 
antagonists have adverse effects that may limit widespread clinical use, such as 
thirst, polydipsia, polyuria, and nycturia, which can cause sleep disturbance. A 
final consideration is that polycystic liver disease is a common manifestation of 
ADPKD and curtailing the growth of the liver is a desirable therapeutic target. 
Because the V2R is not expressed in liver tissue, no liver-specific therapeutic 
action of V2R antagonists may be expected. Recent randomized clinical trials 
suggest that somatostatin analogues ameliorate polycystic liver disease (18-22). 
These trials included only a limited number of patients with ADPKD, making it 
difficult to reach a definitive conclusion on the possible renoprotective efficacy 
of these drugs. Therefore, these trials do not allow one to conclude that 
somatostatin analogues should be standard care for patients with ADPKD at 
high risk of disease progression.  
 
The DIPAK (Developing Interventions to Halt Progression of Autosomal 
Dominant Polycystic Kidney Disease) 1 Study is designed to validate the efficacy 
of the somatostatin analogue lanreotide to reduce disease progression in 
patients with ADPKD with CKD stage 3. 
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METHODS 
 
Study setting and population 
The DIPAK 1 Study is designed as a multicenter, open-label, randomized, 
controlled, parallel-arm trial in 300 participants with ADPKD and a high 
likelihood of disease progression. It will include individuals with an ADPKD 
diagnosis based on Ravine criteria, aged 18-60 years, with an estimated 
glomerular filtration rate (eGFR) of 30-60 mL/min/1.73 m2 (23, 24). Detailed 
patient inclusion and exclusion criteria are listed in Box 1. The eGFR cutoff 
values in combination with the age criteria ensure that only individuals with a 
high likelihood of disease progression will be included. Also, the inclusion 
criteria are easy to translate into clinical practice (in contrast to inclusion 
criteria based on total kidney volume), which increases the external validity of 
the data. Furthermore, interventions initiated in individuals with eGFR < 30 
mL/min/1.73 m2 are less likely effective. 
 
Study Design 
Individuals meeting the entry criteria and completing baseline assessments will 
be enrolled in 1 of the 4 participating University Medical Centers in the 
Netherlands (Groningen, Leiden, Nijmegen, and Rotterdam). The planned 
recruitment period is 21 months. After informed consent is obtained and 
eligibility is assessed (Box 1), patients will be randomly assigned to standard 
care (control) or standard care plus 4-weekly lanreotide injections. 
Randomization will be performed using an interactive voice response system, 
with stratification for eGFR at time of screening (≤45 and >45 mL/min/1.73 
m2), sex (male/ female), and age (≤45 and >45 years). There are no specific 
demands set to the number of patients to be included per stratum.  
 
Figure 1 presents a schematic of the trial design. One week after the first 
injection, the patient will receive a telephone call to assess adverse events. 
Participants will be evaluated in person at weeks 4 (T4), 8 (T8), and 12 (T12) 
and every 12 weeks thereafter until the end of the trial (end-of-treatment visit 
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scheduled to be at week 120). The last dose of lanreotide will be given at week 
116. Participants will be seen 12 weeks after the end of the trial for a follow-up 
visit. Total duration of the study therefore will be 132 weeks. In case a 
participant does not tolerate medication and treatment ends, an early end-of-
treatment visit will be performed within 1 week after the next injection should 
have been administered and the participant will continue regular study visits. 
 
Trial treatments 
Treatment will consist of 120 mg of lanreotide administered subcutaneously 
every 4 weeks. The dosage will be eGFR (body surface area unadjusted) 
dependent. Participants who reach for the second time an eGFR < 30 mL/min 
during the study will receive lanreotide, 90 mg, subcutaneously every 28 days. 
Participants experiencing intolerable adverse effects will also have their 
medication dose adjusted (stepwise, from 120 to 90 to 60 to 0 mg). Lanreotide 
will be administered by trained nurses.  
 
The dosage and frequency of treatment with lanreotide is based on a pilot study 
(18) in which a dosage of 120 mg subcutaneously once every 28 days was 
effective in decreasing the rate of liver and kidney volume growth in individuals 
with polycystic liver disease. The dosing scheme of 120 mg once every 28 days 
furthermore is approved by the European Medicines Agency and US Food and 
Drug Administration for other indications. There is only limited information on 
the use of lanreotide in individuals with decreased kidney function (25). 
Although the therapeutic index of lanreotide is broad, we decided to adjust the 
dose of lanreotide to kidney function given the limited pharmacokinetic data. 
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Figure 1: Trial design of the DIPAK-1 study. ADPKD, autosomal dominant polycystic kidney 
disease; BV, baseline visit before start of treatment; eGFR, estimated glomerular filtration rate; 
EOS, end-of-study; FU, follow-up; lab, laboratory; MRI, magnetic resonance imaging; SV, 
screening visit; UMC, University Medical Center. 
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Box 1. Eligibility criteria of the DIPAK1 study 
 
 
Inclusion criteria 
• Diagnosis of ADPKD, based upon the modified Ravine criteria23 
• Age between 18 and 60 years. 
• eGFR (MDRD) between 30 and 60 ml/min/1.73 m2. 
• Providing informed consent. 
 
Exclusion criteria 
• Patients who, in the opinion of the study investigator may present a safety risk. 
• Patients who are unlikely to adequately comply with the trial’s procedures [due for 
instance to medical conditions likely to require an extended interruption or 
discontinuation, history of substance abuse or noncompliance). 
• Patients taking medications likely to confound endpoint assessments (e.g. chronic 
NSAID, cyclosporine, lithium, immunosuppressant use)  
• Patients having other systemic diseases that have the potential to influence kidney 
function (e.g. SLE, diabetes mellitus requiring treatment and patients with 
proteinuria > 1 g /24hr). 
• Patients who underwent surgical or drainage interventions for cystic kidney disease 
the year before study-entry or are likely candidates for these procedures within 2 
years of start of the study. (e.g. a patient that had previous successful cyst 
reduction surgery and now pain attributed to one dominant cyst.) 
• Patients taking other experimental (i.e., not approved by FDA or EMA for the 
indication of ADPKD) therapies aimed at attenuating disease progression in 
ADPKD. 
• Patients having used Lanreotide (or another somatostatin analogue) in the 3 
months before study start. 
• Patients with known intolerance for Lanreotide (or another somatostatin 
analogue).  
• Unwillingness to comply with reproductive precautions. Women who are capable 
of becoming pregnant must be willing to comply with approved birth control 
from two-weeks prior to, and for 60 days after taking investigational product. 
• Women, who are pregnant or breastfeeding.  
• Patients, who suffer from cardiac arrhythmia’s that are thought to be dangerous in 
combination with Lanreotide administration 
• Patients, who ever suffered from symptomatic gallstones and did not undergo 
cholecystectomy. 
• Patients, who have a medical history of pancreatitis. 
 
Patients having contraindications to, or interference with MRI assessments can enter 
the study, but will not be assessed for change in kidney and/or liver volume.  
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Standard care 
Participants will not be allowed to participate in other (experimental) trials 
investigating pharmaceutical agents or strategies aimed at intervening with the 
natural disease course of ADPKD. Participants with hypertension (defined as 
systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm 
Hg) will be treated with angiotensin-converting enzyme inhibitors, or in case of 
intolerance for angiotensin-converting enzyme inhibitors, with angiotensin 
receptor blockers. Although definitive evidence is lacking, these 2 classes of 
antihypertensive drugs are regarded as first-line agents for the treatment of 
hypertension in individuals with CKD, including ADPKD (1, 26, 27). If 
hypertension remains despite the use of these agents, the choice of additional 
antihypertensive medication will be at the discretion of the treating physician. 
Use of estrogens and oral contraceptives is discouraged per protocol in women 
with significant liver cysts because these drugs may increase liver cyst growth in 
women with ADPKD (28, 29). However, the decision to prescribe these drugs 
will be at the discretion of the treating physician. Similarly, dietary advice 
(reduction in sodium, caffeine, and protein intake and increase in water intake) 
will be at the discretion of the treating physician because dietary interventions 
have not yet been proven to decrease the rate of disease progression in ADPKD. 
 
Primary endpoint 
The primary outcome variable is rate of change in kidney function for 
lanreotide-treated versus control patients. This is defined as the slope through 
serial eGFR values over time during the treatment phase of the study. The value 
obtained at week 12 will be used as the first eGFR for slope analysis. If 
participants reach end-stage kidney disease or die, only eGFR values before 
these events will be taken into account.  
 
Kidney function has been chosen as the primary end point instead of total 
kidney volume because the clinical relevance of this latter parameter is still 
uncertain. eGFR values obtained at weeks 4 and 8 during the treatment phase 
of the study will be used for safety analyses, but not for efficacy analysis. 
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Kidney function will be estimated using the creatinine-based 4-variable MDRD 
(Modification of Diet in Renal Disease) Study equation (24). This equation is 
validated in individuals with eGFR < 60 mL/min/1.73 m2 and generally is used 
in Dutch clinical practice. Furthermore, to rule out an effect of change in muscle 
mass or tubular creatinine secretion due to treatment, as a sensitivity analysis, 
cystatin C will be measured to estimate GFR (using the CKD-EPI [CKD 
Epidemiology Collaboration] equation). 
 
Secondary endpoints 
Secondary end points are separated into end points for the kidney, liver, and 
quality of life and are listed in Box 2.  
 
We thought that it was useful to assess change in liver volume only in 
participants who have a polycystic liver and therefore decided not to analyze 
this secondary end point in those who have no or only a limited number of liver 
cysts because this will only dilute the effect size of the drug under investigation. 
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Box 2. Primary and secondary end points in the DIPAK1 study 
 
 
Primary end point 
Rate of change in kidney function for lanreotide-treated vs control patients (ie, the 
slope through serial eGFR values over time during treatment phase of study, where 
value obstained at week 12 is used as first eGFR for slope analysis and only eGFR 
values prior to end-stage kidney disease or death are taken into account). 
 
Secondary end points 
Kidney function 
1. Change in kidney function as assessed as pretreatment eGFR (the average of the 
screening visit (SV) and at the baseline visit (BV)) versus eGFR 12 weeks after 
cessation of treatment (obtained at the follow-up visit, FU). 
2. Incidence of a confirmed 30% decrease in eGFR and/or need for kidney 
replacement therapy computed from pretreatment. 
 
Kidney volume 
• Change in total kidney volume (MRI) as assessed at the baseline visit before start 
of treatment (BV) versus the value obtained 12 weeks after cessation of treatment 
(obtained at the follow-up visit, FU). 
 
Liver 
• Change in total liver volume (MRI) in the subset of subjects with moderate to 
severe polycystic liver disease (defined as a liver volume ≥2000 ml), as assessed at 
the baseline visit before start of treatment (BV) versus the value obtained 12 
weeks after cessation of treatment (at the follow-up visit, FU).  
 
Quality of life 
• Change in quality of life as assessed at the baseline visit (BV) versus the value 
obtained 12 weeks after cessation of treatment (obtained at the follow-up visit) 
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Data collection 
Figure 1, Table 1, and Table S1 (provided as online supplementary material) 
show the data to be obtained during study visits. Health-related quality of life 
will be assessed using an ADPKD-specific questionnaire, including questions 
regarding polycystic liver disease (30). Blood pressure will be assessed with an 
automatic device for 10 minutes during study visits. Blood and urine chemistry 
will be analyzed locally. In addition, a blood sample will be shipped to the core 
laboratory for storage (−80°C), and assessment of key efficacy variables 
(creatinine and cystatin C) will be performed after completion of the study in 
one run per participant to minimize interlaboratory and interassay variation. 
These centrally assessed laboratory variables will be used for efficacy analyses. 
Of note, storing blood samples at room temperature for up to 4 days does not 
influence creatinine (31) and cystatin C concentrations, nor does frozen storage 
at −80°C for prolonged periods (32).  
 
At the baseline visit, at the end of the treatment phase of the study (week 120 or 
at early termination visit), and at follow-up, magnetic resonance (MR) imaging 
(MRI) will be performed, using a standardized protocol without use of 
intravenous contrast. The MRI acquisition protocol includes T2-weighted 
single-shot fast gradient spin-echo images with fat-saturation. MR images will 
be sent to the central reading facility, using a secure server. MRI end point data 
will be analyzed and read centrally using Analyze 11 software (AnalyzeDirect 
Inc) to assess total kidney volume with a stereology method. To ensure that 
valid MR images are obtained, quality control will be performed within 48 
hours by trained personnel. In case a scan is rejected, it will be repeated before 
the injection of lanreotide.  
 
Lanreotide serum levels will be measured after completion of the trial using 
blood samples for post-hoc assessment of the association between drug blood 
levels and efficacy. A web-based electronic case report form has been designed 
to enter study data to ensure correct and timely data collection in a central 
database. 
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Estimation of power and sample size 
In a cohort of patients with ADPKD participating in the MDRD Study (baseline 
measured GFR, 25-55 mL/min), the mean slope of GFR decline on treatment 
was 5.2 mL/min per year with a calculated standard deviation of 4.3 (33). In 
the recent Everolimus ADPKD Study (baseline eGFR, 30-90 mL/min/1.73 m2 ), 
mean change in eGFR was 4.2 mL/min/1.73 m2 with a similar standard 
deviation of 4.3 (13). The annual slope of GFR in this study is expected to be 
similar to the MDRD Study and steeper than in the Everolimus ADPKD Study 
because in the present study, only individuals with decreased kidney function 
will be included (CKD stage 3). Assuming an average change in eGFR of 5.2 
mL/min/1.73 m2 per year in untreated patients and a standard deviation of 4.3 
in both treatment groups, 120 individuals per study group are needed to detect 
a 30% reduction in the rate of kidney function loss between treatment groups, 
with 80% power to detect this difference and 2-sided α = 0.05. Taking into 
account the possibility of 20% protocol violators and/or dropouts, our aim is to 
include 150 participants per group. 
 
Statistical analysis 
Analyses will be done after completion of the study. To assess differences 
between treatment groups in baseline characteristics for continuous data, t test 
will be used for normally distributed data, and Mann-Whitney U test, for non-
normally distributed data. The χ2 test will be used to compare dichotomized 
variables between groups. (Generalized) mixed models will be used to analyze 
the primary end point (difference in change in kidney function in lanreotide-
treated patients vs controls). All available eGFR values will be taken into 
account until a participant reaches end-stage kidney disease. We will explore 
whether missing eGFR values are random, and if necessary, we will use other 
statistical models that handle informative dropout. 
In addition, we will perform linear regression analysis (calculating a slope 
through the available eGFR values per individual) as sensitivity analysis for the 
primary end point and secondary end points involving change in a variable. 
Incidences of worsening kidney function, end-stage kidney disease, and death 
Appendix 233 
will be investigated using Cox proportional hazard models. Kaplan-Meier 
graphs will be prepared. All P values will be 2 tailed, and the level of 
significance will be set at P < 0.05. All analyses will be performed as intention-
totreat analyses. Perprotocol analyses will be done as secondary analyses. The 
main analyses also will be performed in a priori–defined subgroups: baseline 
age younger than or equal to/ older than median, baseline eGFR less than or 
equal to/greater than median, baseline total kidney volume less than or equal 
to/greater than median, and men versus women. Of note, we will perform 
analyses for change in liver volume as a secondary analysis, with a sensitivity 
analysis with adjustment for use of estrogens or oral contraceptives. To control 
for type I errors, P < 0.01 will indicate statistical significance for the subgroup 
analyses. Furthermore, we will investigate correlations investigating changes in 
kidney volume versus changes in liver volume over time. 
 
Ethical considerations 
The Medical Ethics Committee of the University Medical Center Groningen 
approved the protocol and informed consent form. The trial is to be conducted 
in accordance with the International Conference of Harmonization Good 
Clinical Practice Guidelines and will adhere to the ethical principles that have 
their origin in the Declaration of Helsinki.  
 
All participants have the right to withdraw at any time during the study. 
Further stopping rules for patients and the trial are given in Table S2 online. 
 
Study organization 
A steering committee oversaw the design and will overview the conduct of the 
study; a central study coordinator will coordinate the study. An independent 
data safety monitoring board has been established to monitor the safety and 
efficacy of the trial and can advise to stop the study based on serious adverse 
events and/or interim analysis of adverse effects. An academic contract research 
organization will monitor study progress and quality and completeness of study 
data. 
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DISCUSSION 
 
The DIPAK 1 Study seeks to determine whether lanreotide attenuates kidney 
function deterioration in patients with ADPKD.  
 
In ADPKD, well-described genetic defects initiate the formation of cysts (34-
37). Cysts further expand due to disturbances in cell proliferation, apoptosis, 
cell-matrix interactions, and fluid secretion. One of the factors that potentially 
can affect these processes is 3′,5′-cyclic adenosine monophosphate (cAMP). 
Elevated cAMP levels might hasten cyst growth and overall kidney enlargement 
in patients with PKD (38). cAMP production can be inhibited by blocking the 
V2R, but also by activation of the somatostatin receptor (6, 39, 40). There are 
5 receptors for somatostatin. Octreotide and lanreotide bind with high affinity 
to somatostatin receptor 2 (39, 41, 42). Detection of the somatostatin receptor 
2 in kidney tubules and its inhibitory effect on cAMP production suggest a 
potential effect of somatostatin on cyst fluid secretion and enlargement in 
patients with ADPKD (43, 44). In experimental models of PKD, somatostatin 
analogues have been shown to inhibit hepatorenal cystogenesis (45, 46).  
 
In humans, to date, only 3 small-scale studies have been performed with 
somatostatin analogues in ADPKD. In these studies, kidney function was not a 
primary outcome measure. Ruggenenti et al. (8) performed a randomized 
crossover study comparing the effect of a 6- month treatment regimen of 
octreotide, a long-lasting somatostatin analogue, with no treatment in 14 
patients with ADPKD (mean baseline measured GFR, 57.1 [range, 24.4-95.3] 
mL/min). GFR, measured using iohexol clearance, did not change significantly 
during both treatment periods. Although total kidney volume increased 
significantly in both groups, the increase in kidney volume was reduced, with 
60% reduction by administration of octreotide (P < 0.05). van Keimpema et al. 
(18) performed a randomized clinical study with a 6-month regimen of 
lanreotide, administered in the normal clinical dose of 120 mg once every 28 
days subcutaneously in 54 patients, 32 of whom had ADPKD. In participants 
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with ADPKD, total liver volume decreased significantly with lanreotide 
compared to placebo (P < 0.01), and total kidney volume decreased by 17 mL 
(1.5%) in the lanreotide group and increased by 50 mL (3.4%) in the placebo 
group (absolute difference, P < 0.02). This beneficial effect was maintained in 
the following 6 months (47). Lanreotide treatment decreased serum creatinine 
levels (P = 0.079). In addition, at 6 months, lanreotide improved general healthy 
perception.  
 
Hogan et al. (19) randomly assigned 42 patients with polycystic liver disease (of 
whom 34 had ADPKD) to 12 months’ treatment with octreotide or placebo. 
Mean baseline GFR was 71 (range, 20-124) mL/min/1.73 m2 . Total liver 
volume decreased 4.95% in the octreotide group compared with an increase of 
0.92% in the placebo group (P = 0.048). Among patients with ADPKD, the 
kidney growth rate was significantly reduced in the octreotide group compared 
with nontreated patients (0.25% vs 8.61%, respectively; P = 0.045). GFR 
decreased by 5.1% with octreotide and 7.2% with placebo (difference not 
statistically significant) (19). After 2 years of octreotide treatment, the reduction 
in total liver volume was maintained (−5.96% compared to baseline), but the 
inhibition of kidney growth during the first year was not sustained during the 
second year (48).  
 
Caroli et al. (22) recently reported results of a single-blind randomized 
controlled trial involving 79 patients with ADPKD with eGFR ≥ 40 
mL/min/1.73 m2 . Total kidney volume increased significantly less with 
octreotide compared to placebo after 1 year of treatment. After 3 years of 
treatment, the mean increase in total kidney volume again was smaller in the 
treated group, but results were not statistically significant. During the entire 
follow-up period, the rate of eGFR decline (measured by iohexol clearance) 
tended to be slower in the octreotide group than in the placebo group, but the 
difference was not statistically significant. After 1 year of treatment, there was 
no difference in GFRs. The long-term GFR decline from year 1 to year 3 was 
almost 50% slower in the octreotide group than in the placebo group (2.28 vs 
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4.32 mL/min/1.73 m2 per year, respectively; P = 0.03). It should be noted that 
at baseline in the placebo group, GFR was lower and total kidney volume was 
higher, which may have led to a worse prognosis in the placebo group 
independent of treatment. These data led the authors to conclude that their 
findings present the background for large randomized controlled trials to assess 
the protective effect of somatostatin analogues against loss of kidney function 
and progression to end-stage kidney disease (22).  
 
To our knowledge, 3 trials are ongoing with somatostatin analogues in patients 
with ADPKD (n = 48 with pasireotide and n = 43 with lanreotide, both directed 
at liver volume (49, 50) and n = 80 with octreotide directed at kidney volume 
and rate of GFR decline (51)). Although these trials are important, the lower 
number of included patients may preclude definitive conclusions on the efficacy 
of somatostatin analogues for renoprotection in this patient group.  
 
The most common adverse effects of lanreotide are injection-site discomfort and 
erythema, diarrhea, abdominal cramping, (asymptomatic) biliary sludge or 
gallstones, and abnormal glucose metabolism (52). Less common adverse effects 
are allergic skin reactions and acute pancreatitis. Diarrhea and abdominal 
cramping are expected to occur in the first days after the first injections when 
lanreotide reaches peak blood concentrations. These symptoms resolve 
spontaneously in most cases during continued use when more stable blood 
concentrations are reached (steady-state phase) (53). In case these symptoms do 
not resolve, pancreatic enzymes may be prescribed, which generally improve 
these symptoms (18). Of the 118 patients with ADPKD who were included in 
the 3 aforementioned studies with somatostatin analogues, only 2 patients 
stopped study medication permanently, and in only 4 patients did dosages have 
to be lowered (8, 18, 19).  
 
The present costs associated with lanreotide are a disadvantage. In the 
Netherlands, a 120- mg lanreotide injection costs $2,310. This is approximately 
$30,000 per year for an injection schedule of once every 4 weeks. If proved 
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effective, new price agreements may be necessary to improve the cost-
effectiveness ratio of lanreotide administration for ADPKD.  
 
Recently, the Tolvaptan Efficacy and Safety in Management of ADPKD and Its 
Outcomes (TEMPO) 3-4 Study, a randomized controlled trial in 1,445 patients 
with ADPKD, showed renoprotection of the V2R antagonist tolvaptan (16). 
Inclusion criteria were different from those in this study. Only patients with 
ADPKD with estimated creatinine clearance > 60 mL/min were included. The 
efficacy and safety of tolvaptan in patients with ADPKD with CKD stages 3-4 
are unproved to date. Patients with ADPKD with lower eGFRs have higher 
vasopressin levels (54, 55). Consequently, such individuals might require higher 
dosages of a V2R antagonist to effectively block the receptor. We found in an 
experimental model for ADPKD that a fixed dose of a vasopressin receptor 
antagonist showed less efficacy when administered at a later stage of disease 
(56). Because V2R antagonists might be less effective in a later stage of disease, 
we chose to compare lanreotide with standard care and not in addition to 
vasopressin receptor antagonists. The positive findings in the TEMPO 3-4 Study 
nevertheless are encouraging for the present study because both V2R 
antagonists and somatostatin analogues lower intracelluar cAMP levels (6).  
 
Study limitations include the design as an open randomized controlled trial. 
Administration of lanreotide, which is a gel, will result in temporary injection 
infiltrates in the majority of actively treated individuals. Manufacturing a 
placebo that has a similar effect is not possible from a technical point of view. 
This precludes execution of this trial as a double-blinded randomized controlled 
trial. To minimize bias, efficacy end points will be assessed in a blinded fashion 
(eGFR and MRI kidney and liver volume measurements will be done centrally 
by personnel blinded for treatment allocation). Furthermore, the primary 
outcome is change in kidney function from 12 weeks after the start of 
treatment, instead of from randomization. This is done because in the first 3 
months during treatment, dose adjustments of lanreotide and/or 
antihypertensive drugs may be needed, which may induce acute renal 
Urinary Extracellular Vesicles: Biomarkers and beyond 238 
hemodynamic effects that may compromise an accurate assessment of eGFR 
slope (57). However, a necessary assumption for this end point to be valid is 
that changes in eGFR during the first 12 weeks after randomization are fully 
reversible during the 12 weeks after discontinuation of the drug, after 
completion of the intervention. We cannot prove this assumption until the trial 
has finished. Therefore, after completion of the trial, this will be studied 
extensively, and in case the change in eGFR is not fully reversible, our primary 
end point requires support by one or more secondary kidney end points.  
 
Another limitation is that kidney function will be estimated and not measured, 
potentially inducing more variability. However, serial measurement of kidney 
function in 300 patients with ADPKD in 4 different centers is not feasible, and 
it recently has been shown that measured GFR and eGFR in ADPKD are highly 
correlated.58 Finally, in this study, total kidney volume will be measured using 
MRI, a method that is well validated (4, 14).  
 
In conclusion, to our knowledge, the DIPAK 1 Study is the first larger scale 
clinical study that will investigate the efficacy of somatostatin analogue on 
attenuation of kidney function decline in ADPKD. 
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